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Abstract 
Obesity is associated with an increased risk of diabetes type 2, dyslipidaemia and 
atherosclerosis. These cardiovascular and metabolic abnormalities are exacerbated by 
dietary fats such as cholesterol and its metabolites. High adipose tissue 
glucocorticoid levels, generated by the intracellular enzyme 11β-hydroxysteroid 
dehydrogenase type 1 (11β-HSD1) are also implicated in the pathogenesis of obesity, 
metabolic syndrome and atherosclerosis. Transgenic mice over-expressing 11β-
HSD1 selectively in adipose tissue develop the metabolic syndrome whereas 11β-
HSD1-/- mice have a ‘cardioprotective’ phenotype, deriving in part from improved 
adipose tissue function. Consistent with this, prototypical therapeutic 11β-HSD1 
inhibitors ameliorate metabolic disturbances associated with obesity. 
 
11β-HSD1 also inter-converts the atherogenic oxysterols 7-ketocholesterol (7KC) 
and 7β-hydroxycholesterol (7β-HC). Work presented in the first part of the thesis 
defines the impact of these alternative substrates on the metabolism of 
glucocorticoids in adipocyte cell lines (3T3-L1 and 3T3-F442A). 11β-HSD1 
catalyses the reduction of 7KC in mature adipocytes leading to accumulation of 7β-
HC. Oxysterol and glucocorticoid conversion by 11β-HSD1 was competitive and 
occurred within a physiologically-relevant IC50 range of 450nM for 7KC inhibition 
of glucocorticoid metabolism. Working as an inhibitor of 11β-HSD1 activity, 7KC 
decreased the regeneration of active glucocorticoid and limited the process of 
preadipocyte differentiation. 7-oxysterols did not display intrinsic activation of the 
glucocorticoid receptor (GR). However, when co-incubated with glucocorticoid, 
7KC repressed, and 7β-HC enhanced GR transcriptional activity. The effect of 7-
oxysterols resulted from the modulation of 11β-HSD1 reaction direction, at least in 
transfected HEK293 cells, and could be abrogated by over-expression of hexose 6-
phosphate dehydrogenase, which supplies NADPH to drive the reductase activity of 
11β-HSD1. 
 
11β-HSD1 inhibition protects from atherosclerosis, yet it is unknown whether it is an 
effect of alterations in the metabolism of 7-oxysterols. 7KC and 7β-HC did not 
activate the potential cognate receptor LXRα and FXR/RXR in transactivation 
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assays. No differential regulation of key gene targets of LXRα, FXR and RORα in 
the liver and fat depots of high fat fed 11β-HSD1-/- and wild type mice was 
observed. 
 
To further determine the molecular basis for the metabolically beneficial phenotype 
of 11β-HSD1-/- mice I analysed global gene expression in subcutaneous and 
mesenteric adipose tissues of high fat-fed (4 weeks) 11β-HSD1-/- and congenic 
C57BL/6J mice by microarrays, followed by pathway analysis, gene clustering and 
realtime-PCR validation of transcripts with >1.5-fold difference between genotypes. 
11β-HSD1-/- mice gained less weight and distributed adipose tissue to subcutaneous 
rather than visceral depots. Broadly, high fat-fed 11β-HSD1-/- mice showed up-
regulation of transcripts in subcutaneous fat (70% of 1622 differentially-expressed 
transcripts), but down-regulation in mesenteric adipose tissue (73% of 849 
transcripts). Genes up-regulated in 11β-HSD1-/- subcutaneous adipose were 
associated with β-adrenergic signaling, glucose metabolism, lipid oxidation, 
oxidative phosphorylation, MAPK, Wnt/β-catenin, EGF, and PI3K/AKT insulin 
signaling pathways. Increased subcutaneous fat insulin signaling was confirmed by 
increased IRS-1 and Akt phosphorylation in vivo. Down-regulated genes in 11β-
HSD1-/- mesenteric fat were associated with immune cells, NK-kappaB, Jak/Stat, 
SAPK/JNK, chemokine, toll-like-receptor and Wnt signaling pathways suggesting 
reduced immune cell infiltration in mesenteric adipose in high fat-fed 11β-HSD1-/- 
mice. 11β-HSD1 deficiency protects against metabolic disease by increasing 
peripheral fat insulin sensitivity and through a novel mechanism involving reduction 
in visceral fat immune/inflammatory cell function. 
 
Data presented in this thesis contribute to the understanding of the role of 11β-HSD1 
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The following introductory chapter describes the biology of 11β-HSD1, an enzyme 
amplifying intracellular glucocorticoid level. Evidence for the role of 11β-HSD1 in 
the pathogenesis of the metabolic syndrome and atherosclerosis is discussed. Finally, 
a list of the aims of this thesis is presented. 
 
1.1 Glucocorticoids, obesity and metabolic disease 
The prevalence of obesity and its metabolic complications has been increasing 
rapidly over the last two decades 
(http://www.cdc.gov/nccdphp/dnpa/obesity/trend/maps/). Obesity is associated with 
an increased risk of type 2 diabetes, metabolic syndrome, cardiovascular disease, 
stroke and certain cancers. The World Health Organization has estimated that 
worldwide 1.6 billion adults are overweight with at least 400 million of them 
clinically obese (http://www.who.int/mediacentre). These gloomy raw statistics 
include increasing numbers of children and adolescents, foreshadowing a worsening 
trend in the future. Given that medical science has always risen to epidemic 
challenges, the paralleled increase in our understanding of metabolic pathways 
underlying obesity and its metabolic consequences is not surprising. Whether or not 
obesity in the absence of its complicating disorders increases mortality remains 
contentious (Flegal et al., 2005). What is clear is that obesity is a major risk factor 
for several disorders that are themselves associated with high morbidity and 
mortality. These include type 2 diabetes, dyslipidaemia, hypertension and 
cardiovascular disease (which, together with visceral/abdominal obesity, comprise 
the Metabolic Syndrome), as well as several cancers, respiratory disorders, 
gallstones, osteoarthritis, depression and anxiety. Whilst prevention of these 
complications of obesity is a major impetus for research into prevention and 
treatment, another important if more contentious driving force of the extensive 
research in the field of obesity is the growing public expectation of a pharmaceutical 
antidote to our ‘obesogenic environment’. Many novel druggable molecular targets 
have recently been identified. Several have entered drug development and even 
clinical practice, including rimonabant, a selective endocannabinoid (CB1) receptor 
antagonist, and exenatide, a glucagon-like peptide-1 (GLP-1) mimetic. 
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Growing evidence indicates the cooperation between metabolic and inflammatory 
pathways is disrupted in the pathogenesis of the metabolic complications of obesity 
(Hotamisligil, 2005). Identification and targeting central molecules involved in 
integration of metabolic and immune/inflammatory responses appears to have good 
prospects for a successful therapeutic approach in the metabolic syndrome. The 
promising reports announcing the benefits of thiazolidinediones, statins and 
salicylates to control inflammatory processes and to improve metabolic parameters 
support this notion. 
 
1.1.1 Glucocorticoids 
Glucocorticoids are well known ubiquitous hormones playing a key role in 
modulating immune and inflammatory responses, regulating energy metabolism and 
cardiovascular homeostasis and the body’s responses to stress. Opposing the action 
of insulin, glucocorticoids stimulate production of glucose, switching the 
homeostatic balance towards catabolism. Thus, glucocorticoids promote 
gluconeogenesis but inhibit beta-cell insulin secretion and peripheral glucose uptake 
(Dallman et al., 1993, Sapolsky et al., 2000). They also increase protein breakdown 
and lipolysis with consequent fatty acid mobilization. Patients with endogenous or 
exogenous glucocorticoid excess (Cushing’s syndrome) develop visceral obesity, 
insulin resistance, diabetes type 2, dyslipidemia, hypertension and increased 
cardiovascular mortality.  
 
The striking similarity of phenotype between rare Cushing’s and the common 
Metabolic Syndrome/idiopathic obesity spectrum has spurred the search for a 
common underlying mechanism. However, plasma cortisol levels are not notably 
elevated in simple obesity or the Metabolic Syndrome, at least in the absence of 
marked complications. It has been hypothesised that tissue-specific differences in 
glucocorticoid metabolism and hence increased local cellular corticosteroid exposure 
may explain this apparent paradox. Since most of the features of Cushing’s syndrome 
are reversible by removal of glucocorticoid excess, manipulations reducing cortisol 
action at a local cellular or tissue level might provide a novel therapeutic strategy for 
the Metabolic Syndrome. 
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Glucocorticoids (cortisol in humans and most mammals, corticosterone in rats and 
mice) are produced by the adrenal cortex and regulated by ACTH under the control 
of hypothalamic-pituitary-adrenal (HPA) axis. As little as five percent of cortisol 
circulates free in the plasma, with the majority bound with high affinity 
corticosteroid-binding globulin, which may act as a transporter of steroid to target 
cells, as well as lower affinity proteins such as albumin. The production of 
glucocorticoids is contingent upon the pronounced circadian rhythm (high during the 
active phase, low during quiescence/sleep) and episodic stressful events which 
stimulate the HPA axis, considerable variations of free plasma cortisol occur. The 
dynamic range encompasses very low nanomolar levels at the nadir to low 
micromolar concentrations during severe stress (Stewart and Krozowski, 1999). 
Cortisol is believed to diffuse across cell membranes and then binds to cytoplasmic 
glucocorticoid receptors (GR) and, in some tissues, mineralocorticoid receptors 
(MR), which then translocate to the nucleus. GR and MR are ligand-gated 
transcription factors (Dostert and Heinzel, 2004) which regulate a plethora of genes 
directly or through interactions with other transcription factors (Barnes, 2006a, 
Barnes, 2006b).  
 
Until recently, it was axiomatic that the major determinant of corticosteroid action 
was the level of free cortisol in the plasma and the densities of GR and MR in target 
tissues. However, it has recently become apparent that tissue specific metabolism of 
glucocorticoids, notably by 11β-hydroxysteroid dehydrogenases (11β-HSDs) alters 
tissue glucocorticoid levels and hence receptor access. 11β-HSD catalyses the 
interconversion of non-receptor-binding and therefore inert 11-ketosteroids, 
cortisone and 11-dehydrocorticosterone (11-DHC), and their receptor-binding active 
11-hydroxy forms, cortisol and corticosterone (Fig. 1.1.). Inactive cortisone 
circulates unbound at around 100nM in humans and therefore its concentration is 
greater than active cortisol, notably during the diurnal nadir. In rats, 11-DHC levels 
are also around 50-100 nM, though its levels in mice are lower.  
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1.2 11β-hydroxysteroid dehydrogenases  
Two isoforms of 11β-HSD are known, the products of distinct genes (Stewart and 
Krozowski, 1999). 11β-HSD2, a high affinity NAD-dependent dehydrogenase, is 
expressed mainly in mineralocorticoid target tissues (kidney, colon, salivary glands) 
(van Uum et al., 2004). This distribution reflects its role in protecting intrinsically 
non-selective MR from activation by cortisol and corticosterone and therefore 
enabling selective aldosterone binding (Edwards et al., 1988). Additionally, 11β-
HSD2 is highly expressed in the placenta and the developing fetus, providing a 
potent barrier to maternal glucocorticoids (Seckl and Meaney, 2004).  
In contrast 11β-HSD1 is a lower-affinity NADP(H)-dependent enzyme, which 
though bi-directional in purified preparations and tissue homogenates, acts as a 
predominant 11-ketoreductase in intact cells and organs (Jamieson et al., 2000, 
Odermatt et al., 2006). 11β-HSD1 is expressed primarily in tissues with high 
sensitivity to glucocorticoids (liver, adipose tissue, brain, lung) (Bujalska et al., 
1997, Seckl and Walker, 2001, Jamieson et al., 1995). 11β-HSD1 is active as a dimer 
and exhibits cooperative kinetics with cortisone and 11-DHC as substrates (Maser et 
al., 2002). Thus, 11β-HSD1 dynamically adapts to nanomolar as well as micromolar 
concentrations of 11-keto steroids. Both isozymes contain an N-terminal membrane-
insertion sequence, thus enabling anchoring in the endoplasmic reticulum (ER) 
(Odermatt et al., 1999). The catalytic moiety of 11β-HSD2 faces the cytoplasm, 
while 11β-HSD1 is directed into the ER lumen (Odermatt et al., 2006). This has 
significant implications for cofactor availability (NAD+/NADPH ratio) and potential 
bi-directionality of 11β-HSD1. The co-localization of 11β-HSD1 in the lumenal 
surface of the ER membrane with hexose-6-phosphate dehydrogenase (H6PDH), 
which catalyzes the first two steps of the pentose-phosphate pathway generating 
NADPH, provides a supply of co-substrate to drive the predominant oxoreductase 
direction of 11β-HSD1 in intact cells (Banhegyi et al., 2004, Atanasov et al., 2004). 
H6PDH-/- mice are unable to convert 11-dehydrocorticosterone to corticosterone, 





Figure 1.1 Schematic representation of the intracellular 11β-HSD1-dependent regeneration 
of glucocorticoids. 
Glucocorticoids diffuse across cell membrane and bind to glucocorticoid receptors (GR; 
yellow) in the cytoplasm. When not activated by the ligand, GR are protected from the 
trafficking to the nucleus by binding to chaperons and forming the complex. Once activated 
by the ligand, a complex is translocated rapidly into the nucleus where it binds to the 
promoter region of glucocorticoid-responsive genes and leads to an increase or repression of 
genes transcription. Since the production of glucocorticoids is contingent upon circadian 
rhythm, considerable variations of free plasma cortisol occur during diurnal changes. 
Inactive form of glucocorticoid (blue) circulates unbound, and therefore its concentration is 
usually greater than active form (red). 11β-HSD1 (acting predominantly as a NADPH-
dependent reductase in vivo) is located in the endoplasmic reticulum (ER). It interconverts 
active and inactive glucocorticoids, thus regulating glucocorticoid receptor activation 
intracellularly. 
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1.3 11β-HSD1 in obesity and the metabolic syndrome 
To test the hypothesis that tissue-specific regulation of 11β-HSD expression and 
activity contributes to obesity and its metabolic consequences several animal studies 
have been performed. In leptin-resistant fatty Zucker rats, obesity associates with 
decreased 11β-HSD1 activity and expression in the liver, but increased 11β-HSD1 in 
the adipose tissue, notably in visceral fat (Livingstone et al., 2000a). Similar changes 
have been reported in leptin deficient ob/ob mice (Liu et al., 2003). It is noteworthy 
that basal 11β-HSD1 levels are higher in peripheral (subcutaneous) than in central 
(visceral/mesenteric) adipose tissue in such rodent models. 
 
Initial studies of humans, which measured the ratio of cortisol to cortisone 
metabolites in urine as an indirect index of total body 11β-HSD activity, produced 
inconsistent results, reporting increased (Tiosano et al., 2003, Rask et al., 2001), 
decreased (Stewart et al., 1999, Rask et al., 2001) and unchanged (Fraser et al., 
1999) urinary ‘11β-HSD index’ values in obesity (Summary of representative human 
studies in Table 1.1.). Such ratios, however, are inadequate as they may be 
influenced by other enzymes involved in the metabolism of cortisol (11β-HSD2, 5α- 
and 5β-reductases, 3α-HSDs, etc). Additionally, opposing, tissue-specific changes in 
11β-HSD1 are difficult to dissect with such ‘whole body’ estimates. More recent 
studies have attempted various tissue-specific measures in humans to accommodate 
such concerns. Such work has generally, but not exclusively, suggested that obese 
humans, as monogenic obesity in rodents, show selective down-regulation of 11β-
HSD1 in liver and up-regulation in adipose tissue. 
 
1.3.1 Down-regulation of hepatic 11β-HSD1 in obesity: a potential protective mechanism 
against diabetes. 
Hepatic 11β-HSD1 activity (measured as the conversion of an oral dose of cortisone 
into cortisol in plasma after ‘first pass’ metabolism) has been consistently decreased 
in obesity (Rask et al., 2002, Rask et al., 2001, Stewart et al., 1999). This is not just 
driven by insulin resistance since down-regulation of hepatic 11β-HSD1 activity is 
not seen in lean subjects with type 2 diabetes (Valsamakis et al., 2004). The absence 
of hepatic 11β-HSD1 down-regulation in obese diabetics emphasizes its possible role 
 23
in pathogenesis. This raises the intriguing hypothesis that 11β-HSD1 inhibition in 
obese people who develop impaired glucose tolerance may protect from progression 
to the type 2 diabetes. In obese rats, the down-regulation of hepatic 11β-HSD1 
activity apparently requires elevated circulating glucocorticoid levels and/or weight 
gain, but not insulin resistance alone since neither thiazolidinediones nor metformin 
reversed the finding in Zucker rats (Livingstone et al., 2000b). The fundamental 
mechanism involved thus remains obscure. 
 
1.3.2 Increased glucocorticoid regeneration in adipose tissue: a possible cause of metabolic 
syndrome.  
Increased fat mass in obese subjects is suggested to be associated with increased pre-
adipocyte proliferation, differentiation and accumulation of lipid droplets, yet the 
underpinning mechanisms remain unclear. Hence 11β-HSD1 is highly expressed in 
fat and its mRNA and activity increases significantly with differentiation of 3T3-L1 
pre-adipocytes to mature adipocytes (Napolitano et al., 1998), a new concept of its 
role as an autocrine regulator of fat mass emerged. Most human studies show 
increased 11β-HSD1 in subcutaneous fat tissue in obesity (Kannisto et al., 2004, 
Rask et al., 2001, Rask et al., 2002, Lindsay et al., 2003, Wake et al., 2003, 
Paulmyer-Lacroix et al., 2002) (Table 1.1.). However, Tomlinson et al. (Tomlinson 
et al., 2002) found no correlation of 11β-HSD1 in human fat tissue with obesity and 
hypothesised that this may have important implications for the enhancement of pre-
adipocytes proliferation. It can not be excluded, however, that even if there is no 
increase in the enzyme activity per gram of visceral adipose tissue, an increase in the 
volume of abdominal fat in obese subjects may account for the high cortisol levels 
delivered by the portal vein to the liver.  
 
It has been suggested that visceral fat is more sensitive to glucocorticoids (higher GR 
and 11β-HSD1 expression) and therefore it was hypothesised that high ratio of 
cortisol/cortisone reactivation in visceral adipose tissue may be responsible for the 
‘Cushing’s disease of the omentum’(Bujalska et al., 1997). Introduction of a novel 
method by Andrew et al. (Andrew et al., 2002) using deuterated cortisol tracer 
infusion enabled measurement in vivo of 11β-HSD1 activity in the human splanchnic 
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bed (Basu et al., 2005) and, separately, in liver to allow an estimate of visceral 
adipose tissue activity (Sandeep et al., 2005). Such work showed that the splanchnic 
bed produces approximately one-quarter of the amount of cortisol produced by the 
adrenal cortex (Basu et al., 2005). Furthermore, one-third of the splanchnic 
contribution to cortisol production appears to be from liver, with the rest assumed to 
be largely from visceral fat and other mesenteric sources, at least in healthy subjects 
(Andrew et al., 2005). Using this technique, Sandeep et al. (Sandeep et al., 2005) 
compared 11β-HSD1 activity in lean and obese subjects. Obese men had no 
difference in whole-body regeneration cortisol from cortisone, but exhibited greater 
conversion of [3H]cortisone to [3H]cortisol in abdominal subcutaneous adipose 
tissue, as measured directly by microdialysis, suggesting again the down-regulation 
of 11β-HSD1 in liver in obesity. Thus, in obesity whole-body 11β-HSD1 activity is 
not reliably altered because increased activity of cortisol regeneration in adipose 
tissue is balanced by the parallel decrease of hepatic activity. The data support the 
notion that 11β-HSD1 regeneration of glucocorticoids in visceral fat contributes 
substantially to the concentration of cortisol in the portal vein and therefore is an 
important determinant of the development of insulin resistance associated with 
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↑ 11β-HSD1 activity in stromal 
cells from visceral, but not 
subcutaneous fat.  
Increased visceral 11β-HSD1 
activity correlates with obesity. 
Visceral and sc fat 
biopsies, stromal 
cells culture 








↓ 11β-HSD1 activity in obese 
subjects 
11β-HSD1 inhibition correlates with 




(Stewart et al., 
1999) 




↑ 11β-HSD1 in sc fat and 
↓ hepatic 11β-HSD1 in obesity 
Increased adipose and decreased 
hepatic 11β-HSD1 correlate with 
obesity.  
Urine cortisol 




(Rask et al., 
2001) 
12 lean and 
18 obese 
patients 
↑ 11β-HSD1 mRNA in sc fat in 
adipocytes and in visceral fat 
in both adipocytes and stroma 
from obese patients.  
Over-expression of 11β-HSD1 in fat 
correlates with metabolic disorders 
linked to obesity. 
In situ hybridisation (Paulmyer-




↑ 11β-HSD1 in fat and 
↓ hepatic 11β-HSD1 in obesity 
↑ cortisol clearance  
Increased 11β-HSD1 in fat, 
decreased in liver and enhanced 
inactivation of cortisol by A ring 
reductases with compensatory 
activation of the HPA axis correlate 
with obesity 
Urine cortisol 












healthy men  
Normal 11β-HSD1 activity in 
adipose tissue and ↓ hepatic 
11β-HSD1 
In subjects with impaired 
glucose intolerance. 
Enhanced in vivo peripheral tissue 
sensitivity to glucocortiocids, tissue-
specific alterations in 11β-HSD1 
activity and increased excretion of 
A-ring reduced metabolites of 
cortisol correlate with impaired 













No difference in adipose 11β-
HSD1 mRNA between 
visceral and sc fat tissue, ↑ 
11β-HSD1 activity in visceral 
preadipocytes.  
No correlation of 11β-HSD1 mRNA 
with obesity. Enhanced 
preadipocyte proliferation within 
visceral adipose tissue contribute to 
increases in visceral fat in obese 
patients. 








↑ adipose 11β-HSD1 activity 
and increased urinary 
excretion of 5alpha- and 5β-
reduced cortisol metabolites in 
obesity. Fatty liver is 
associated with selective 
increase of 5β-reduced 
cortisol metabolites 
No correlation of visceral fat mass 
with changes in cortisol metabolism. 
Urine cortisol 







↑Adipose 11β-HSD1 in 
obesity 
Sc adipose 11β-HSD1 activity 
correlates with central adiposity and 
hyperinsulinemia. No difference in 
enzyme activity between Pima 
Indians and Caucasians. 




16 men and 
16 women 
↑ Adipose 11β-HSD1 mRNA 
and activity in obesity 
Adipose 11β-HSD1 mRNA and 
activity correlate with obesity. Leptin 
but not angiotensinogen and GR 
were correlated with 11β-HSD1 and 
obesity. 
Sc fat biopsies (Wake et al., 
2003) 





No change in 11β-HSD1 
activity in diabetic subjects. 
Impaired 11β-HSD1 activity 
correlates with obesity in healthy 
subjects but not in diabetics. Failure 
to down-regulate11β-HSD1 activity 
with diabetes may potentate 









↑ Adipose 11β-HSD1 mRNA 
and protein in obesity  
Increased 11β-HSD1 mRNA in sc fat 
correlates with obesity and insulin 
resistance. 





low fat diet 
↑ Adipose 11β-HSD1 activity 
and mRNA in isolated 
adipocytes  
Weight loss increases 11β-HSD1 
mRNA in adipose tissue. Decreased 
11β-HSD1 activity and expression in 
obesity may act as a compensatory 
mechanism to enhance insulin 
sensitivity.  
Urine cortisol 









 Splanchnic 11β-HSD1-dependent 
re-generation of cortisol contributes 
significantly to the whole body 
cortisol production. Thus, alterations 
in splanchnic cortisol production 




isotype infusion (in 
vivo splanchnic 
11β-HSD1 activity) 
(Basu et al., 
2004) 
6 lean and 6 
obese men 
↑ In vivo 11β-HSD1 activity in 
sc fat and unchanged total 
splanchnic 11β-HSD1 activity 
in obese men. 
Increased 11β-HSD1 activity 
selectively in adipose tissue 
correlates with obesity. Obese men 
are less susceptible than lean men 
to the insulin-sensitizing effects of 
carbenoxolone.  
Isotype infusion (in 
vivo splanchnic 
11β-HSD1 activity), 
microdialysis of sc 
fat 
(Sandeep et al., 
2005) 
9 healthy men ↑ 11β-HSD1 activity in fat 
after meal. 
Hyperinsulinaemia and increased 
FFA induce acute increases in 11β-
HSD1 activity in adipose tissue. 
Isotype infusion (in 
vivo splanchnic 
11β-HSD1 activity), 
microdialysis of sc 
fat 




↑ 11β-HSD1 activity following 
mixed meal 
Increased total body cortisol 
production after an ingestion of a 
mixed meal does not originate from 
alter splanchnic cortisol production. 
Isotype infusion (in 
vivo splanchnic 
11β-HSD1 activity) 





↑ 11β-HSD1 and ↓11β-HSD2 
mRNA in sc fat in obese 
women 
Increased 11β-HSD1 mRNA 
positively correlates with the waist 
circumference and is associated 
with decreased insulin sensitivity. No 
effect of weight loss on the 
expression of 11β-HSD1 and 11β-
HSD2. 
Sc fat biopsies (Engeli et al., 
2004) 
Table 1.1 Summary of the representative human studies 
The table presents an overview of the most significant human studies testing the hypothesis 
that suggests that changes in 11β-HSD1 expression/activity contribute to obesity and its 
metabolic complications. It highlights the relationship between the method employed in the 
study and the corresponding outcomes. 
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1.3.3 The role of 11β-HSD1 in the pancreas and muscle 
11β-HSD1 is expressed in islets of Langerhans isolated from ob/ob mice and also 
from human pancreas (Davani et al., 2000). 11β-HSD1 is increased in islets of 
diabetic but not pre-diabetic Zucker rats (Duplomb et al., 2004). Higher levels of 
11β-HSD1 mRNA and enzyme activity have been correlated with the appearance of 
diabetes and are increased further with disease progression (Duplomb et al., 2004). 
Moreover, in Zucker rats, troglitazone-induced improvement in metabolic 
abnormalities correlated with a 40% decline in 11β-HSD1 mRNA in the islets 
(Duplomb et al., 2004). Incubation of islets with 11-dehydrocorticosterone resulted 
in dose-dependent inhibition of insulin secretion; the effect was reversed by 
carbenoxolone (Davani et al., 2000). Selective inhibition of 11β-HSD1 or GR 
antagonist treatment in ob/ob mice attenuated 11-dehydrocorticosterone-induced 
enhancement of 11β-HSD1 activity (Ortsater et al., 2005). Any fundamental 
mechanistic importance of these interesting observations remains unclear. 
 
Alongside liver and fat, skeletal muscles are a major target for insulin-mediated 
glucose uptake. In obese patients presenting with features of metabolic syndrome it 
has been demonstrated that decreased levels of non-oxidative glucose disposal are 
determined by impaired insulin action predominantly in skeletal muscle (Thorburn et 
al., 1990). In human skeletal myoblasts, 11β-HSD1 correlates with insulin sensitivity 
and blood pressure (Whorwood et al., 2002). Little else is known about the 
importance of the low levels of 11β-HSD1 in skeletal muscle. In contrast, 11β-HSD1 
is more clearly expressed in vascular smooth muscle (Walker et al., 1992). 11β-
HSD2 is also present in the endothelium so 11β-HSD1 effects are likely to be very 
cell-specific. Whilst 11β-HSD1 has no effect on vasoconstrictor/dilator function in 
healthy vessels (Christy et al., 2003), a role in angiogenesis, typically inhibited by 
glucocorticoids, has recently been reported (Small et al., 2005). 11β-HSD1 maintains 
an anti-angiogenic tone in vivo. Perhaps in consequence, 11β-HSD1-/- mice have 
markedly improved myocardial function (ejection fraction) 1 week after 
experimental infarction despite identical infarct size. Selective 11β-HSD1 inhibition 
also reduces atheroma formation (Hermanowski-Vosatka et al., 2005), an effect 
which may include effects in vascular smooth muscle. 
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1.3.4 Polymorphisms in the gene encoding 11β-HSD1  
There are 11 reported cases of deficiency of 11β-HSD1, at least as reported under the 
term ‘cortisone reductase deficiency’ (CRD) (Draper and Stewart, 2005). Most of the 
cases affect women. The clinical presentation resembles polycystic ovarian 
syndrome (PCOS) with acne, hirsutism, oligo-amenorrhoea and infertility. Obesity 
has been reported for a few cases (Phillipov et al., 1996). The phenotype is thought 
to be due to ACTH-mediated androgen excess secondary to the failure to regenerate 
cortisol which results in feedback activation of HPA axis. Although no gross 
deletions or re-arrangements in HSD11B1 have been found in most CRD cases 
(Biason-Lauber et al., 2000, Nikkila et al., 1993, Nordenstrom et al., 1999), two 
polymorphisms in complete linkage disequilibrium within intron 3 of HSD11B1 were 
described in 3 cases associated with exon 5 polymorphisms of H6PD gene (encoding 
H6PDH) (Draper et al., 2003). Thus, a concept emerged that CRD is caused by a 
combination of mutations in HSD11B1 and H6PD. However, White (White, 2005) 
found the co-occurrence of these polymorphisms in normal subjects. San Millan et 
al. also showed that the triallelic genotypes HSD11B1 83,557insA and H6PD R453Q 
found in CRD do not always cause CRD but that in their group of patients with 
PCOS, the H6PD gene variant was associated with increased cortisol and 17-
hydroxyprogesterone levels (San Millan et al., 2005). Gambineri et al. reported that 
HSD11B1 83,557insA contributed to increased cortisol clearance and compensatory 
adrenal hyperandrogenism in lean women with PCOS but might potentially play a 
protective role against obesity and dyslipidemia (Gambineri et al., 2006). 
 
1.4 Does elevated adipose 11β-HSD1 cause metabolic disorders?  
1.4.1 Transgenic over-expression of 11β-HSD1 models the metabolic syndrome. 
To dissect the pathogenic implications of elevated adipose 11β-HSD1 in obesity, 
transgenic mice with two-to three-fold over-expression of 11β-HSD1 in fat were 
generated, exploiting the adipocyte fatty acid binding protein (aP2) promoter 
(Masuzaki et al., 2001) (Table 1.2). These aP2-HSD1 transgenic mice have elevated 
corticosterone levels in adipose tissue but unaltered plasma concentrations. The mice 
develop many features of the metabolic syndrome: glucose intolerance and insulin 
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resistance (exacerbated further by high fat feeding), dyslipidemia, apparent leptin 
resistance (Masuzaki et al., 2001) and hypertension associated with renin-
angiotensin-aldosterone system activation (Masuzaki et al., 2003). Adipokines 
associated with insulin resistance (resistin, TNF, leptin) are elevated and insulin-
sensitising adiponectin is reduced. aP2-HSD1 mice are hyperphagic and obese, 
predominantly in the visceral fat depot. Expression of the GRα receptor was higher 
in visceral compared to subcutaneous fat (although unaltered by transgene 
expression) while the expression of the transgene HSD11B1 was similar in all fat 
depots (Masuzaki et al., 2001). The greater effects in visceral adipose may reflect the 
higher GR and/or higher lipoprotein lipase (LPL) in mesenteric fat depot.  
 
aP2-HSD1 transgenic mice have elevated corticosterone and free fatty acids levels in 
the hepatic portal vein that drains blood from visceral fat to the liver. To examine the 
impact of elevated liver glucocorticoids mice over-expressing 11β-HSD1 selectively 
in the liver under the control of the ApoE promoter have been generated (Table 1.2). 
ApoE-HSD1 transgenic mice develop mild insulin resistance, fatty liver and 
dyslipidemia without impairment of glucose tolerance, obesity or changes in adipose 
distribution (Paterson et al., 2004). Interestingly, ApoE-HSD1 transgenic mice have 
higher hepatic expression of LXR and PPARα suggesting increased lipid synthesis as 
well as clearance, and CYP7a, indicating enhanced bile acid synthesis. The mice are 
also hypertensive, perhaps driven by increased angiotensinogen synthesis in the liver. 
ApoE-HSD1 mice may model the attenuated metabolic syndrome without obesity, 
and indeed increased 11β-HSD1 activity in liver is seen in patients with the insulin 
resistance of myotonic dystrophy (Johansson et al., 2001). In idiopathic 
steatohepatitis, liver 11β-HSD1 levels are not down-regulated (Westerbacka et al., 
2003), but any role of the enzyme in this prevalent problem are speculative.  
 
1.4.2 Is 11β-HSD1 a therapeutic target? 11β-HSD1-/- mice resist the metabolic syndrome. 
Elevated 11β-HSD1 levels in adipose tissue in human obesity and the phentoype of 
two murine models over-expressing 11β-HSD1 in adipose tissue and liver provided 
evidence that inhibition of glucocorticoid regeneration especially in fat might be a 
therapeutic target for metabolic syndrome. Since carbenoxolone does not inhibit 11β-
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HSD1 in adipose tissue in vivo (Livingstone and Walker, 2003, Sandeep et al., 
2005), 11β-HSD1-/- mice have offered a unique possibility to model the potential 
effects of this possible therapeutic strategy. 11β-HSD1-/- mice are viable and healthy 
(Kotelevtsev et al., 1997), but are unable to convert inert 11-dehydrocorticosterone 
to corticosterone. To compensate for their decreased production of active 
glucocorticoids 11β-HSD1-/- mice have adrenal hyperplasia and 
hyperresponsiveness to exogenous ACTH in vitro and in vivo (Harris et al., 2001). 
11β-HSD1-/- mice have improved glucose tolerance, plausibly due to decreased 
activation of key enzymes involved in gluconeogenesis in the liver (PEPCK and 
glucose-6-phosphatase), but do not show hypoglycemia when fasted (Kotelevtsev et 
al., 1997). 11β-HSD1-/- mice have reduced triglyceride and NEFA levels, lower 
hepatic fibrinogen synthesis (reduced hypercoagulability) and raised HDL 
cholesterol (increased apolipoprotein AI, reduced apolipoprotein CIII), factors 
associated with a cardioprotective phenotype. These changes are driven by increased 
lipid β-oxidation (mCPT-I, UCP-2, ACO) and increased PPARα (Morton et al., 
2001). 
 
Moreover, 11β-HSD1-/- mice are insulin-sensitized, notably in adipocytes in vitro 
(Morton et al., 2004b) and adipose tissue ex vivo (decreased resistin and TNFα but 
increased adiponectin and PPARγ) (Morton et al., 2001). A key action of insulin is to 
stimulate the up-take of glucose into cells by inducing translocation of glucose 
transporters. Binding of insulin to the receptor induces a conformational changes 
resulting in the autophosphorylation of a number of tyrosine residues (Van 
Obberghen et al., 2001) and subsequently leading to the phosphorylation of insulin 
receptor substrate family IRS proteins and activation a key downstream effector 
AKT (otherwise known as PKB) (Saltiel and Kahn 2001). The analysis of the 
phosphorylation sides of these molecules in adipose tissue of 11β-HSD1-/- mice will 
be discussed in Chapter 5.  
Additionally, on a high cholesterol diet, wild-type mice showed a switch in 
lipoprotein profile from HDL to LDL whereas 11β-HSD1-/- mice have lower plasma 
cholesterol level and a higher HDL to total cholesterol ratio. On the obesity-prone 
C57Bl/6J genetic background, high-fat diet-fed 11β-HSD1-/- mice gain significantly 
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less weight than controls, despite relative hyperphagia. With high fat diet 11β-HSD1-
/- mice preferentially gain weight in peripheral rather then in visceral fat depots. It 
has been suggested increased expression of PPARγ and UCP-2 in 11β-HSD1-/- 
visceral adipose tissue could explain those changes in accumulation of fat (Morton et 
al., 2004b, Morton et al., 2001). 
 
To determine whether loss of glucocorticoids specifically in the adipose tissue might 
protect from the development of metabolic syndrome, mice ectopically over-
expressing 11β-HSD2 (the reverse 11β-dehydrogenase enzyme which potently 
inactivates corticosterone), under the control of the murine aP2 promotor (ap2-
HSD2) have been generated (Kershaw et al., 2005) (Table 1.2). Surprisingly, 
expression and activity of the transgene was higher in subcutaneous than other fat 
depots. On high fat diet, aP2-HSD2 mice show decreased food intake and increased 
energy expenditure (Kershaw et al., 2005). They resist weight gain and have 
improved glucose tolerance and insulin sensitivity (Kershaw et al., 2005). On high 
fat diet these mice exhibit increased expression of PPARγ, UCP-2, PEPCK and 
adiponectin, and reduced expression of leptin, TNFα and resistin in adipose tissues 
(Kershaw et al., 2005). Thus, apart from food intake (see below), aP2-11β-HSD2 
mice are phenotypically similar to 11β-HSD1-/- mice emphasizing the importance of 
adipose tissue as a target for enzyme inhibition. 
 
Although 11β-HSD1-/- mice resist the metabolic consequences of a high fat diet, 
they show hyperphagia suggesting that 11β-HSD1 plays a role in the central control 
of food intake and that this predominates over fat-derived signals (Densmore et al., 
2006). Normal C57Bl/6 mice fed a high fat diet show a rapid increase in 11β-HSD1 
and down-regulation of agouti-related peptide (AgRP) specifically in the arcuate 
nucleus, but show no increase in food intake to this palatable diet. In the absence of 
11β-HSD1 (knockout mice), high fat diet paradoxically up-regulates the orexigenic 
AgRP mRNA associated with hyperphagia. Thus it has been proposed that induction 
of 11β-HSD1 in the arcuate serves to constrain intake of palatable energy dense 
foods by reducing AgRP expression with which the enzyme is co-localized. 
However, pharmacological glucocorticoid manipulations increase AgRP suggesting 
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an indirect effect. This might be an opioid pathway since treatment of high fat-fed 
mice with the opioid antagonist naloxone induces a rise in arcuate AgRP and blocks 
the rise in 11β-HSD1 (Densmore et al., 2006). The precise anatomy of the circuitry 






Effect on enzyme activity Phenotype Ref. No. 
aP2-HSD1 transgenic  ↑ 11β-HSD1 in adipose tissue Visceral obesity 
Insulin resistance 
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11β-HSD1-/- No 11β-HSD1 activity Resistance to diet-induced obesity 
Peripheral fat redistribution 
Hyperphagia 
Absence of hyperglycemia upon 
starvation  
and stress challenges 
↑ insulin sensitivity 
HPA axis hyperactivity to stress 
Adrenal hyperplasia 
↑ HDL, ↓ LDL, ↓ TG 
↓ fibrinogen  









Yau et al., 
2001, Harris 
et al., 2001) 
aP2-HSD2 transgenic ↑ 11β-HSD2 predominantly in 
subcutaneous  
adipose tissue 
Resistance to diet-induced obesity 
Hypophagia  
Increased energy expenditure 






Table 1.2 Transgenic mice models with genetic manipulation of 11β-HSD1. 
To identify the tissue-specific role of 11β-HSD1, several transgenic mice models were 
generated. Overexpression of 11β-HSD1 selectively in adipose tissue was associated with 
manifestation of phenotypic features resembling full metabolic syndrome. In contrast, 11β-
HSD1-/- mice or mice with overexpression of 11β-HSD2 in adipose tissue presented with 
‘cardioprotective’ phenotype. 
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1.4. How is 11β-HSD1 regulated? 
Expression of 11β-HSD1 is regulated by many factors including glucocorticoids, 
insulin, growth hormone, thyroid and sex hormones, cytokines, PPARα, PPARγ and 
perhaps other nuclear receptors (Fig.1.2.). In vivo in rat liver and hippocampus 
glucocorticoids have been reported to regulate temporally 11β-HSD1 expression and 
activity (Jamieson et al., 2000). In human skeletal muscle 11β-HSD1 expression is 
up-regulated by physiological concentrations of cortisol in a dose-dependent manner 
(Whorwood et al., 2002). 11β-HSD1 expression and activity is increased with 
differentiation from pre-adipocytes to mature adipocytes and with differentiation to 
the adipocyte phenotype in 3T3-L1 cells (Napolitano et al., 1998). Insulin stimulates 
11β-HSD1 mRNA and activity through a posttranscriptional mechanism in 
adipocytes (Balachandran et al., 2008). Pro-inflammatory cytokines such as IL-1β 
and TNFα have been reported to up-regulate 11β-HSD1 in adipocytes (Tomlinson et 
al., 2001) and aortic smooth muscle cells (Cai et al., 2001). Growth hormone (GH) 
inhibits 11β-HSD1, in part through insulin-like growth factor-I (IGF-I) (Moore et al., 
1999) and the effect depends on sex-specific pattern of release (Liu et al., 1997). 
Patients with acromegaly treated with a GH receptor antagonist show changes in 
cortisol metabolism (Trainer et al., 2001). Furthermore, it has been reported that 
ligands activating two nuclear receptors at the heart of lipid metabolism, LXR and 
PPARγ, down-regulate 11β-HSD1 expression and activity in vitro and in vivo in 
adipose cells (Berger et al., 2001, Stulnig et al., 2002). Addition of cycloheximide 
revealed that ongoing protein synthesis is necessary for the effects of either LXR or 
PPARγ agonists on 11β-HSD1 mRNA, indicating indirect molecular mechanisms. 
The association of these nuclear receptors with the role of 11β-HSD1 will be 
discussed in detiles in the introduction to Chapter 4.  
 
In terms of more direct effects, CCAAT/enhancer binding protein alpha (C/EBPα) 
binds to several sides of 11β-HSD1 promoter and positively regulates its activity in 
hepatocytes both in vitro and in vivo (Williams et al., 2000). C/EBPβ (the key 
mediator of inflammatory and metabolic signaling) also binds and activates 11β-
HSD1 transcription following glucocorticoid treatment (Sai et al., 2008). This could 
potentially explain the link between inflammatory and metabolic pathways. Finally, 
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it should be pointed out that the regulation of 11β-HSD1 transcription and activity is 
tissue-specific. Whilst some cells in the lung exploit a distinct promoter (Bruley et 
al., 2006) this is not the case for adipose and most other tissues. The mechanisms 
underpinning the strikingly discordant changes in 11β-HSD1 transcription in 
adipose, liver and other metabolic tissues remains unknown. 
 
1.4.3 High-fat diet induced down-regulation of 11β-HSD1 activity 
To gain an insight into the molecular mechanism that drives diet-induced obesity in 
mice Morton et al. (Morton et al., 2004c) studied the expression of 11β-HSD1 in 
both obesity and metabolic disease-prone (C57Bl/6J) and resistant (A/J ) strains. 
With chronic high fat diet C57Bl/6J mice increased weight and became profoundly 
hyperinsulinemic and glucose intolerant. A/J mice in contrast resisted these 
metabolic changes. Intriguingly, high fat diet decreases 11β-HSD1 in all fat depots, 
whereas in liver the enzyme is unaffected. 11β-HSD1 activity was down-regulated 
with high fat diet in all adipose depots in both strains. However, A/J mice have lower 
basal expression and greater down-regulation of 11β-HSD1 by HF in adipose tissues. 
It was therefore hypothesised that down-regulation of adipose tissue 11β-HSD1 with 
high fat diet is protective mechanism against metabolically detrimental 
consequences. These data suggest that individual susceptibility for the development 
of metabolic disease as a consequence of long term high fat diet exposure is related 
inter alia to the degree of down-regulation of 11β-HSD1 in adipose tissue, it perhaps 
relates to the genetics of murine strain differences. The molecular explanation for the 
down-regulation of 11β-HSD1 upon HF diet and its variation with strain is unknown 
and may relate to polymorphisms of HSD11B1, as mooted in humans (San Millan et 
al., 2005, Robitaille et al., 2004, Nair et al., 2004, Gambineri et al., 2006). 
Alternatively differences in free fatty acids and lipid products could activate nuclear 
receptors including LXR and PPARs and consequently variably down-regulate 11β-
HSD1. 
 
1.4.4 Regulation of human 11β-HSD1 activity by feeding 
While insulin and other hormones exert direct effects on 11β-HSD1 in rodents, the 
regulatory mechanism in humans is poorly understood. Weight loss has been 
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reported to increase 11β-HSD1 mRNA in human fat (Tomlinson et al., 2004). 
Recently it has been hypothesised that in humans 11β-HSD1 may be also involved in 
acute metabolic response to feeding (Basu et al., 2006, Wake et al., 2006). Sandeep 
et al. provided evidence that insulin induced a rapid down-regulation of adipose 11β-
HSD1 in lean but not in obese patients (Sandeep et al., 2005). Failure to reduce 
adipose tissue cortisol generation by insulin in obese subjects may be a decisive 
factor determining susceptibility to further obesity. Postprandially, when insulin is 
secreted, cortisol availability in adipose tissue appears to be controlled independently 
from the alterations of HPA axis (Wake et al., 2006). Additionally, in obese men, a 
longer term low-carbohydrate diet enhanced cortisol regeneration by 11β-HSD1 and 
reduced cortisol inactivation by A-ring reductases in liver (Stimson et al., 2007). 
Thus, dietary macronutrient composition may contribute to tissue-specific 










igure 1.2 Schematic overview of the regulators of 11β-HSD1 activity. 
he figure represents an overview of studies that analysed influence of various factors on the 
p-regulation (pink triangle) and downregulation (blue triangle) of 11β-HSD1 activity. Note: 
he effect may be tissue- and species-specific. 
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1.5 The role of 11β-HSD1 in resolution of inflammation 
The anti-inflammatory properties of glucocorticoids are well known and these 
steroids are commonly used in clinical treatment of inflammatory disorders. 
Notwithstanding this, it has been suggested that while glucocorticoids have 
immunosuppressive effects in pharmacological doses, at physiological levels they 
provide a more “immunomodulatory” influence (Sapolsky et al., 2000). Chronic 
inflammation in such conditions as rheumatoid arthritis and asthma is believed to 
result from disturbance of the equilibrium between the type-1 (pro-inflammatory) 
and type 2 (anti-inflammatory) immune responses (McEwen et al., 1997). It has 
recently been proposed that 11β-HSD1 may be involved in the resolution of 
inflammation (Chapman et al., 2006b). Reduced 11β-HSD1 has been reported in the 
synovium in rheumatoid arthritis, suggesting deficient glucocorticoid regeneration 
may be implicated in pathogenesis (Schmidt et al., 2005). 11β-HSD1 but not 11β-
HSD2 is expressed in differentiated macrophages, denritic cells, T and B cells and 
acts as a reductase (Zhang et al., 2005, Freeman et al., 2005, Thieringer et al., 2001). 
Moreover, macrophages deficient in 11β-HSD1 are less able to ingest and therefore 
remove apoptotic neutrophils in vitro and in vivo, suggesting that deficiency of the 
enzyme may indeed contribute to the persistence of inflammation, at least in the 
peritoneum (Gilmour et al., 2006b). Cytokines up-regulate 11β-HSD1 activity in 
many key cells involved in the inflammatory response including glomerular 
mesangial cells (Escher et al., 1997, Tetsuka et al., 1999), macrophages (Thieringer 
et al., 2001, Gilmour et al., 2006b), T, B and dendritic cells (Freeman et al., 2005, 
Zhang et al., 2005), human fibroblasts derived from synovium, bone marrow and 
skin (Hardy et al., 2006) and adipocytes (Tomlinson et al., 2001). Perhaps this 
engenders a local feedback mechanism where pro-inflammatory stimuli enhance re-
generation of active glucocorticoids and therefore minimize any tendency to prolong 
inflammation. 
 
Regulation of 11β-HSD1-mediated re-generation of active glucocorticoids in 
immune competent cells also appears to act as an autocrine mechanism regulating 
function. Dendritic cells stimulated by innate immunity signals increase cortisone 
reductase activity (Freeman et al., 2005), whereas, when activated by adaptive 
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immune response (CD40 ligation) their capacity to generate active cortisol decreases. 
Intracellular reactivation of glucocorticoids by 11β-HSD1 has been also 
demonstrated to provide CD4+, CD8+ and B220+ lymphocytes with an intracrine 
mechanism controlling their viability (Zhang et al., 2005). Thus, 11β-HSD1-
dependent control of glucocorticoid bio-availability inside immune cells may provide 
a checkpoint attenuating unwanted immune activity. Thus, modulation of 11β-HSD1 
activity selectively in immune-inflammatory cells may present as a new therapeutic 
strategy for chronic inflammatory disease. 
 
1.6 Inhibition of 11β-HSD1 as a therapeutic target 
It has been hypothesised that decreasing glucocorticoid activity in adipose tissue and 
liver might protect against the detrimental metabolic consequences of obesity 
(Walker and Andrew, 2006). Two principal therapeutic strategies to diminish the 
exaggerated activation of a receptor may be identified: antagonism of the receptor 
and/or its signaling pathway or reducing ligand availability, either systemically or 
locally. Administration of the GR antagonist RU38486 in Cushing’s syndrome 
patients and in db/db mice decreases plasma glucose levels (Friedman et al., 1997, 
Nieman et al., 1985). This approach is, however, limited by the difficulties of 
achieving any tissue-specificity and the adverse consequences of general 
glucocorticoid deficiency (e.g. Addison’s disease). Moreover, long-term therapy with 
GR antagonists leads to compensatory activation of the HPA axis and reversal of the 
competitive blockade as well as adrenal hyperplasia (Lamberts et al., 1991). Thus, 
targeting pre-receptor glucocorticoid activation by 11β-HSD1 has some attractions if 
any compensatory HPA axis activation is incomplete and adrenal stress responses are 
maintained. 
 
1.6.1 Natural 11β-HSD1 inhibitors 
Derivatives of the licorice root (Glycyrrhiza glabra), including glycyrrhetinic acid 
and its synthetic hemisuccinyl ester, carbenoxolone, are potent (IC50 nM in vitro), but 
non-specific 11β-HSD inhibitors (Monder et al., 1989). A variety of endogenous 
steroids and their metabolites (Latif et al., 2005), as well as bile acids such as 
chenodeoxycholic acid (Diederich et al., 2000), have 11β-HSD inhibitory properties. 
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Various environmental chemicals and food ingredients also interfere with 
glucocorticoid metabolism by 11β-HSDs (Schweizer et al., 2003), notably flavanone, 
2’-hydroxyflavanone-extracts from fruits and vegetables and coffee extracts 
(Atanasov et al., 2006). 11β-HSD1 has also recently been reported to catalyze inter-
conversion of additional substrates including 7oxy-dehydroepiandrosterone 
metabolites and 7-oxysterols (Robinzon et al., 2003, Schweizer et al., 2004). Thus, 
11β-HSD1-dependent glucocorticoid conversion may perhaps be attenuated by 
competition for these alternative substrates.  
 
1.6.2 Studies with ‘natural’ 11β-HSD inhibitors 
Studies using the prototypic drug, carbenoxolone, showed hepatic insulin 
sensitization in lean healthy subjects (Walker et al., 1995) and patients with type 2 
diabetes (Andrews et al., 2003), but not obese men (Sandeep et al., 2005) (Table 
1.3). The insulin sensitization appears due reduced hepatic glucose production and 
glycogenolysis rather than any effect on peripheral glucose uptake, perhaps because 
carbenoxolone fails to inhibit 11β-HSD1 in adipose tissue in rats or humans 
(Sandeep et al., 2005, Livingstone and Walker, 2003). This raises the notion that a 
successful inhibitor for the treatment of obese patients with diabetes type 2/metabolic 
syndrome should be effective in adipose tissue. Interestingly, a recent study on 
healthy women with normal BMI reported significant changes in circumference and 
thickness of the superficial thigh fat layer after one month treatment with topical 
glycyrrhetinic acid (Armanini et al., 2005). Such non-selective licorice-based 
compounds also potently inhibit 11β-HSD2 causing renal sodium retention, 
hypertension and hypokalaemia (Stewart and Edwards, 1991, Walker et al., 1992, 
Schuster et al., 2006). They also have effects on other short-chain dehydrogenases, 
such as 15-prostaglandin dehydrogenase (Schuster et al., 2006) and on gap junctions 
(Sagar and Larson, 2006), though these effects occur at higher concentrations than 
11β-HSD inhibition.  
 
1.6.3 Novel compounds selectively inhibiting 11β-HSD. 
Biovitrum first reported selective 11β-HSD1 inhibitors (Table 3). Their 
arylsulphonamidothiazole compounds efficiently inhibit 11β-HSD1 both in vitro and 
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in vivo and showed impressive isoform-specificy (>200fold selectivity over human 
and murine 11β-HSD2) (Barf et al., 2002b). BVT.2733 has an IC50 of 96nM for 
mouse 11β-HSD1 (Alberts et al., 2002b). In vivo BVT.2733 lowers plasma glucose 
and insulin in various hyperglycemic mice (ob/ob, db/db and KKAy), reduces 
hepatic expression of PEPCK and G-6-P mRNAs and therefore decreases hepatic 
glucose production (Alberts et al., 2003b). In accordance to observations in humans, 
inhibition of 11β-HSD1 achieves beneficial glucose lowering only in diabetes type 2 
mice models but doesn’t alter plasma glucose levels in controls (Alberts et al., 
2003b). Moreover, BVT.2733 decreased cholesterol, free fatty acids and triglyceride 
levels, replicating the phenotype of 11β-HSD1-/- mice. 
 
Merck’s compound 544 (Table 1.3.) also shows selective inhibition of 11β-HSD1 
activity (Hermanowski-Vosatka et al., 2005). The drug lowers body weight and 
appetite in diet-induced obesity in mice. In parallel to previous findings, compound 
544 also lowers fasting glucose, improves insulin resistance, glucose tolerance and 
serum lipids in a mouse model of diabetes type 2. Intriguingly, it has a pronounced 
atheroprotective effect in vulnerable ApoE-/- mice (Hermanowski-Vosatka et al., 
2005). Furthermore, RU486 showed very similar effects to the 11β-HSD1 inhibitor, 
suggesting that reducing the intracellular glucocorticoid signal accounted for the 
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Table 1.3. Prototypic 11β-HSD1 inhibitors. 
The table summarises results of the early pharmaceutical programs targeting 11β-HSD1. It 
presents a short description of the efficacy of non-selective and prototypic selective 11β-




1.6.4 A viable drug target for cognitive impairment? 
Glucocorticoids play myriad important functions in the central nervous system. They 
are involved in neurotransmission, cellular metabolism, neuronal division and 
survival (Woolley et al., 1990, Swaab et al., 2005, Landfield et al., 1978). Chronic 
elevation of glucocorticoids, as in Cushing’s syndrome, is associated with affective, 
cognitive and even psychotic disorders (Swaab et al., 2005). Accumulating evidence 
suggest that cognitive impairments with aging associate with elevated glucocorticoid 
levels in rodents and humans (Meaney et al., 1995). Indeed, maintenance of low 
glucocorticoid level throughout life, either via neonatal ‘programming’ of tighter 
HPA axis control or by adrenalectomy with low-dose glucocorticoid replacement in 
mid-life, prevent the emergence of cognitive deficits with age (Meaney et al., 1988, 
Landfield et al., 1981). 
 
11β-HSD1 is widely expressed in brain (Moisan et al., 1990), notably in 
hippocampus, cerebellum and neocortex suggesting its potential involvement in such 
processes as memory and learning. The enzyme is also expressed, albeit at lower 
levels, in the hypothalamus and anterior pituitary indicating a role in neuroendocrine 
control (Seckl, 1997). 11β-HSD1 is maintained in primary cultures of hippocampal 
cells, where it is a reductase and inhibited by carbenoxolone. The enzyme acts in 
vivo to amplify the known neuro-endangering actions of glucocorticoids, potentiating 
excitatory aminoacid-induced neurotoxity (Rajan et al., 1996, Ajilore and Sapolsky, 
1999). This appears to be important in vivo, as aged 11β-HSD1-/- mice resist the 
usual cognitive impairments seen in aged wild type mice [129]. In situ hybridization 
studies in post-mortem human brain confirmed the expression of 11β-HSD1 but not 
11β-HSD2 in hippocampus, prefrontal cortex and cerebellum (Sandeep et al., 2004). 
In two small, randomized, double-blind, placebo-controlled, crossover studies, 
carbenoxolone improved verbal fluency in healthy elderly men and verbal memory in 
patients with diabetes type 2 (Sandeep et al., 2004). Similar finding have been 
reported in rodents (Yau et al., 2001). 
 
Finally, a potential link between cognition and metabolism should be highlighted. 
Since 11β-HSD1-/- mice are insulin sensitized and have an atheroprotective lipid 
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profile, it might be anticipated that the neuroprotective effect of the enzyme 
inhibitors could be secondary to metabolic and vascular effects. Chronic 
hyperglycemia in type 2 diabetes indeed associates with mild cognitive impairments 
(Strachan et al., 1997). Polymorphisms in HSD11B1 gene have been linked to 
diabetes type 2 and hypertension, at least in Native Americans, and a rare 
polymorphism (rs846911-C/A) has been correlated with an increased risk of 
Alzheimer’s disease (de Quervain et al., 2004). However, in a study of 194 
participants of the Scottish Mental Survey the common variants did not associate 
with cognitive impairment with ageing and the rare polymorphism was not detected 
(Deary et al., 2006). However, although carbenoxolone enhances insulin sensitivity 
in healthy young volunteers (Walker et al., 1995) and patients with diabetes type 2 
(Andrews et al., 2003), in the elderly cognition studies there were no effects on 
indices of glycaemic control or serum lipids. The potentially synergistic effects of 
11β-HSD1 inhibition on the brain and metabolism appear propitious, but the locus of 
action of selective 11β-HSD1 inhibitors needs to be defined. 
 
1.6.5 Topical 11β-HSD1 inhibitors for the treatment of glaucoma 
Raised intraocular pressure is a well-recognized feature of Cushing’s syndrome. 
Topical or systemic glucocorticoid administration results in rise in intraocular 
pressure and subsequently may cause iatrogenic glaucoma. Intraocular pressure is 
kept under control by the balance between the production and outflow of aqueous 
humour. Mammalian ocular tissues involved in the regulation of aqueous humour 
express 11β-HSD1 (Stokes et al., 2000). In the support of the hypothesis that 11β-
HSD1 enhanced activity may be important for the etiology of glaucoma systemic 
administration of carbenoxolone to healthy volunteers resulted in a reduction of 
intraocular pressure (Rauz et al., 2003). Selective 11β-HSD1 inhibitors administered 
topically are a potential novel therapy for glaucoma.  
 
1.6.6 New perspective for the treatment of glucocorticoid-induced osteoporosis 
Glucocorticoids play an important role in human osteoblast differentiation, 
proliferation and matrix mineralization (Cooper et al., 1999, Eijken et al., 2005, 
Eijken et al., 2006). Clinical use of glucocorticoids is associated with the 
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development of osteoporosis. Although young 11β-HSD1-/- mice have normal bones 
(Justesen et al., 2004), this may not be pertinent to elderly humans. 11β-HSD1 is 
expressed in human bone and cultured osteoblasts and is regulated by pro-
inflammatory cytokines and glucocorticoids (Cooper et al., 2000, Cooper et al., 
2002). Moreover, 11β-HSD1 is regulated in differentiation dependent manner in 
osteoblasts (Eijken et al., 2005): non-differentiated pre-osteoblasts have low alkaline 
phosphatase activity but increased 11β-HSD1 activity; the opposite features are 
found in differentiated osteoblasts. Interestingly, in primary cultures of human 
osteoblasts 11β-HSD1 activity increases with age of the patient, suggesting a link 
with the age-related incidence of osteoporosis (Cooper et al., 2002). The level of 
11β-HSD1 activity in human bone correlates with susceptibility of glucocorticoid 
(prednisone)-induced changes on bone turnover, although this is perhaps expected 
since inert prednisone is converted by 11β-HSD1 to active prednisolone (Cooper et 
al., 2003). Inhibition of 11β-HSD1 by carbenoxolone suppresses bone resorption 
markers (Cooper et al., 2000). The role of 11β-HSD1 inhibitors upon human bones 
in vivo requires further study. 
 
1.7 11β-HSD1 inhibition and atherosclerosis. 
Treatment of ApoE-/- mice, which are susceptible to ‘western’ diet induced 
atheroma, with 11β-HSD1 inhibitors protects against the development of 
atherosclerosis (Hermanowski-Vosatka et al., 2005). Since a decrease in 
atherosclerosis is more pronounced than might be expected by the serum lipid-
lowering effect, it raises the possibility that the additional factors may play a role. 
The inflammatory component of atherogenesis involves monocyte accumulation, 
differentiation into macrophages and foam cell formation. As atherosclerotic lesions 
advance, macrophages increasingly take up oxidized lipoproteins and vascular wall 
cells secrete inflammatory cytokines, growth factors and adhesion molecules which 
together contribute to the formation of advanced lesions. 11β-HSD1 is expressed in 
both vascular smooth muscle cells, perhaps endothelial cells (Cai et al., 2001, 
Hatakeyama et al., 2001), differentiated macrophages (Gilmour et al., 2006b, 
Thieringer et al., 2001), and is up-regulated by inflammatory cytokines providing a 
local mechanism to control inflammation (Cai et al., 2001). However, by analogy 
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with the peritoneum, deficiency of 11β-HSD1 should exacerbate inflammation, 
potentially worsening disease. Alternatively 11β-HSD1 in inflammatory cells may 
impact upon their infiltration, proliferation and differentiation, which may be 
enhanced by glucocorticoids in the physiological range (Chapman et al., 2006a). In 
this case, inhibition of the enzyme might be advantageous in the developing 
atherosclerotic lesion. 
 
Another important possible indication for 11β-HSD1 inhibitors is associated with the 
ability of glucocorticoids to enhance angiogenesis (Small et al., 2005). In vitro and in 
vivo studies demonstrated that 11β-HSD1, by locally amplifying glucocorticoid 
action in the vessel wall, tonically represses angiogenic responses. Moreover, seven 
days after coronary artery ligation 11β-HSD1-/- mice show increased vascularisation 
in the infarcted myocardium, associated with partial protection against myocardial 
dysfunction (Small et al., 2005). Effects of 11β-HSD1 inhibition on pathological 
neovascularisation, for instance in the diabetic eye, and in cancers and metastasis 
remain to be determined, but are potential toxicities. 
 
1.7.1 A novel role of 11β-HSD1 in the metabolism of oxysterols. 
One of the alternative pathways of bile acid synthesis, initiated by sterol 27-
hydroxylase (CYP27; 27-OHase) and characterized in a syndrome called 
cerebrotendinous xanthomatosis (Fujiyama et al., 1991), involves the conversion of 
7KC to 7β-HC. This syndrome, clinically presenting with early development of 
atherosclerosis, is caused by a mutation in 27-hydroxylase and is associated with an 
increased level of 7KC in the plasma. Hence it has been hypothesised that dietary 
7KC is metabolised in the liver exclusively by 27-OHase. However, contrary to 
expectations, when Lyons et al. constructed 27-OHase-/- mice they detected 
increased metabolism of 7KC compared with wild- type controls (Lyons et al., 
2002). This suggested the existence of an additional pathway of 7KC metabolism in 
the liver. This was supported by Song et al. who confirmed that an NADP+-
dependent 7α-hydroxycholesterol dehydrogenase in hamster microsomes generating 
7KC as a product belonged to the 11β-hydroxysteroid dehydrogenase family and had 
high specificity for corticosterone, cortisol and 7α-hydroxycholesterol (Song et al., 
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1998). It was likely this was the major hepatic route of metabolism of dietary 7KC. 
Furthermore, a non-specific 11β-HSD1 inhibitor (carbenoxolone) caused almost 
complete inhibition of 7-oxysterol metabolite formation in hepatic microsomes (Hult 
et al., 2004). The novel role of 11β-HSD1 in the metabolism of 7-oxysterols showed 
high species-specific dependence of products (Schweizer et al., 2004, Maeda et al., 
2002, Song et al., 1998). Schweizer et al. demonstrated the stereo-specific inter-
conversion of 7KC and 7β-HC by rat and human 11β-HSD1 (Fig.1.3), whereas the 
hamster enzyme inter-converted 7α-, 7β-HC and 7KC (Schweizer et al., 2004). 
 
7-oxygenated forms of cholesterol are present in the plasma (Corradini et al., 2005, 
Iuliano et al., 2003, Zieden et al., 1999), with much higher concentrations in foam 
cells and atherosclerotic plaques (Schroepfer, 2000). Thus, 11β-HSD1 plays an 
apparent role in the clearance of highly atherogenic 7KC to more soluble 7β-HC 
(Schweizer et al., 2004). Whether or not loss of this reaction contributes to the 
beneficial effects of 11β-HSD1 inhibition in atherosclerotic plaque formation 
remains unclear. In this thesis I tested the hypothesis that these cholesterol 
metabolites might act through liver X receptor (LXR) or farnesoid X receptor (FXR) 
pathways. The review of literature describing the role of these nuclear receptors in 
cholesterol and lipid metabolism and their hypothetical association with 11β-HSD1-
dependent conversion of oxysterols will be discussed in detiles in the introduction to 






Figure 1.3 Schematic representation of 11β-HSD1-dependent conversion of 7KC to 7β-HC.  
7-hydroxycholesterol is a major product of cholesterol peroxidation, however, being very 
unstable it undergoes a rapid conversion to 7KC and 7β-HC. 11β-HSD1 dependent 
conversion of 7KC to 7β-HC is the first example showing that these highly atherogenic 





The primary aim of this thesis was to study the fat depot-specific effects of 11β-
HSD1 deficiency on adipose tissue gene expression. Given recently reported novel 
role of 11β-HSD1 in the metabolism of 7-oxysterols the possible impact of non-
glucocorticoid mediated pathways was investigated.  
 
The following list of aims was addressed: 
 
1) To establish whether 11β-HSD1 converts 7-oxysterols in adipocytes and to study 
the mutually competitive metabolism of glucocorticoids and oxysterols. 
 
2) To investigate the potential implication of 11β-HSD1 in activation of LXR and 
FXR dependent pathways.  
 
3) To map the key pathways downstream of 11β-HSD1 in both peripheral 
(subcutaneous) and visceral (mesenteric) adipose depots using micro-array and bio-
informatics techniques. 
 
4) To characterize depot-specific mechanisms of 11β-HSD1 deficiency leading to 
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2 Materials and Methods 
2.1 Introduction 
Unless otherwise stated all chemicals, reagents and drugs were purchased from 
Sigma-Aldrich, UK. 7KC, 7β-HC and chenodeoxycholic acid (CDCA) were from 
Steraloids, [1,2,6,7-H3]-corticosterone, [1,2,6-H3]-KC from Amersham Pharmacia 
Biotech (Aylesbury, UK). 11-[1,2,6,7-H3]-Dehydrocorticosterone was prepared as 
described previously though conversion of [1,2,6,7- H3]-corticosterone by 11β-HSD 
2 from rat placenta (Brown et al., 1993). All HPLC grade solvents were purchased 
from Rathburn Chemicals (Walkerburn, UK). All enzymes for molecular biology 
were purchased from Promega (Southampton, UK). Anti-IRS-1 was obtained from 
Upstate Biotechnology, Inc. (Lake Placid, NY, USA). Anti-Akt, Anti-Phospho-Akt 
(Ser 473), Anti-Phospho-Tyrosine and Anti-rabbit and Anti-mouse IgG were from 
Cell Signaling Technology (Beverly, MA, USA). Protein A-Sepharose was from 
Amersham Biosciences (Little Chalfont, UK). NuPAGE 4-12% Bis-Tris Gel and 
nitrocellulose Membrane were purchased from Invitrogen (Paisley, UK). Human 
recombinant insulin was purchased from Eli Lilly and Co. (Windlesham, UK). 
Routine reagents were obtained from Sigma Aldrich (Suffolk, UK) unless specified 
elsewhere.  
 
2.2 Buffers and Solutions 
 
Alkaline SDS solution 0.2M NaOH, 1% w/v SDS 
Borate Buffer 8.25g boric acid, 2.7g NaOH, 3.5ml conc. HCl and 5g BSA made up to 
1litre with distilled water, pH 7.4. Stored at -20°C and thawed at room 
temperature immediately before use. 
C buffer 63g glycerol, 8.77g NaCl, 186mg EDTA, 3,03g Trizma base in 500ml 
dH2O. pH adjusted to 7.7 
Caesium Chloride/TE 
solution 
100g CsCl dissolved in 100ml TE buffer (see below) 
Calcium-free Buffer Krebs buffer (see below) without CaCl2
DEPC-treated water Distilled water mixed with diethylpyrocarbonate (DEPC; 300µl/ 100 
ml), shaken and left for 1-24 h prior to autoclaving 
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1Kb DNA ladder 20µg 1Kb ladder (Life Technologies, Paisley, UK), in 200µl distilled 
water with 10% (v/v) loading buffer 
0.5M EDTA (pH 8.0) 800ml water was added to 186.1g Na2EDTA.2H2O. pH was adjusted to 
8.0 with NaOH and the volume adjusted to 1000ml 
GTE 50mM glucose, 25mM tris (hydroxymethyl)-aminomethane (tris), 
10mM EDTA, pH8.0 
5M K acetate 3M potassium, 5M acetate. 60 ml of K acetate and 11.5 ml of glacia 
acetic acetate were diluted in 28.5 ml depH2O 
Krebs’-Ringer Bicarbonate 
(KRB) Buffer 
118mM NaCl, 3.8mM KCl, 1.19mM KH2PO4, 2.54mM CaCl2, 1.19mM 
MgSO4, 25mM NaHCO3 in distilled water, pH 7.4. Stored at 4°C and 
supplemented with 0.2% w/v glucose immediately before use 
LB agar Luria-Bertoni broth with 15g agar per litre broth added before 
autoclaving 
Loading buffer 40% sucrose w/ v, 0.25% bromophenol blue (w/v) in distilled water 
Luria-Bertoni broth 10g bactotryptone, 5g bacto yeast extract, 5g NaCl made up to 1 litre 
with distilled water and autoclaved immediately 
Luciferase assay buffer 40mM Tricine, 67mM DTT, 0.2mM Na2EDTA.2H2O, 2mM MgSO4, 
0,25mM coenzyme A, pH 7.8 
Lysis buffer 25mm Tris phosphate pH 8.0, 2mM DTT, 1% Triton X-100, 10% 
glycerol 
Oil Red O 0.5g of oil red O in 100 ml isoproplanolol 
4% Paraformaldehyde in 
0.1M phosphate buffer 
20mM NaH2PO4, 80mM Na2HPO4 in 1l DEPC-treated water, heated to 
80°C prior to addition of 40g paraformaldehyde. Stirred for 1 hour to 
dissolve and stored at 4°C 
Phosphate Buffer 0.2M NaH2PO4 0.6M Na2HPO4, 5mM EDTA. Autoclaved before use 
Phosphate buffered Saline 
(PBS) 
0.1M phosphate buffer, 0.0027M KCl, 0.137M NaCl in distilled water, 
pH 7.4, autoclaved before use. Obtained by dissolving 1 tablet per 200 
ml water (Sigma) 
10x Reverse Transcription 
buffer 
0.1M Tris-HCl, 0.5M KCl, 1% Triton X (ready mixed from Promega) 
RNase Buffer 0.5M NaCl, 10mM Tris-HCl, 1mM K2-EDTA in 10ml distilled water 
20x Saline Sodium Citrate 
buffer (SSC) 
3M NaCl, 0.3M Na citrate in 1l DEPC-treated water, pH 7.0, 
autoclaved before use 
Sodium Phosphate Buffer 40mM NaH2PO4, 0.32M sucrose, 1mM DTT 
Sucrose buffer 250mM sucrose, 10mM Hepes, pH7.5 
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10xTBE buffer: 0.9M Tris, 0.9M Boric acid, 20mM EDTA in distilled water 
Tris-EDTA (TE) buffer 10mM Tris-HCl, 1mM EDTA, pH 7.5, autoclaved before use 
Thermophilic DNA 
polymerase 10x reaction 
buffer 




200mM Tris-HCl, 50mM NaCl, 30mM MgCl2, and 10mM spermidine 
(ready mixed from Promega) 
 
Table 2.1 List of buffers and solutions  
 
2.3 Animals  
Male C57BL/6J mice (Charles River, UK) were obtained at 4-6 weeks of age. 
Animals were housed in 7.696 litre (16cm wide, 37cm long and 13cm high) cages 
and maintained under controlled conditions of light (12-h light/120h dark cycle: 
lights on 07:00h–20:00h) and temperature (21-22°C), and allowed free access to 
drinking water and standard chow (Special Diet Services, Witham, UK) or 
specifically designed high fat diets (see below). Mice homozygous for a targeted 
disruption of the 11β-HSD1-/- gene have been described elsewhere (Kotelevtsev et 
al., 1997). The disrupted 11β-HSD1 allele (originally on a 129/OLA background) 
has been rederived onto a C57BL/6J background. All experiments conformed to 
ethical codes of the University of Edinburgh and Home Office (UK) regulations 
according to the Animals (Scientific Procedures) Act 1986. Experiments using 
animals were performed under the Prof. Jonathan Seckl’s Programme Licence and 
my own Personal Licence (2004-2009). As a requirement of the Home Office I 
obtained appropriate qualifications by attending the Animal Handling Course 
organized by the University of Edinburgh in September 2004.  
 
2.3.1 Genotyping  
Genomic DNA was extracted from tails of 11β-HSD1-/- mice using Tissue 
Nucleospin Macherey-Nagel kit (Dueren, Germany) according to the manufactures 
instructions. DNA was diluted 1:50 in water. 2µl of diluted DNA were added per 
tube for PCR reaction. Three following primers were used: oligo ex13f1: 5’-TTC 
TTC GTG TGT CCT ACA GG-3’, oligo ex13r1: 5’-CCC GCC TTG ACA ATA 
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AAT TG-3’, Yuri2oligo4: 5’-CAC TGC ATT CTA GTT GTC GTT TGT CC-3’. 
PCR was performed according to the following protocol: 34 cycles of denaturation in 
95º for 5 min, annealing in 53º for 1 min and extension in 72º for 3 min. 
 
2.3.2 High fat diet experiments 
11β-HSD1-/- mice and their congenic controls were fed a chow or high fat diet 
(research diet-R12331-w/sucrose and 58% of calories as saturated fat-hydrogenated 
coconut oil, previously optimized for weight gain and insulin resistance (Black et al., 
1998)) for 4 or 10 weeks, as indicated for particular experiment. Animal weight and 
food intake were recorded weekly.  
 
2.3.3 Animal sacrifice and harvesting of tissues. 
At the end of study period animals were fasted for 6 h to obtain plasma for fasting 
glucose and insulin measurements. In all experiments mice were killed by 
decapitation in an adjacent room at around 2:00 pm within 1 min of disturbing each 
cage to minimize stress to the animals. Trunk blood was collected in EDTA-tubes 
and plasma prepared by centrifuged (13000rpm, 10mins, 4ºC) which was then snap 
frozen on dry ice in Eppendorf tubes, and stored at -80ºC. White adipose tissue 
(WAT) was dissected post mortem from thigh and axillary (subcutaneous) and 
mesenteric depots (intra-abdominal) then frozen rapidly in liquid nitrogen for insulin 
signaling studies or on dry ice for RNA extraction.  
 
2.3.4 Plasma assays 
2.3.4.1 Plasma insulin measurement  
Fasting insulin concentrations in plasma was measured using Ultra sensitive rat 
insulin ELISA kit (Crystal Chem, IL, USA). This assay works according to 
principles of Enzyme-Linked ImmunoSorbent Assay. In the first phase a sample of 
mouse plasma containing insulin was applied on a microplate 96 well plate coated 
with guinea pig anti-insulin antibody and incubated for 2 h in 4ºC to allow binding. 
Unbound material was removed by washing in washing buffer. In the second reaction 
the horseradish peroxidase-conjugated anti-insulin antibody was bound to the guinea 
pig anti-insulin antibody/mouse insulin complex immobilized on the microplate well. 
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Again the excess of material was removed by washing. In the final step the bound 
horseradish peroxidase conjugate was detected by the addition of 3,3’,5,5’-
tetramethylbenzidine (TMB) substrate solution. The insulin concentration was 
determined by measuring the absorbance at a wavelength 450nm subtracting 
wavelength: 630nm and calculating the insulin concentration according to the 
standard curve. 
 
Reagent supplied in the kit: antibody-coated microplate, mouse insulin standard, 
anti-insulin enzyme conjugate stock solution, enzyme conjugate diluent, enzyme 
substrate solution, enzyme reaction stopping solution, sample diluent, washing buffer 
stock solution. A standard curve was constructed by preparing serial solutions from 
rat insulin stock solution (10000 pg/ml) by dilution in Diluent 2 and represented a 
range of concentrations of insulin (0, 156, 313, 625, 1250, 2500, 5000, 10000 pg/ml).  
 
2.3.4.2 Plasma glucose measurement  
Quantification of plasma glucose was performed using Infinity™ glucose hexokinase 
reagent (ThermDMA, CO, USA), which works according to the hexokinase/glucose-
6-phosphate method and enables the measurement of produced NADPH 
proportionally to the amount of glucose in the sample. Glucose concentration was 
determined according to the standard curve. 2µl of plasma were diluted in 200µl 
reagent and incubated for 3 minutes in 37ºC. The absorbance was measured in 
340nm. 
 
2.3.4.3 Plasma corticosterone measurement in radioimmunoassay (RIA). 
Samples were diluted 1:10 in borate buffer and denaturated by incubation for 30 
minutes at 75ºC. Assays were performed in 96-well plates. 20µl of sample and 50µl 
of mix containing labeled tracer antigen (³H-corticosterone diluted in borate buffer 
and anti-corticosterone antibody) were added per well. Plates were left to equilibrate 
for 1h at room temperature. In order to separate antibody-bound from free tracer, 
50µl of SPA beads (Amersham, UK) was added per well and left for 24 h incubation 
at room temperature. Radioactivity was detected by β-counter (Liquid Scintillation 
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igure 2.1 Example of the standard curve for corticosterone measurement in 
adioimmunoassay (RIA). 
 axis represents concentration of corticosterone in nM, Y axis represents average 
easurement of radioactivity counts measured by β-counter. 
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2.4 Cell cultures 
2.4.1 Reagents  
 
Dulbecco’s Modification of Eagle’s Medium (DMEM) 
New Born Calf Serum (NBCS) 




Bovine Serum Albumin (BSA) 
GIBCO, Invitrogen (Life Technologies) 
GIBCO, Invitrogen (Life Technologies) 
GIBCO, Invitrogen (Life Technologies) 
GIBCO, Invitrogen (Life Technologies) 
GIBCO, Invitrogen (Life Technologies) 
GIBCO, Invitrogen (Life Technologies) 
GIBCO, Invitrogen (Life Technologies) 
60 mm plate dishes w/poly-D-lysine 
6 well plastic plates 
6 well plastic dishes w/collagen I 
12 well plastic dishes w/collagen I 
Becton and Dickinson 
Becton and Dickinson 
Becton and Dickinson 
Becton and Dickinson 
75 cm2 cell culture flasks 
5, 10, 25 ml sterile pipettes 
Cornig BV (Costar labs) 
Cornig BV (Costar labs) 
15, 50 ml Falcon tubes Greiner Bioone 






Sigma-Aldrich Company Ltd 
Sigma-Aldrich Company Ltd 
Sigma-Aldrich Company Ltd 
Sigma-Aldrich Company Ltd 
Sigma-Aldrich Company Ltd 
Sigma-Aldrich Company Ltd 
 
Table 2.2 List of reagents used for cell cultures.  
 
2.4.2 Cells 
Murine 3T3-F442A cells were a gift from Prof. Bruce Spiegelman’s Laboratory 
(Harvard University, USA). The original stock was passaged into various flasks and 
stored in liquid nitrogen. Murine 3T3-L1 cells were purchased from American Type 
Cell Collection (ATCC, LGC Promochem, UK) passaged into various flasks and 
stored in liquid nitrogen for future usage. HEK 293 (human embryonic kidney) cells 
were a gift from Dr Scott Webster (Univerity of Edinburgh, UK). 
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2.4.3 Maintenance of cells in culture  
3T3-F442A and 3T3-L1 cells were maintained in 75 cm 2 flasks at 37°C with 5% 
CO2, 95% O2 in Dulbecco’s minimal essential medium (DMEM) supplemented with 
10% heat-inactivated new born calf serum, penicillin /streptomycin (100µg/ml) and 
L-glutamine (2mM). Cells were passaged every two days (until 70% confluent). 
HEK 293 cells were cultured in 75 cm 2 flasks coated with poly-D-lysine in DMEM 
supplemented with 10% heat-inactivated foetal calf serum, penicillin /streptomycin 
(100µg/ml) and L-glutamine (2mM). Cells were routinely split 1:4 when confluent. 
 
To harvest and split cells, they were washed with serum-free DMEM (8ml), then 
treated with trypsin/EDTA (5ml) for 1-2 min to release the cells from the flask 
surface. Trypsin was inactivated by the addition of culture medium containing serum 
and the cells diluted into new flasks or into culture plates. 
 
2.4.4 Differentiation of 3T3-F442A and 3T3-L1 preadipocytes into adipocytes  
Preadipocytes were differentiated in 6 or 12 well plates coated with collagen I (BD 
Bioscience). 1x105 cells per well in DMEM supplemented with 10% heat-inactivated 
foetal calf serum, penicillin /streptomycin (100µg/ml) and L-glutamine (2mM) were 
plated. Two-day post-confluent medium from the culture of 3T3-F442A cells was 
changed for the differentiation medium (DMEM supplemented with 10% fetal 
bovine serum (FBS), antibiotics, glutamine) with the addition of 5µg/ml insulin. The 
media were changed every second day. Experiments were performed on day 7 to 10 
of differentiation. 
 
3T3-L1 cells were differentiated as previously described (Stulnig et al., 2002). Two 
days post-confluent cells were incubated for two days in DMEM medium enriched 
with 10% FBS, 1% antibiotics, 1% glutamine, 0.5 µM dexamethasone, 200 µM 3-
isobutyl-1-methylxanthine and 1µg/ml insulin and then for three days in medium 
supplemented with 1µg/ml insulin. Experiments were performed on day eight. 
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2.4.4.1 Oil Red O staining  
On day 7 cells were stained with Oil Red O and hematoxyline-ammonium water to 
visualize the lipid droplets and justify the end point of differentiation. The medium 
was aspirated and cells were washed with PBS and fixed with 4% paraformaldehyde. 
6 ml of Oil Red O stock solution were added to 4 ml depH2O and the solution was 
filtered through a Whatman filter paper. 1ml of Oil Red O solution was added per 1 
well of culture 6-well plate, incubated for 15-30 min and then washed with water. In 
further experiments the detection of lipid droplets as an indicator of differentiation 
was determined by phase contrast microscopy.  
 
2.4.4.2 Trypan Blue staining 
Cells pellets were ressuspended in 1ml of PBS. 10µl of cells were added to the same 
volume of 0.4% Trypan Blue for 5min. 5µl was then transformed to a 
haemocytometer with a pipette by capillary action with cover-slip in place. Stained 
(blue) and not stained (transparent) cells were counted in the 16 sub-squares in each 
of the haemocytometer chambers. Staining indicated dead cells and the ratio was 
calculated dividing this number by total cell number and multiplying by 100. To 
calculate total cell number cells were counted according to the following equation: 




2.5.1 11β-HSD1 activity assay 
The 11β-HSD1 activity assays were performed by incubating intact cells in 12-well 
plates with 1ml of serum-free culture media containing 200nM corticosterone (oxo-
reductase) and 5nM [1,2,6,7-H3]- corticosterone as a tracer or the same 
concentrations of 11-dehydrocorticosterone (dehydrogenase) and 11-[1,2,6,7-H3]-
dehydrocorticosterone. The incubation was carried out in serum- and steroid-free 
medium in 37˚C for 4 h. After incubation, media was transferred to a glass tube and 
steroids were extracted with 3ml of ethyl acetate. The aqueous phase was removed 
and organic phase was evaporated. The dried etheric extracts were then resuspended 
in 45µl of ethanol and transferred to silica gel-precoated plastic sheets (Merck, 
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Darmstadt, Germany) for thin-layer chromatographic separation of precursor and 
product in the solvent system chloroform:ethanol (92:8 by vol) (BDH Laboratory 
Supplies, Poole, Dorset, UK) and quantitated after 48 h incubation using a 
phosphorimager (Fuji FLA-2000, Raytek Scientific Ltd, Sheffield, UK). All 
experiments were carried out in triplicate. Enzymatic activity was expressed as 
percentage total radioactivity [(product cpm/substrate cpm+product cpm)x100] after 
correction for values from control (no cell) incubations. 
2.5.2 Conversion of oxysterols 
A well established protocol for the measurement of glucocorticoid conversion in the 
11β-HSD1 activity assay was used in the primary development of the 7-oxysterol 
conversion assay. 3T3-F442A fully-differentiated adipocytes were incubated with 
7KC diluted 1:1000 from ethanol stocks in the medium to final concentrations of 
5µM, 500nM and 50nM. Different time points ranging from 1 to 24 h were tested. 
Initially, I attempted to detect the potential product of 7KC conversion in the 
medium (by analogy to glucocorticoids) using a previously established method of 
HPLC analysis with UV detector (Wamil et al., MSc project 2005, University of 
Edinburgh, unpublished). 40µl of each terminated enzymatic reaction was analyzed 
for conversion by HPLC with a C18 column (Symmetry Shield, 15cm, 4.6mm, 5µm 
pore size, Waters, UK). The system was controlled by the Winflow computer 
programme (JMBS Developments, France). Individual experiments were carried out 
in duplicates with single data points. The mobile phase was acetonitrile/water 
(90:10). The 7KC and 7β-HC absorption were measured at 241nm and 195nm, 
respectively. The amount of product formed was determined by comparison to 
standard curves of authentic 7-oxo-cholesterol derivatives using 5α-cholestanol as an 
internal standard.  
 
The following methods of oxysterol extraction were tested:  
1) Steroids in medium were recovered by solid-phase extraction. Samples of culture 
medium with 7KC from incubation experiments, control medium and standard media 
with 7-KC and 7β-HC were purified through Sep-pak C18 cartridges (Water, Herts, 
UK) according to the manufacture instructions. Columns were washed with 5ml of 
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methanol and 5ml HPLC grade water prior to sample injection and with 5ml water 
after sample application. 2 ml of methanol was used to elute the extracted oxysterols. 
The eluant was dried under a stream of oxygen-free nitrogen at 60°C and 
resuspended in 2ml petroleum ether and 200µl water. This step was repeated 3 times. 
The upper layers were evaporated and resuspended in 500µl of mobile phase (95% 
acetonitrile, 5% water) and prepared for HPLC analysis.  
2) Samples of culture medium with 7KC from incubation experiments, control 
medium and standard media with 7-KC and 7β-HC were mixed with 3 volumes of 
following solvents: petroleum ether, methanol, hexane: iso-proplanolol (2:3 v/v), 
dichloromethane, centrifuged and the upper layers (the bottom layer in case of 
dichloromethane) were taken into new tubes, evaporated and prepared for HPLC 
analysis. 
 
As little as 1-10% of oxysterols added to the medium, either in standards or in tested 
samples, was recovered using the above methods. Secondly, I tested the efficiency of 
oxysterol extraction by increasing the volume of solvents used as an organic phase. 
The recovery from the medium was improved to 50-70% by using 6 volumes of 
dichloromethane. 
 
Optimization of assay conditions: 
In order to investigate whether the observed decrease in the concentration of 7KC 
was caused by degradation, the radio-labeled form of 7KC was used in following 
experiments. Firstly, quantification of the amount of radioactivity in the medium and 
in the cellular pellet (after different time points of incubation with 7KC) was 
performed using Liquid Scintillation Analyzer. This showed that the measured 
decline of radioactivity in the medium could be explained by its accumulation in the 
cellular pellet. Moreover, there was no adherence of oxysterols, either to plastic or to 
glass pipettes and plates. It was confirmed that [1,2,6-H3]-KC had been transported 
through the cell membrane in a linear manner over the time course (Fig. 3.2.). 
Interestingly, after 24h incubation all radioactivity counts were accumulated in the 
cellular pellet with very little remaining in the medium (<17%). Based on these 
findings, the optimal conditions of oxysterol recovery from cell lysates were 
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established. Extraction from lysis buffer using the ethyl acetate as an organic phase 
showed the highest rate of recovery of added radioactive 7KC (90%). Conditions for 
TLC analysis of metabolites using the solvent system 2:3 (v/v) hexane: ethyl acetate 
to separate radio-labeled 7KC and the product of its conversion-7βHC were also 
established. 
 
Experiments were performed according to the following protocol: 
Conversion of [1,2,6-3H]-KC was studied in 3T3-F442A cells. Culture medium 
containing substrate 7KC (5µM, 500nM), including 0.5 µCi [1,2,6-3H]-KC, was 
added to each well. Stocks of sterols were diluted in 100% ethanol and used in 
1:1000 dilutions in culture media. Aliquots were removed at 1, 2, 5 and 24 h. All 
incubations were in triplicate. Incubation was for 24 h at 37ºC in a humidified tissue 
culture incubator gassed with 95% air-5% CO2. Media from individual wells were 
then pipetted into glass tubes, to which 6ml dichloromethane was added and the 
samples were vortexed for 1min. Cells were washed with 1ml PBS, centrifuged for 5 
min at 2000rpm and resuspended in an appropriate volume (100-300 µl) of lysis 
buffer (300 mM NaCl, 50mM Tris-HCl, 1mM EDTA, 5% glycerol, 5% Triton X-
100, pH 7). Lysates were incubated for 10 min at 37˚C. Oxysterols were extracted by 
adding 3 ml of ethyl acetate to the lysis buffer. The organic phase was removed to the 
fresh tube and solvent evaporated under oxygen free nitrogen at 50°C. Oxysterol 
extracts were resuspended in mobile phase consisting of water (15%) and acetonitrile 
(85%) and injected into the HPLC system with radioactivity detector (LD509 
Berthold absorbance detector), using a Sun Fire C18 column (15 cm, 4.9 µm particle 
size; Waters, Macclesfield, UK). A flow rate of 1.0ml/min and a column temperature 
of 40°C allowed the best resolution of the metabolites. Non-radioactive 7-oxysterol 
standards were employed to optimize resolution conditions with an on-line dual 
wavelength absorbance UV detector in HPLC using C18 column (Symmetry Shield, 
15cm, 4.6mm, 5µm pore size, Waters, UK). The wavelength of UV detection was 
determined by the structural characteristics of the analytes similar to the previous 
conditions (Wamil et al, 2005, MSc manuscript, University of Edinburgh, 
unpublished). The percent conversion of substrate to product was calculated by the 
measurement of peak areas. Assays were performed in duplicate and also without 
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cells as controls. 7β-HC and 7KC were detected at retention times 28 and 32 
minutes, respectively. No additional products of 7KC conversion were observed, 
either by HPLC or by TLC. The complete inhibition of the 7-oxysterol conversion by 
the selective 11β-HSD1 inhibitor was used as a control for autoxidation during 
sample preparation. Additionally, in samples, in which 11β-HSD1 has been heat 
inactivated, no product of the reaction was present. 
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Ethyl acetate 3:1 (v/v)  
50-70% recovery 
Dichloromethanol 6:1 (v/v) 
4 
 
Figure 2.2. Schematic representation of the protocol used for experiments investigating 7-
oxysterol conversion in adipocytes. 65
 
2.6 Recombinant DNA techniques 
2.6.1 Bacterial transformation 
For cloning of DNA, Escherichia coli HB101 cells (Promega, Southampton, UK) 
were grown in 100ml of Luria-Bertoni (LB) broth at 37°C in a shaking incubator 
until they reached mid-log phase. They were then centrifuged at 1000 x g for 5min at 
4°C (Heraeus, Germany), the pellet re-suspended in 20ml cold calcium chloride 
(0.1M) and left on ice for between 10min and 2h. The centrifugation step was 
repeated to re-pellet the cells and the cells were re-suspended in 2ml cold calcium 
chloride (0.1M). The competent cells were stored on ice at 4˚C for up to 4 days 
before transformation. 
 
200µl of competent cells was mixed with 50ng plasmid DNA and left on ice for 20-
30 min. To incorporate the plasmid DNA into the competent cells they were 
subjected to 42°C for 50s and placed back on ice for 2-3 min. The cells were spread 
onto LB agar plates containing ampicillin (100µg/ml) to allow only the grow of 
colonies containing incorporated DNA. The plates were left to dry and then they 
were incubated for 16 h at 37°C. Plates with transformed colonies were stored at 4˚C. 
 
2.6.2 Plasmid DNA preparation 
Following transformation, single colonies were picked and used to seed 5ml of LB 
containing ampicillin (100µg/ml). After 8h incubation in a rotating incubator at 
37°C, cultures were transferred into 500ml LB broth (containing 100µg/ml 
ampicillin) and shaking overnight in a 2l flask at 37°C. The resulting culture was 
pelleted by centrifugation at 6000 rpm for 5min at 4°C (Heraceus, Germany) and the 
pellets resuspended in ice-cold GTE (12ml) mixed with 24ml of fresh alkaline-SDS 
and incubated on ice for 5 min before the addition of 16ml of ice-cold 5M K acetate. 
The mixture was centrifuged at 6000 rpm for 10min. The mixture was filtered 
through two layers of sterile gauze into fresh centrifuge pots containing 32ml 
isopropanol and left at room temperature for 30min to precipitate the DNA. DNA 
was recovered by centrifugation at 10000 rpm in a Beckman J20 rotor for 5min at 
4˚C. The pellet was dried and resuspended in 2.2ml TE buffer, 2.95g of CsCl was 
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added and dissolved and then ethidium bromide (100µl, 10mg/ml) was added. The 
mixture was transferred to Beckman Quickseal ultracentrifuge tubes, topped up with 
1g/ml CsCl/TE solution and the volume adjusted to balance tubes. They were then 
centrifuged at 70000 rpm for 17h at 20°C in a Beckman J20 rotor. The DNA was 
separated into bands that could be visualised by the pink colour of the ethidium 
bromide. These DNA bands were removed using a 21gauge needle and syringe, 
transferred to fresh ultracentrifuge tubes, topped up with 1g/ml CsCl/TE solution and 
centrifuged at 100000 rpm for 4h at 20°C. The DNA bands were collected as above 
and the ethidium bromide was removed by extracting repeatedly with equal volumes 
of isopropanol until the pink colour disappeared. The supernatant was removed and 
the pellet was washed with 70% ethanol. The DNA was transferred to dialysis tubing 
and dialysed against three changes of TE buffer. The concentration and purity of the 
recovered plasmid DNA was measured spectrophotometrically using a GeneQuant 
RNA/DNA Calculator (Pharmacia Biotech, Sweden). DNA was diluted 1:100 in 
DEPC-treated water and the optical density at λ260nm and λ280nm was determined. 
Plasmids were stored at -20°C. 
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2.7 RNA extraction and analysis 
2.7.1 Materials 
RNA extraction  
RNeasy Lipid Tissue Midi kit Qiagen 
Trizol Invitrogen 
Rnase Plus Bio 101 matrix  
RNA wash concentrate 
Anachem 
Anachem 
Dithiothreitol (DTT) Sigma-Aldrich Company Ltd 
Reverse Transcriptase Invitrogen 
SuperScript III kit 
Dnase amlification Grade 
Invitrogen 
PCR reaction Promega 
1.5mM MgCl2 Promega 
AmpliTaq Gold 
Taqman Real Time Assays 
Applied Biosystems 
Invitrogen 
Oligonucleotid primers for RT-PCR 
dNTPs 
Invitrogen 
396 well plates Promega 
Ultra pure Rnase, DNase free water Sigma 
 
Table 2.3 List of reagents used for RNA extraction.  
 
 
2.7.2 Primers and probes for real time PCR were designed by Applied Biosystems 




Gene Assay ID 
11β-HSD1 Mm00476182_m1 


























Table 2.4 TaqMan gene expression assays (Applied biosystems, UK) 
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2.7.3 RNA extraction from tissues and cells 
Tissues were collected from mice and frozen on dry ice immediately after dissection 
and stored at –80˚C until required. To obtain the best quality material for micro-array 
experiments RNA from adipose tissues was extracted using RNeasy Lipid Tissue 
Midi kit according to the manufacture’s instructions (Qiagen, UK). 
 
In order to extract RNA from cells, the medium was removed, and cells were washed 
with 1ml of PBS and 1ml of Trizol (per well of a 6 well plate). Cells were 
resuspended by pipetting up and down, collected in eppendorfs and immediately 
frozen on dry ice. Due to the inherent instability of RNA, special care was applied 
when working with it to avoid degradation by ribonucleases.  
 
RNA extraction was carried out using Trizol Reagent (Invitrogen, UK)-a mono-
phasic solution containing phenol and guanidine isothiocyanate. This reagent 
maintains RNA integrity whilst disrupting cells and dissolving cell components. 
 
2.7.3.1 Homogenization 
Trizol was added and samples were homogenized using an Ystral mechanical 
homogeniser (Scientific Instruments Centre, UK) at maximal speed. To remove 
insoluble material and small amounts of unhomogenized tissue samples were 
centrifuged at 12000 rpm at 4°C for 10min The supernatant was removed to a fresh 
eppendorf.  
 
2.7.3.2 Phase Separation 
Following homogenisation, samples were allowed to equilibrate to room temperature 
then left for 5 minutes to allow complete dissociation of the nucleoprotein 
complexes. For cell experiments, apart from homogenisation the same protocol was 
followed as for homogenised tissue. 0.3ml chloroform per 1ml Trizol was added to 
each sample and vortexed for 15s. Samples were left on ice for 15 min and then 
centrifuged at 12000 rpm at 4°C for 15min resulting in a lower red phenol-containing 
phase (containing proteins), an interphase (containing DNA and denatured proteins) 
and an upper aqueous phase containing RNA.  
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2.7.3.3 RNA Precipitation 
The upper aqueous phase from each sample was transferred into a fresh eppendorf 
and the RNA was precipitated by addition of 30µl RNaid Plus Bio 101 matrix 
(Anachem, UK). To allow binding of RNA to the RNA matrix samples were shaken 
at room temperature for 3min and then incubated at room temperature for 10min and 
then centrifugated at 12000 rpm at 4°C for 10min. 
 
2.7.3.4 RNA Wash 
Following centrifugation the supernatant was removed and the RNA pellet was 
washed with RNA wash concentrate diluted by the addition of 30% v/v absolute 
ethanol. The wash was repeated three times. 
 
2.7.3.5 RNA Resuspension 
Following the RNA wash, the ethanol was removed and the pellets were briefly air-
dried for 5min. RNA pellets were dissolved in 20µl DEPC-treated water containing 
10mM DTT and 400U/ml RNAse inhibitor and incubated at 55°C for 12min. 
Samples were vortexed after 6 min of incubation. Then samples were immediately 
centrifuged 13000 rpm at 4°C for 2min. Supernatant was aliquoted in three 
eppendorfs (6µl) and stored at -80°C. 
 
2.7.3.6 RNA quality and integrity 
RNA concentration and purity was assessed using a GeneQuant RNA/ DNA 
Calculator (Pharmacia Biotech, Sweden). RNA was diluted 1:100 in DEPC-treated 
water and the optical density at wavelength 260nm and 280nm was determined to 
assess concentration and purity. RNA was only used with a λ260/λ280 of between 
1.6 and 1.9. Integrity of RNA was assessed by elecrophoresis in a 1% agarose/TBE 
gel containing 500ng/µl ethidium bromide. Visualization showed two clear bands 
corresponding to 18S and 28S rRNA. 
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2.7.4 Reverse transcriptase reaction 
The Super Script III First-Strand Synthesis System for RT-PCR has been used to 
synthesize cDNA from total RNA. The enzyme is used to synthesize cDNA at a 
temperature range of 42-55ºC. In order to remove all traces of genomic DNA 
contamination from RNA samples containing 1µg RNA were treated with DNase I, 
Amplification Grade (Invitrogen, UK), which digests single- and double-stranded 
DNA to oligodeoxyribonucleotides. Samples were then immediately preceded for 
first strand cDNA synthesis. Reactions containing 0.5µg Oligo(dT)20 primers (a more 
specific priming method which hybridize to 3’poly(A) tails), 1mM dNTP and the 
whole samples of RNA resulted from previous reaction were heated at 65°C for 
15min followed by 5min on ice to inactivate enzymes. A master mix was performed 
containing 5x First Strand Buffer (250mM Tris-HCl, 375mM KCl, 15mM MgCl2), 
0.1mM DTT, 40U RNaseOUT and 200U SuperScript III. RNaseOUT Recombinant 
Ribonuclease Inhibitor, also included in the enzyme mix, is an RNase inhibitor 
protein that safeguards against the degradation of target RNA due to ribonuclease 
contamination of the RNA preparation. 7µl was added to each sample. Reactions 
were carried out in Eppendorf thermocycler. Samples were incubated for 55min at 
50°C. Reaction was terminated by heating for 10min at 75°C. Finally, to remove the 
RNA template from the cDNA:RNA hybrid molecule after first-strand synthesis 1µl 
(2 U) of E. coli RNase H were added and samples were incubated for 20min at 37°C. 
Negative controls containing DEPC-H2O instead of enzyme or omitting RNA were 
run in parallel to determine contamination of PCR reagents.  
 
2.7.5 PCR reactions 
PCRs were carried out on an Eppendorf Mastercycler Gradient (Eppendorf, 
Germany) with a heated lid. The Invitrogen AmpliTaq system was used for PCR 
during this project. Reactions were carried out in 0.5 ml reaction tubes in a total 
volume of 20µl containing 2µl of cDNA, 2µl of 10x AmpliTaq buffer, 2µl 1.5 mM 
MgCl2, 0.1µl of dNTP, 1U AmpliTaq and 13.4µl of DEPC-H2O. Samples were 
heated to 95°C for 3min for initial denaturation, then underwent 35 cycles of PCR 
amplification (denaturation at 95°C for 45s, primer annealing at primer-specific 
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temperature for 30s and elongation at 72°C for 1min 30s). Upon completion of the 
PCR programme, samples were incubated at 72°C for a further 5min to ensure 
elongation of products to full length and chilled to 4°C prior to gel electrophoresis. 
 
2.7.6 Quantitative Real Time PCR 
mRNA expression was quantitated by Light Cycler ® 480 thermocycler (Roche, 
UK). Reactions were carried out in 396 well plates. The commercially available 
TaqMan® gene expression assays for the selected genes were purchased from 
Applied Biosystems. Triplicate reactions were carried out for each sample. Each 
reaction contained per 10µl of total volume: 2µl of diluted cDNA, 5µl of Roche 
Probe Master Mix, 2.5µl DEPC-H2O and 0.5µl appropriate assay. Mouse TATA box 
binding protein (TBP; Applied Biosystems, UK) assay was used to normalise the 
transcript levels for all chosen genes. In preliminary experiments TBP, 18S and actin 
were used to confirm the relevance of internal standard. Hence the expression levels 
of TBP were in the same range of concentrations as most of chosen genes and did not 
show variations in relation to genotype and tissue TBP was used as an internal 
standard. A standard curve for each primer-probe set was generated in triplicate by 
serial dilution of cDNA pooled from all samples tested. This curve was then used as 
a reference standard for extrapolating quantitative information for mRNA targets of 
unknown concentrations (Fig. 2.3.). Samles of cDNA were diluted 1:20 in water to 
ensure that the level of experession of the gene of interest will be in the middle of the 
standatr curve. Samples for TBP and tested genes were run in triplicates and the 
mean values were used to calculate transcript level. Values were calculated as a 






Figure 2.3 An example of a qRT-PCR standard curve. 
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2.7.7 Transient transfections 
The plasmids used were pGEM3 (inert DNA) (Promega, UK), pKC275 (a β-
galactosidase expression plasmid which was used as an internal control for 
transfection efficiency) (Amersham Pharmacia, UK), pLTR-Luc (full length MMTV 
LTR driving the expression of a luciferase gene) (Prima et al., 2000) and pEGFP-GR 
(Prima et al., 2000) a rat glucocorticoid receptor, CMX-Gal4-hLXRa, (an expression 
construct containing the LXR-  ligand binding site; amino acids 166-447), 
pMH100X4–thymidine kinase–luc (pMH100X4–TK–luc), a luciferase reporter 
construct (Willy et al., 1995), human FXR (Dupont Pharmaceutical, France) 
expression constructs, 3XR-FXRE-pTA-Luc (containing 3 copies of FXRE from 
murine I-BABP) (Zhang et al., 2003). 
 
2.7.7.1 GR, LXRα and FXR activation in cell lines. 
Transient transfections were carried out using the Gene Juice Transfection Reagent 
(Novogen, UK). Cells were seeded at 2x105 per well in 6 well plates coated with 
poly-D-lysine (Sigma, UK) a day before transfections. DNA solutions were briefly 
vortexed to mix and added dropwise to serum free 100µl OPTIMEM mixed with 4µl 
Gene Juice Transfection Reagent with slow agitation and incubated at room 
temperature for 15min. Then they were added slowly dropwise to the dishes of cells. 
After overnight incubation, medium was replaced for charcoal-stripped FCS medium 
and cells were transfected with a total 1µg of DNA comprising 0.1µg pEGFP-GR 
(Prima et al., 2000), 0.5µg pLTR-Luc (Prima et al., 2000) and 0.1µg pKC275 
(internal control). Alternatively, for LXRα activation, cells were transfected with 
0.1µg CMX-Gal4-hLXRa, an expression construct LXR- , 0.5µg TK-MH100X4-
Luc reporter plasmid (a kind gift from Prof. David J. Mangelsdorf, Southwestern 
Medical Center, Dallas, Texas) and 0.5µg pKC275 (Pawar et al., 2002, Willy et al., 
1995). For FXR activation assays, cells were transfected with 0.1µg pS65 hFXR, 
0.1µg hRXRα (a gift from Dr Karen Chapman, University of Edinburgh), 0.1µg 
FXRE-pTA-Luc and 0.5µg pKC275. After overnight incubation steroids and 
oxysterols were added for 16-24 h before harvesting and lysis of cells. GR was 
activated with 11-DHC and corticosterone (100nM-1000nM), LXRα with 20µM 
22(R)-hydroxycholesterol and 250nM T0901317 and hFXR/RXRα with 
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chenodeoxycholic acid (20 and 40µM). 24h later, cells were harvested for assays. 
Medium was aspirated, cells were washed with 1ml PBS and 200µl lysis buffer was 
added to the dishes. After incubation at room temperature for 15min, cells were 
scraped and pipetted into eppendorf tubes; cell debris was pelleted by centrifugation 
at 13000 rpm for 2min in a microcentrifuge. All transfections were carried out in 
triplicates and mean ratio of luciferase/β-galactosidase activities were calculated. 
 
2.7.7.2 Luciferase assays 
Luciferase assays were performed in duplicate on the same day that cells were 
harvested. 40µl sample was added to 100µl 2x assay buffer with 5µl 0.1M ATP in a 
96 well plate. Luciferase activity was measured using a Lumat LB9501 luminometer 
(Berthold) that injected 105µl 1mM beetle luciferin (Sigma, UK). Values recorded 
were the means of the duplicates. 
 
2.7.7.3 β-galactosidase assays 
β-galactosidase activity was assayed using a Galacto-Light Plus (Applied 
Biosystems, UK). Galacton-Plus substrate was diluted 1:100 with Reaction Buffer 
Diluent to make the reaction buffer which was then dispensed in 67µl aliqouts into 
96 well plate. 10µl sample was added, left to incubate at room temperature for 15-
60min and then assayed using a Lumat LB9501 luminometer which injected 105µl 
Light Emission Accelerator. Data were analysed using a Microsoft Excel 
spreadsheet. To standardize the transfection efficiency, the relative light units 
obtained in the luciferase assay were divided by optical density obtained in the β-
galactosidase assay. Presented values of fold luciferase increase were the means of 
two duplicates of luciferase activity/β-galactosidase activity. The mean value 
obtained for empty vector was then set to a value of 1 and mean experimental 
activities expressed relative to this value. 
 
2.7.8 GR trafficking 
pEGFP-rGR and NGFP-GR (positive control) were obtained from P. Lefebvre 
(Inserm, Little Cedex, France)(Prima et al., 2000). HEK 293 cells stably transfected 
with human 11β-HSD1 were kindly provided from Dr Scott Webster 
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(Endocrinology, University of Edinburgh). Cells were grown on poly-D-lysine-
coated glass slides in 6 well plates containing 2ml serum-stripped medium. Cells 
were transfected as described above with 1µg EGFP-GR per well and incubated for 
48h. Cells were then incubated for an appropriate time with 7-oxysterols and 
glucocorticoids. After washing the cells with 1ml PBS and fixation with 4% 
paraformaldehyde cells were stained with DAPI for nuclear visualization. The 
localization of GFP-GR was detected by fluorescence and confocal microscopy 
(LSM510, Zeiss, Oberkochen, Germany). The EGFP was excited with the 488 nm 




DNA micro-arrays are used to measure simultaneously changes in the level of 
expression of many genes. Depending on the chip type, the entire genome or clusters 
of genes representing the chosen pathways can be interrogated. A traditional micro-
array chip is a library of microscopic DNA probes (approximately 200microns in 
size) attached to glass, plastic or silicon chip. Other types of micro-array chips are 
also used to detect SNPs in the genome, to perform chromatin immunoprecipitation 
based on CHIP-on chip technology or comparative genomic hybridizations.  
 
The most important applications for the use of micro-array technology include: 
1) Genes expression profiling 
2) Pharmacogenomics 
3) Toxicology screening 
4) Diagnostics  
 
2.8.2 Design 
Experimental design has to include consideration of sufficient biological replicates 
according to the expected biological variance. Replicates of the same RNA aliquot or 
the same treatment can additionally improve precision. Noteworthy probes of cDNA 
representing the same gene or a particular sequence are spotted on the chip in 
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replicates. Thus, the careful planning needs to be employed in order to draw 
biologically valuable conclusions.  
 
 
A scheme of micro-array experiment design. 
 
A) Biological question 
B) Experimental design 
C) RNA extraction 
D) Quality control- Bioanalyser system Agilent Technologies 
E) Target sample preparation and hybridization  
F) Image acquisition (scan of a chip) 
G) Image quantification 
H) Background correction 
I) Normalization 
J) Data analysis and interpretation 
K) Verification of results by RT-PCR and Western blotting 
L) Biological interpretation 
 
2.8.3 Data analysis 
The most common use of the micro-array experiment is to extract differentially 
expressed genes from a large number of genes presented on a chip by comparison 
between two experimental conditions (transgenic versus wild-type animal in our 
experiment). However, the identification of differentially regulated genes in this 
simple experimental setup may be complicated by high biological variability and the 
consequent “noisiness” of the data. Thus, selection between the biologically relevant 
changes and false positive findings is one of to the most challenging steps in micro-
array studies. Regarding these issues, a number of obstacles could be identified. The 
choice of the most reliable method of data-mining and statistical analysis is usually 
underestimated. Most currently used programs use basic statistics and give a similar 
outcome when applied to the set of micro-array data. Significantly, the level of 
rejection of the borderline genes may differ between the methods. This can have 
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serious consequences if it is acknowledged that biological relevance may not 
correspond directly to the statistical significance or the highest fold changes but 
rather to the direction of changes in functional gene classes. Thus, in my project 
analysis of the data was performed using two different approaches. The first 
technique was based on the calculation of rank products (RP) from replicate 
experiments (Breitling et al., 2004a, Breitling et al., 2004b, Breitling et al., 2004c, 
Breitling and Herzyk, 2005b, Breitling and Herzyk, 2005a). This approach was 
designed at the Sir Henry Wellcome Functional Genomics Facility at University of 
Glasgow (http://www.gla.ac.uk/functionalgenomics/). According to its designers, 
using RP can lead to a sharp reduction in the number of replicate experiments needed 
to obtain reproducible results (Breitling et al., 2004a, Breitling et al., 2004b, 
Breitling et al., 2004c, Breitling and Herzyk, 2005b, Breitling and Herzyk, 2005a). 
Furthermore, the results were also analysed using a basic statistical approaching (the 
Limma tool on BioConductor: http://www.bioconductor.org ). The results are 
presented as lists of differentially-regulated genes.  
 
2.8.4 Pathway analysis 
Micro-array experiments usually generate long lists of differentially regulated genes 
but they provide few clues as to how those changes can be biologically relevant in 
establishing a given phenotype. This also turned out to be the case in my experiment. 
If the understanding of the results is limited to the knowledge of the investigator and 
his/her current ideas, the exploration of the data can be significantly reduced. 
Additionally, another issue appeared. I had to overcome an intuitive concept that 
interesting genes would show the highest fold changes. My data set contained only a 
limited number of genes with high fold changes. These were especially related to 
metabolically important genes. Thus, I decided to address these problems by 
focusing on all functional gene classes similarly regulated in this particular 
experimental setup, rather than on single genes. Both techniques used for the data-
mining provided tools that enabled pathway analysis. Interactive Group Analysis 




Additionally, a newer approach of genome-wide, micro-array data analysis using a 
network-based method was used (Calvano et al., 2005, Cobb et al., 2005, Forster et 
al., 2003). I used a web-based tool developed by Ingenuity System Inc. 
(http://www.ingenuity.com ), which provides a modeling of networks representing 
transcriptional interactions among significantly changed genes. Every gene 
interaction in the network is supported by published scientific articles. Moreover, 
apart from known interactions providing a framework, the software enables creation 
of novel associations among significantly up-regulated and down-regulated genes. 
The software also allows to analyze the whole pool of differentially changed genes 
with respect to known functions and canonical pathways as well as to extract 
variability between whole comparisons (http://www.ingenuity.com ). 
 
2.8.5 Micro-array experiment 
RNA samples were used for target preparation and subjected to hybridizations to an 
Affymetrix Mouse Genome 430 2.0 GeneChips. Samples were processed by the 
micro-array team at The Sir Henry Wellcome Functional Genomics Facility 
(SHWFGF) in Glasgow. RNAs were processed through standard Affymetrix 
protocols (http://www.affymetrix.com ). Samples of RNA extracted from paired 
samples of whole subcutaneous and mesenteric adipose tissue of 5 11β-HSD1-/- and 
5 congenic C57Bl6/J control mice were hybridized to 20 Affymetrix Mouse Genome 
430 2.0 GeneChips, and data were extracted through the GCOS software. CEL files 
were made available for further data processing. CEL files for all 20 chips were 
imported into the Affy package of BioConductor 
(http://www.bioconductor.org/packages/bioc/ ), where they were processed 
(background subtraction and normalization) with the Robust Multichip Average 
(RMA) algorithm. Differential expression was determined by linear modeling using 
the Limma tool on BioConductor, followed by multiple detection correction by the 
Benjamini and Hochberg FDR method (www.bioconductor.org ). Once expression 
data were processed, they were exported in text format and imported into a MySQL 
database. In addition, annotation data for the genes were obtained from NetAffx 
(http://www.affymetrix.com/analysis/index.affx ). A web accessible front-end query 
tool was built that allows querying of the data by expression data (normalised 
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expression, fold-changes, p-values) and by sequence annotation (gene title and 
symbol, Entrez gene ID, Affymetrix ID, and Gene Ontology data). Once the query is 
performed, and table with the results is presented, along with several hyperlinks to 
data in on-line databases (Entrez gene, PubMed, MGI, iHOP). Although data quality 
control was good (Fig.2.4. and 2.5.), there appeared be “biological noise”, especially 
in the 11β-HSD1-/- group. High variability did not correlate with the physiological 
measurements of glucose/insulin. Due to this only a small number of differentially 
regulated genes reached statistical significance and the following analysis was based 
predominantly on the significance of pathways. In this case, WebGestalt 
(http://bioinfo.vanderbilt.edu/webgestalt, Vanderbilt University, USA) and the 
Ingenuity Pathways Analysis (IPA) program (http://www.ingenuity.com/index.html) 
were used to further analyze the gene cluster functions that were significantly 
regulated. The micro-array data set with associated > 1.5-fold differential expression 
levels between genotypes in the subcutaneous and mesenteric adipose tissue was 
imported into IPA. This set of genes was used as the reference set for function and 













igure 2.4 Histiogram of Affymetrix CEL-level data.  
he graph shows the distribution of intensities of probes across the chips. Each chip is 
epicted as one line (a different colour for each one). The Y axis shows the dencity of 
roportion of probes that have the log intensity shown on the X axis. This helps to spot chips 
ith a high background often indicating problems with processing. Histiograms of log 
ntensities are diagnostic measurements used to assess the quality of the arrays. No spatial 













gure 2.5 RNA degradation plot (Affy package on BioConductor) of chips. 
e plot shows the output from the AffyRNAdeg function on the Affy package. RNA 
gradation plot shows the mean expression from the 5' to the 3' end of the mRNA. Every 
ip is represented with a single line. In an ideal situation the lines would be flat, but it is 
ually not the case. If the lines are not flat, the slopes and profiles should be as similar as 
ssible. If all lines have similar slopes, the in vitro transcription has worked similarly across 
 samples. 
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2.9 Insulin signaling in vivo  
12-week-old male 11β-HSD1-/- and congenic C57Bl/6J mice were divided into four 
groups (n=6) with similar body weight and assigned to receive two kinds of diet: 
standard chow diet or HF diet (as described above) for 10 weeks. At the end of diet 
period mice were fasted for 6h and then injected i.p. with 0.75mU/g humulinS or 
saline. Blood samples were taken before and after fasting for glucose and insulin 
measurements. At 15min after the injection subcutaneous and mesenteric fat depots 
and liver were dissected and snap frozen in liquid nitrogen and stored at -80. Tissues 
were homogenized in ice-cold lysis buffer (50mM Tris, pH 7.4, 0.27M sucrose, 1mM 
Na-orthovanadate, pH 10, 1mM EDTA, 1mM EGTA, 10 mM Na β-
glycerophosphate, 50mM NaF, 5mM Na pyrophosphate, 1% (w/v) Triton X-100, 
0.1% (v/v) 2-mercapto ethanol, 1 tablet of complete TM protease inhibitor (Roche, 
UK). Extracts were centrifuged at 13,000 rpm for 20min to remove insoluble 
material. The supernatants were used for Western blotting. 
 
2.9.1 Protein concentration measurements. 
Protein concentrations in tissue homogenates were determined by the method of 
Bradford (protein assay kit; Sigma-Aldrich, UK). Assay is based on the colorimetric 
method and the protein concentrations in each tissue homogenate is estimated 
according to the standard curve based on serial dilutions of bovine serum albumin 
standards (0.1–1.2mg/ml). Measurements were performed at λ595nm using a 
spectrophotometer. Samples were prepared in a dilution allowing estimations in the 
middle range of the standard curve. 
 
2.9.2 Western blotting 
For immunoprecipitations, 1mg of supernatant was mixed with 2µg IRS-1 per tube 
and protein A-Sepharose (Amersham, UK). The precipitated proteins or whole-tissue 
extracts were denatured with Laemmli sample buffer containing 100mM 
dithiothreitol by heating in a boiling water bath for 5min, after which they were 
subjected to SDS-PAGE on 4-12% Bis-Tris gels (Invitrogen, UK) in MOPS SDS 
Running Buffer (Invitrogen, UK). For total extracts, 50µg of proteins were used. 
Proteins were transferred onto nitrocellulose membranes (Invitrogen, UK) at 150mA 
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over 1h 15min in Transfer Buffer (Invitrogen, UK), blocked for 2h at room 
temperature in 5% (wt/vol) skimmed milk/Tris-buffered saline (50 mmol/l Tris-HCl, 
pH 7.6, and 150 mmol/l NaCl) supplemented with 0.1% (vol/vol) Tween 20, and 
probed overnight at 4˚C with antibodies against total AKT (1:1000), or phospho-
AKT Ser473 (1:1000) or phosphor-IRS-1 (1:2,000). Nitrocellulose membranes were 
washed three times in Tris-buffered saline/0.1% (vol/vol) Tween 20 for 10min before 
incubation with either HRP–anti-mouse IgG (1:5,000) or HRP–anti-rabbit (1:1,000). 
Protein signals were visualized using enhanced chemiluminescence for 1min, 
wrapped in Saran Wrap and exposed to Amersham HyperfilmTH ECL 
autoradiographic film (Amersham, UK). The x-ray film was developed using a 
Konica SRX-101A X-ray processor (Konica Corporation, Japan). 
 
2.10 Fat cell size measurement 
Mean diameter of mature adipocytes in every group was measured by counting 20 
randomly selected areas in sections from mesenteric and subcutaneous fat depot of 
11β-HSD1-/- and control mice on chow and HF diet (10 weeks).  
 
2.11 Statistical analysis 
Data were analysed using a Microsoft Excel spreadsheet and expressed as means ± 
SEM accompanied by the indicated number of independent experiments. All 
statistical analyses were performed using GraphPad prism (Version 3) and SigmaStat 
software. Initially, the analysis of distribution normality was performed using the 
Shapiro-Wilk W test integrated in GraphPad prism. The groups were then compared 
using parametric tests: Student’s t-test or a one-way or two-way ANOVA, as stated, 
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3 7-oxysterols modulate glucocorticoid activity in adipocytes 
3.1 Introduction 
Obesity is a known risk factor of cardiovascular diseases, yet the molecular link 
between increased fat mass and atherosclerosis is still unknown. It has been 
estimated that adipose tissue stores over half of total body cholesterol, mainly as free 
cholesterol (Krause and Hartman, 1984) and this proportion increases with the 
hypertrophy of adipocytes (Le Lay et al., 2001). Adipocytes also remove serum 
oxidized low density lipoproteins (oxLDL) through scavenger receptors (CD36, 
OLR1, SR-B1) (Krause and Hartman, 1984, Chui et al., 2005), a major source of 
atherogenic 7-oxysterols. Insulin, a critical regulator of adipocyte biology, promotes 
lipids storage and up-take of cholesterol (Tondu et al., 2005). It has been observed 
that adipocyte cholesterol levels increase in proportion to the triglyceride content 
(Kovanen et al., 1975, Schreibman and Dell, 1975) and that cholesterol-depletion in 
adipocytes causes perturbation in fatty acids and glucose metabolism (Pohl et al., 
2004, Le Lay et al., 2001). Rates of adipocyte lipolysis, a process that increases with 
the insulin resistance of hypertrophic obesity, are also linked to cholesterol efflux 
(Verghese et al., 2007). Thus, the ability of adipocytes to store and metabolise 
cholesterol may be crucial for the regulation of the whole body lipid/cholesterol 
homeostasis and thereby atherosclerosis risk. Hypertrophied adipocytes from 2 obese 
rodent models showed elevated mRNA levels of HMG CoA reductase and the LDL 
receptor suggesting that these cells are cholesterol deficient and have increased 
cholesterol biosynthesis and uptake in proportion with icreased fat cell size (Boizard 
et al., 1998, Le Lay et al., 2001). Thus, adipose tissue is a potential sump for harmful 
cholesterol metabolites and these protective qualities are lost during insulin resistant 
obesity. 
 
Patients with glucocorticoid excess (Cushing’s syndrome) develop visceral obesity, 
insulin resistance, diabetes type 2, dyslipidemia and have an increased risk of 
cardiovascular mortality. Tissue-specific differences in local cellular glucocorticoid 
exposure may explain the Cushing’s-like features of idiopathic obesity/metabolic 
syndrome in the absence of elevated plasma cortisol levels (Seckl and Walker, 2004). 
One contention is that the 11-keto-reduction of inert cortisone (11-
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dehydrocorticoisterone in mice and rats) to active cortisol (corticosterone) by the 
activity of the intracellular enzyme 11β-HSD1 is elevated specifically in adipose of 
obese humans and rodents (Seckl and Walker, 2004, Livingstone et al., 2000a, 
Livingstone et al., 2000b, Rask et al., 2002) . Transgenic mice over-expressing 11β-
HSD1 selectively in adipose tissue develop many features of the metabolic 
syndrome, including glucose intolerance, insulin resistance, dyslipidemia and 
hypertension (Masuzaki et al., 2001) whereas 11β-HSD1-/- mice are protected from 
these deleterious effects upon high fat feeding (Morton et al., 2001, Morton et al., 
2004b). Crucially, 11β-HSD1-/- mice also exhibit an atheroprotective phenotype, 
with raised HDL cholesterol (Morton et al., 2001). Further, treatment of 
atherosclerosis-prone ApoE-/- mice with an 11β-HSD1 inhibitor attenuates 
atherogenesis (Hermanowski-Vosatka et al., 2005). Taken together these data 
suggest a role for elevated adipose 11β-HSD1 levels driving adipocyte hypertrophy 
and insulin resistance that, together with consequent downstream vascular 
(Hermanowski-Vosatka et al., 2005) and hepatic lipid and cholesterol handling 
effects (Morton et al., 2001, Morton et al.,2004b) , is potentially proatherogenic. 
 
It was reported recently that 11β-HSD1 inter-converts 7-ketocholesterol (7-KC) and 
7β-hydroxycholesterol (7β-HC) in the liver (Schweizer et al., 2004). 7KC, followed 
by 7β-HC are the most abundant oxysterols in oxLDL (Brown et al., 1997) and their 
concentrations correlate with atherosclerosis risk (Ferderbar et al., 2007). Whilst 
present in nanomolar concentrations in the plasma under physiological conditions 
(Corradini et al., 2005, Iuliano et al., 2003, Zieden et al., 1999), these 7-oxygenated 
metabolites are found in micromolar concentrations in human foam cells, 
atherosclerotic plaques and plasma of dyslipidemic patients (Schroepfer, 2000). 7-
oxysterol levels in adipose tissue have not been reported. 
 
Given the key role of adipose tissue in modulating whole body cholesterol 
homeostasis (Pohl et al., 2004, Le Lay et al., 2001) we hypothesised that metabolism 
of these oxysterols by 11β-HSD1 might provide a novel link between obesity, 
adipose glucocorticoid action and atherogenesis. 
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Aims: 
1. To investigate whether differentiated 3T3-F442A adipocytes metabolise 7-
oxysterols and whether this reaction is 11β-HSD1–dependent.  
2. To study the competitive nature of glucocorticoid and 7-oxysterol metabolism 
in cultured adipocytes. 
3. To investigate whether 7-oxysterols activate glucocorticoid receptors and/or 
interfere with the GR translocation.  
4. To investigate the impact of 7-oxysterols on the differentiation of adipocytes. 
3.2 Methods: 
3.2.1 11β-HSD1 activity in fully differentiated adipocytes. 
3T3-F442A cells were cultured and differentiated according to the standard protocol 
as described in section 2.4.3 and 2.4.4. 
 
An initial validation experiment was performed to confirm previously described 
preferential reductase direction of 11β-HSD1 (Napolitano et al., 1998). The enzyme 
activity assay in fully-differentiated 3T3-F442A adipocytes was measured by thin 
layer chromatography (TLC) as described in section 2.5.1. Two time points (1h and 
3h) were chosen based on previous reports.  
 
3.2.2 Accumulation of [3H]3-7KC in adipocytes measured by β-counter. 
Initially, based on the well established protocol of 11β-HSD1 activity for 
glucocorticoid conversion (as described in chapter 2 in section 2.5.1.), I attempted to 
detect the potential product of 7KC conversion in the culture medium. Although I 
significantly improved recovery of oxysterols from the medium using 6 volumes of 
dichloromethane instead of ethyl acetate I detected only decreasing amounts of 7KC 
over time and no product in the medium. To solve problems with the detection of 7-
oxysterols in the culture medium 3T3-F442A adipocytes were incubated with radio-
labeled 7KC. Several methods of extraction were tested in the preliminary stage of 
the study as described in details in section 2.5.2. 
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Radioactivity was measured in the medium and in the cellular pellet using a β-
counter as described. After 24 h incubation all radioactivity counts were accumulated 
in the cellular pellet. Based on these findings, I established the optimal conditions of 
oxysterol recovery from both medium and cell lysates. 
 
3.2.3 Metabolism of [3H]3-7KC in adipocytes. 
The conversion of 7KC to 7β-HC was investigated using high performance liquid 
chromathography (HPLC). 7KC and 7β-HC were extracted from the culture medium 
and lysed cells using the new established method described in details in section 2.5.2 
The selective 11β-HSD1 inhibitor (Merck, compound 544 (Hermanowski-Vosatka et 
al., 2005)) was used as a control. 
 
3.2.4 11β-HSD1 activity assays 
3.2.4.1 Glucocorticoid conversion measured by TLC (section 2.5.1) 
3.2.4.2 7-oxysterol conversion measured by HPLC (section 2.5.2) 
11β-HSD1 activity in fully-differentiated intact 3T3-F442A adipocytes was assayed 
in the medium to which appropriate substrate with radio-labeled tracer was added. 
For the enzyme competition assays, the 2 substrates (11-DHC and 7KC) were added 
in the medium: one in a constant concentration and the other in a range of 
concentrations. TLC and HPLC (as described in section 2.5) were used for 
measurement of 11β-HSD1-dependent glucocorticoid and 7-oxysterols metabolism, 
respectively. 
 
3.2.5 Glucocorticoid receptor studies  
3.2.5.1 Transient transfection with GR or/and H6PDH 
HEK 293(11β-HSD1) cells were cultured as described in section 2.4.2. 
Two different transfections experiments were carried out as follow: 
 
1) For assessment of glucocorticoid receptor activation, HEK 293(11β-HSD1) cells-
stably transfected with human 11β-HSD1, were transfected with human GR and a 
luciferase reporter gene linked to the mouse mammary tumour virus long terminal 
repeat (MMTV-LTR) containing several GREs as described in section 2.7.7. 
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Transfected cells were incubated with active (corticosterone) or inactive (11-DHC) 
glucocorticoid and/or with 7-oxysterols.  
 
2) HEK 293(11β-HSD1)+GR were co-transfected with H6PDH to test whether the 
observed modulation of GR activity depends on the availability of co-factor.  
 
3) Experiments were performed on HEK293+GR cells (not transfected with 11β-
HSD1) as controls. 
 
3.2.5.2 GR translocation 
To investigate whether 7-oxysterols may influence GR trafficking HEK 293 and 
HEK 293(11β-HSD1) cells were transfected with EGFP-GR (rat) as described in 
section 2.7.7. Images of the living cells were captured with fluorescent microscopy. 
Representative experiments were additionally examined under confocal microscopy. 
Untreated cells showed the GR-associated fluorescence only in the cytoplasm 
(negative control). The use of 10-8 cortisone for 60min triggered a complete transfer 
of the EGFP-GR fluorescence from the cytoplasm to the nuclei (positive control). 
Two different experiments were performed: 
 
a) To exclude the inhibitory effect of 7KC on 11β-HSD1-dependent production 
of a GR ligand HEK293(11β-HSD1) cells were co-incubated with 7KC and 
11-DHC. Cells incubated with 11-DHC were used as a positive control. 
Different time-points and concentrations were tested.  
b) To investigate whether the incubation with 7KC or 7β-HC caused 
translocation of EGFP-GR to the nucleus HEK293 cells were incubated with 
either of two 7-oxysterols in various concentrations.  
 
3.2.6 Modulation of 11β-HSD1 reaction direction (HEK293 cells) 
To investigate whether 7-oxysterols influence the direction of glucocorticoid 
conversion 11β-HSD1 activity assays were performed as described in section 2.5.1. 
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3.2.7 3T3-L1 differentiation  
3.2.7.1 Oil Red O staining (section 2.4.4.1.) 
The differentiation of adipocytes was assessed visually by the Oil Red O staining, 
which stains all neutral lipid and lipid moieties.  
 
3.2.7.2 qRT-PCR 
Expression of glucocorticoid-regulated genes (PEPCK and angiotensinogen) were 
investigated in RNA isolated from 3T3-L1 cells by qRT-PCR as described in section 
2.7.6. TATA binding protein mRNA levels were used as an internal control.  
 
3.2.8 Statistics 
Individual experiments were conducted in triplicates and the mean was used for 
statistical analysis. All data are presented as mean ± standard error of the mean 
(SEM) and were statistically analysed by Student’s t-test or one-way or two-way 
ANOVA, as appropriate. Bonferroni or Newman-Keuls post hoc tests were used for 
multiple comparisons. All analysis was performed using Sigma Stat or Graphpad 




3.3.1 11β-HSD1 in differentiated 3T3-F442A adipocytes works predominantly as a reductase.  
11β-HSD1 has been described as a low-affinity NADP-dependent 
dehydrogenase/oxoreductase (Napolitano et al., 1998, Bujalska et al., 2002). 
Depending on the availability of the cofactor 11β-HSD1 inter-converts 
glucocorticoids and 7-oxysterols in liver microsomes (Schweizer et al., 2004). In 
order to establish conditions for the conversion of 7-oxysterols in cultured adipocytes 
I tested the 11β-HSD1 dehydrogenase and reductase activities for the conversion of 
glucocorticoids in differentiated 3T3-F442A adipocytes and confirmed that in our in 
vitro model the dehydrogenase reaction was negligible. After 4 h of incubation with 
11-DHC only the product of the reaction was detected in the medium (Fig. 3.1.). 
 
3.3.2 Differentiated 3T3-F442A adipocytes accumulate 7-oxysterols. 
To investigate whether 11β-HSD1 metabolises oxysterol substrate in adipocytes I 
examined conversion of [3H]3-7KC to 7β-HC in differentiated 3T3-F442A 
adipocytes. After 24 h incubation, most of the added radioactivity was detected in the 
cellular fraction, with <17% remaining in the medium (Fig. 3.2.), suggesting 
sequestration of oxysterols in the adipocytes rather than balanced influx/efflux. 
Radioactivity was measured in whole samples of medium and resuspended cellular 
pellets without performing additional steps of oxysterol extraction. 
 
HPLC analysis of oxysterols extracted from the lysed cells showed two peaks with 
the retention time: 28 and 32minutes, corresponding to 7β-HC and 7KC respectively 
(Fig. 3.3.). Thus, in the adipocytes the metabolism of 7-oxysterols was exclusively 
through 11β-HSD1 and contrary to that, which occurs in other tissues (liver, 
macrophages) 7β-HC was not metabolised further. After 24h ~ 73% of 7KC was 
converted to 7β-HC (Fig. 3.3), indicating a predominant reductase effect on 
oxysterols (similar to glucocorticoid conversion [21]). Consistent with previous 
observations after 24 h incubation no 7-oxysterols were detected in the medium. 
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11β-HSD1 specificity for the conversion of 7KC to 7β-HC in the differentiated 
adipocytes was confirmed using a selective 11β-HSD1 inhibitor (compound 544, 


































igure 3.1 11β-HSD1 activity towards glucocorticoids. 
o measure the 11β-HSD1 activity fully-differentiated 3T3-F442A adipocytes were 
ncubated with 200nM 11-DHC and 5nM of [3H]4-11-DHC as a tracer (reductase assay; 
lack bars) for 1 or 4 hours. The same concentrations were used when cells were incubated 
ith corticosterone (dehydrogenase assay; white bars). Reductase and dehydrogenase 
ctivities were measured in triplicate in 3 independent experiments. Activity is expressed as 
ercent conversion of substrate to product. 11β-HSD1 worked predominantly as a reductase 





















































igure 3.2 Accumulation of 7-oxysterols in fully differentiate
o measure intracellular accumulation of 7KC in differentiate
ere incubated with [3H]3-7KC for up to 24 h. Black and ope
f radioactivity detected in the medium and in lysed cells, resp
adiolabelled 7KC whole cellular pellets (without performing 
xtraction from cells) were resuspended in scintillation fluid (
K) and analysed by Liquid Scintillation Analyzer (Packard, 
 independent experiments, each performed in duplicate. Ther
ffect of time measured by one-way ANOVA with Bonferron
he analysis of medium extracts and F=194.4 for the analysis o
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igure 3.3 Conversion of [3H]3-7KC to 7β-HC by 3T3-F442A in cell lysates and in the 
edium.  
T3-F442A cells were incubated for 2, 5 or 24 h with 500nM 7KC and [3H]3-7KC as a 
racer before extraction and HPLC analysis (as described in Methods in section 2.5.2.). Gray 
ars represent 7β-HC extracted from the cell lysate, open and black bars represented 7KC 
xtracted from the cell lysate and the medium, respectively. The recovery of oxysterols from 
he medium and cellular pellet was 50-70% and 90%, respectively. Data are mean ± SEM 
rom 3 independent experiments, each performed in triplicate. Statistical analysis performed 
y one-way ANOVA with Bonferroni post hoc tests. * p<0.05 for the effect of changes in 
he concentration of radiolabelled extracts over the time course (F=157 for the analysis of 
hanges of 7β-HC, F=55.9 for the analysis of changes of 7KC in lysates, F=24.92 for the 



























igure 3.4 HPLC analysis of oxysterols extracted from 3T3-F442A cells 
PLC analysis of oxysterols extracted from 3T3-F442A cells following 24 h incubation with 
A) [3H]3-7KC or (B) [3H]3-7KC with the addition of 5µM 11β-HSD1 inhibitor (Merck, 
ompound 544). Following assays for 11β-HSD1-dependent conversion of 7-oxysterols, 
xysterols were extracted as described in Methods in section 2.5.2 and resuspended in 
obile phase containg 85% acetonitrile and 15% water and injected into the HPLC system. 
he flow rate of the mobile phase was 1ml/min, the flow rate of scintillant was 1.5 ml/min 
nd the column temperature was set to 40°C. Two peaks were detected with retention times 
8 and 32 min for 7β-HC and 7KC, respectively.  
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3.3.3 7-oxysterols compete with glucocorticoids as substrates for 11β-HSD1. 
To investigate competition between glucocorticoid and oxysterol substrates, both 
were added together to the medium of 3T3-F442A adipocytes. 7KC (1nM–100 µM) 
inhibited the conversion of 11-DHC to corticosterone in a dose dependent manner 
with an IC50 of 450nM (Fig. 3.5A). This appeared to reflect effects upon metabolism 
rather than any cell toxicity since MTS assays (4h incubation in serum-free medium 
with 200nM 11-DHC and a range of 7KC concentrations from 0 to 100µM) indicated 
no effect of 7KC on cell viability at the doses used here. Similarly, 11-DHC (1nM-
100µM) inhibited conversion of 7-KC to 7β-HC (IC50 2740nM; Fig. 3.5B). 
 
3.3.4 7-oxysterols modulate glucocorticoid receptor mediated promoter activation. 
To assess the impact of 11β-HSD1-mediated oxysterol metabolism upon 
glucocorticoid receptor (GR) function, I used HEK293 cell line stably transfected 
with 11β-HSD1 [HEK293(11β-HSD1)] which, unlike 3T3 cells, are more amenable 
to standart transfection techniques. HEK293 cells lack functional GR (Atanasov et 
al., 2004), therefore HEK 293(11β-HSD1) cells were transiently transfected with an 
expression plasmid encoding rat GR and a glucocorticoid-sensitive (MMTV-LTR-
luciferase) promoter-reporter construct (HEK 293(11β-HSD1)+GR). Corticosterone 
and 11-DHC were equipotent in stimulating reporter gene activity at physiologically-
relevant (10nM) concentrations. None of the steroids induced luciferase activity in 
the absence of transfected GR. This effect was mediated by GR as it was blocked by 
addition of the GR antagonist RU38486 (RU486) (Fig. 3.6.). Neither 7KC nor 7β-HC 
(20µM) alone exhibited any direct agonist activity at GR (Fig. 3.6.). 
 
To test whether oxysterols affected the ability of 11β-HSD1 to generate active 
glucocorticoid ligand, HEK 293(11β-HSD1)+GR cells were incubated with 
concentrations of 11-DHC (10nM) or corticosterone and 7KC or 7βHC (20µM) or 
the GR antagonist RU486 (1µM) (Fig. 3.6.). Both active corticosterone and inactive 
11-DHC induced GR-mediated transcriptional activity to a similar extent in HEK 
293(11β-HSD1)+GR cells (Fig. 3.6.), suggesting rapid reactivation of 11-DHC to 
corticosterone. RU486 inhibited glucocorticoid–induced luciferase activity (Fig. 
3.6.). As predicted from the results above, 7KC (20µM) inhibited 11-DHC-induced 
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luciferase activity (Fig. 3.6.). Unexpectedly, 7KC also inhibited corticosterone-
induced luciferase activity. In contrast, 20µM 7β-HC enhanced both corticosterone- 
and 11-DHC-mediated transcriptional activation of the reporter gene (Fig.3.6.). 
Similar results were obtained using another GRE-reporter construct (driven by the 






















































































igure 3.5 Competition between glucocorticoids and 7-oxysterols for 11β-HSD1. 
) Dose-dependent inhibition of glucocorticoid conversion by 7KC. 3T3-F442A adipocytes 
ere incubated with 200nM 11-DHC and 5nM of [3H]3-11-DHC as a tracer with 7KC 
1nM-100µM) for 4 h. Steroids were extracted from the medium by the addition of ethyl 
cetate and analysed by TLC. Data are mean ± SEM of 3 independent experiments, each 
erformed in triplicate and are expressed as a percentage of control (no added 7KC). 100% 
onversion on the graph represents 85% actual conversion in the control. B) Dose-dependent 
nhibition of oxysterol conversion by 11-DHC analysed by HPLC. 3T3-F442A adipocytes 
ere incubated with 200nM 7KC and 5nM [3H]3-KC as a tracer and 11-DHC (1nM-100µM) 
or 4 h. Oxysterols were extracted from cells and analysed by HPLC. Data represent mean ± 
EM of 3 independent experiments, each performed in triplicate and are expressed as 
ercentage of control (no added 11-DHC). 100% conversion on the graph represents 28% 







































igure 3.6 7-oxysterols modulate GR activity of 11-DHC and corticosterone. 
EK 293(11β-HSD1) cells were transfected with EGFP-GR, MMTV-LTR-luciferase and 
RSV-βgal and treated with 10nM glucocorticoid (11-DHC or corticosterone) with the 
ddition of the appropriate 7-oxysterol (20µM) or RU486 (1µM). Values are the ratio of 
uciferase to β-galactosidase activity expressed relative to basal MMTV-LTR activity and are 
eans ± SEM of 6 independent experiments, each performed in triplicate. &p<0.05 
epresents statistically significant effect of active or inactive glucocorticoid alone. *p<0.05 
epresents statistically significant effect of modulation of glucocorticoid-dependent 
ctivation of GR by 7-oxysterols (one-way ANOVA with Newman-Keuls post hoc tests). 
nexpectedly, both active and inactive glucocrticoid-dependent GR activation was inhibited 
y the addition of 7KC. The explanation of these results will be provided in the following 
ections describing the bidirectional function of 11β-HSD1 in HEK293 cells and the 
odulatory role of 7-oxysterols upon reductase/dehydrogenase reaction direction.  
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3.3.5 7-oxysterols do not regulate GR trafficking. 
To explore whether the differences between 7KC and 7β-HC effects on GR-mediated 
transcription were due to effects on receptor translocation to the nucleus, 
visualization of EGFP-tagged GR by fluorescent and confocal microscopy was used.  
 
As expected, un-liganded GR was located in the cytoplasmic compartment, whereas 
after 40min incubation with 500nM of corticosterone or 11-DHC (when cells were 
stably transfected with 11β-HSD1) EGFP-GR was detected exclusively in the 
nucleus. As described previously (Prima et al., 2000), RU486 induced translocation 
of GR to the nucleus (the complex is transcriptionally inactive). In the first set of 
experiments the potential inhibitory effect of 7KC on the production of an active GR 
ligand was investigated in the HEK293(11β-HSD1) cells co-incubated with 7KC and 
11-DHC. Contrary to expectation, there was no evident inhibition of GR 
translocation when 7KC was present in the medium together with a GR ligand. This 
supported the notion that the inhibitory effect of 7KC on glucocorticoid conversion 
was incomplete.  
 
To exclude the possibility that either 7KC or 7β-HC might interfere with the 
inactivated GR trafficking, HEK293 were incubated with 7-oxysterols. The 
incubation with 7-oxysterols (100nM-20µM) for up to 24h in the medium did not 
modify the cytoplasmic localization of EGFP-GR. These findings imply that neither 
7KC nor 7β-HC interfere with the nuclear-cytoplasmic trafficking of the rGR in the 













Figure 3.7 The effect of 7-oxysterols on the rGR trafficking in transiently transfected 
HEK293 cells expressing the EGFP-linked rGR (green fluorescence). 
Confocal microscopic images were captured 24 hours after addition of 20µM 7KC or 7β-HC 
(as described in Methods in section 3.2.5.2). DAPI staining (blue) was used to visualize 
nuclei. 500nM corticosterone was used as a positive control (green fluorescence in the 
nucleus, GR fully translocated into the nucleus) and “vehicle” alone (ethanol, green 
fluorescence in the cytoplasm, GR not translocated, remains in the cytoplasmic 
compartment) was used as a negative control. Pictures are representative of 3 independent 
experiments, each performed in triplicate. 
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3.3.6 Modulation of 11β-HSD1 reaction direction by 7-oxysterols  
One mechanism by which 7KC may reduce GR activation by both corticosterone 
(already active) and inert 11-DHC involves shifting 11β-HSD1 reaction direction 
towards 11β-dehydrogenation. In order to address this HEK 293(11β-HSD1)+GR 
cells were co-transfected with H6PDH, which drives 11β-HSD1 activity towards 
oxo-reduction, regenerating active corticosterone (Atanasov et al., 2004, Bujalska et 
al., 2005). Consistent with this hypothesis and with previous data (Atanasov et al., 
2004), HEK 293(11β-HSD1)+GR cells exhibited bi-directional glucocorticoid 
metabolism, at comparable levels (40-50% conversion), when incubated with either 
11-DHC (Fig. 3.6. and 3.8.) or corticosterone (Fig. 3.6. and 3.8.), but only 11β-
reductase activity when co-transfected with H6PDH (Atanasov et al., 2004) (Fig. 
3.8).  
 
7KC (20µM) inhibited the conversion of 11-DHC to corticosterone (reductase 
direction; Fig. 3.10A), and promoted conversion of corticosterone to 11-DHC 
(dehydrogenase direction; Fig.3.10B) in HEK 293(11β-HSD1) cells without H6PDH 
co-transfection. In contrast, 7β-HC increased the formation of the active 
glucocorticoid by the opposite effect, shifting the 11β-HSD1 reaction direction to 
oxo-reductase (Fig.3.10A and B). 11β-HSD1 inhibitor (Merck, compound 544) used 
in this expiment inhibited both reaction direction in a non-specific way (Fig. 3.10A 
and B). Moreover, when H6PDH was over-expressed, 7-oxysterols no longer had 
effects upon corticosterone-mediated GR transcriptional activity (Fig. 3.8.), and the 
effects of 7β-HC on 11-DHC transactivation via GR was also blocked, suggesting 
that these effects were mediated via changes in 11β-HSD1 reaction direction. 
Additionally, in the absence of 11β-HSD1 7-oxysterols did not influence 
corticosterone-induced GR transcriptional activity (Fig. 3.9). These data suggest that 
in the presence of sub-maximal levels of H6PDH, 7-KC influences glucocorticoid 
metabolism by 11β-HSD1 towards dehydrogenation, but that, in addition, it 
antagonises activation of 11-DHC to active corticosterone by another mechanism, 

































igure 3.8 7-oxysterols do not modulate GR activity in cells co-transfected with H6PDH. 
EK-293(11β-HSD1) cells were transfected as above with GR, MMTV-LTR-luciferase 
ctivity and pRSV-β and co-transfected with H6PDH plasmid and activated as described 
bove with glucocorticoid (10nM 11-DHC and corticosterone) and 7-oxysterols (20µM). 
esults are expressed as the ratio of luciferase to β-galactosidase activity and are the mean 
alues ± SEM of 4 separate experiments. &p<0.05 represents statistically significant effect 
f active or inactive glucocorticoid alone (one-way ANOVA with Newman-Keuls post hoc 

































igure 3.9 7-oxysterols do not modulate GR activity in HEK293 cells. 
EK-293 cells were transfected as above with GR, MMTV-LTR-luciferase activity and 
RSV- β and activated as described above with glucocorticoid (10nM 11-DHC and 
orticosterone) and 7-oxysterols (20µM). &p<0.05 represents statistically significant effect 
f active glucocorticoid alone (one-way ANOVA with Newman-Keuls post hoc tests). 
esults are expressed as the ratio of luciferase to β-galactosidase activity and are the mean 
alues±SEM of 4 separate experiments. No significant effect of co-incubation with 7-





































































igure 3.10 Modulation of 11β-HSD1 reductase activity (A) and dehydrogenase activity (B) 
y 7-oxysterols in HEK293(11β-HSD1) cells. 
ells were incubated for 16h with either 10nM [3H]411-DHC (A) or 10nM [3H]4 
orticosterone (B) with the addition of 7KC (20µM), 7β-HC (20µM) or the selective 11β-
SD1 inhibitor (Merck compound 544, 5µM), as indicated. Values are expressed as percent 
onversion of substrate to product (Y axis of the upper graph shows the conversion of 
orticosterone/added 11-DHC and this represents the reductase direction; Y axis of the lower 
raph shows the conversion of 11-DHC/added corticosterone and this is consistent with the 
ehydrogenase direction) and are means ± SEM of 3 independent experiments. * p<0.05 
one-way ANOVA with Bonferroni post hoc tests). Inhib-11β-HSD1 inhibitor (Merck, 
ompound 544), cort-corticosterone. 
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3.3.7 7KC inhibits 11β-HSD1-mediated 3T3-L1 preadipocyte differentiation only when 11-DHC 
is used to trigger the process. 
Glucocorticoids are required for the differentiation of the 3T3-L1 adipocyte cell line 
(Green and Kehinde, 1975). Given the observations that 7-oxysterols accumulate in 
adipocytes, we hypothesised that 7KC might inhibit 11β-HSD1-dependent, 
glucocorticoid-stimulated preadipocyte differentiation. To investigate whether the 
accumulated high concentration of 7-oxysterols may influence the differentiation 
process and/or lipid storage, 3T3-L1 cells were differentiated with the addition of 
dexamethasone (250nM) in medium enriched with low (1µM), stable concentrations 
of 7-oxysterols. As described previously, 11β-HSD1 showed late phase 
differentiation-dependent expression pattern (Fig. 4.6;(Napolitano et al., 1998)). 
Neither of the 7-oxysterols influenced lipid storage measured by Oil Red O staining 
when 3T3-L1 adipocytes were differentiated according to the standard protocol. 
 
11-DHC (by virtue of its conversion to corticosterone by 11β-HSD1) can substitute 
for dexamethasone in promoting adipocyte differentiation [31]. Supplementation of 
the differentiation mixture (containing 250nM 11-DHC) with 20µM 7KC decreased 
the differentiation of 3T3-L1 preadipocytes measured by Oil red O staining by day 
10 after addition of supplemented medium (Fig. 3.11.). 7KC did not influence 
differentiation induced by dexamethasone or corticosterone suggesting that the 
inhibition of differentiation resulted from inhibition of 11β-HSD1 activity towards 
11-DHC by 7KC. 
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Figure 3.11. 7KC inhibits differentiation of 3T3-L1 adipocytes induced by 11-DHC. 
Representative images of Oil red O stained 3T3-L1 cells 7 days after addition of 
differentiation mixture: (A) undifferentiated cells (negative control), (B) adipocytes 
differentiated by the addition of IBMX, insulin and dexamethasone; (C) IBMX, insulin and 
11-DHC (inactive glucocorticoid); (D) IBMX, insulin and corticosterone (active 
glucocorticoid); (E) IBMX, insulin, dexamethasone and 20µM 7KC; (F) IBMX, insulin, 11-
DHC and 20µM 7KC. Photos are representative of 4 independent experiments, each 
performed in duplicate. Magnification x40. 
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3.3.8 The effects of 7-oxysterols on glucocorticoid-inducible gene expression.  
Ultimately, 7-oxysterols were tested for their effect on glucocorticoid-responsive 
genes. 11-DHC (500nM) inhibited PEPCK and increased angiotensinogen mRNA 
levels as reported previously (Beale and Tishler, 1992, Saye et al., 1989) (Fig. 3.12). 
In conclusion with the previous experiments 7KC alone showed no effect on the 
expression of angiotensinogen (Fig. 3.12). Co-incubation with glucocorticoid and 
oxysterol did not further affect the already decreased PEPCK mRNA levels (Fig. 
3.12). No effect was detected on the level of angiotensinogen after co-incubation 
with 7KC and 500nM 11-DHC for 6h (Fig. 3.12). However, incubation with 10µM 
7KC caused a decrease in PEPCK expression, less than 11-DHC but significant. No 
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igure.3.12 Oxysterols do not regulate glucocorticoid-responsive genes in adipocytes. 
egulation of PEPCK and angiotensinogen mRNA levels by co-incubation with an inactive 
lucocorticoid and 7-oxysterols. Differentiated 3T3-L1 adipocytes were incubated with 
00nM 11-DHC and/or with 7KC (10µM or 1µM as indicated) for 6 hours. mRNA levels of 
ngiotensinogen and PEPCK (glucocorticoid-regulated genes) were measured by qRT-PCR 
s described in chapter 2 in section 2.7.6. Statistically significant effect of treatment 
*p<0.05, one-way ANOVA with Bonferroni post-hoc tests). 
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3.4 Discussion 
A prominent hypothesis underpinning the metabolic and atherosclerotic 
consequences of obesity is increased 11β-HSD1 in adipose tissue (Hermanowski-
Vosatka et al., 2005, Seckl and Walker, 2004). Here it is shown that 7-oxysterols 
accumulate within adipocytes and that 11β-HSD1 also metabolises these highly 
proatherogenic oxysterols, predominantly from 7KC to 7β-HC. I describe a novel 
cross-talk between glucocorticoid and oxysterol pathways in that 7KC inhibits 
glucocorticoid action, whereas 7β-HC enhances glucocorticoid action and provide 
functional evidence that this affects preadipocyte differentiation. The effects appears 
to occur predominantly through substrate competition at the enzyme activity level, 
and may include reversal of 11β-HSD1 reductase activity if 7KC levels are high and 
co-factor levels are limiting within the cell. 
 
Adipocytes accumulated the 7-oxysterol substrate/product of 11β-HSD1, converted 
the 7KC with preferential 11β-reduction activity, as previously described in liver 
(Schweizer et al., 2004) and sequestered the 7β-HC product within the cells. The 
accumulated intracellular 7KC interfered with the ability of 11β-HSD1 to regenerate 
active glucocorticoids. The relatively low, physiologically-relevant IC50 for 
inhibition of glucocorticoid regeneration by 7KC suggests that such competition may 
occur in adipose tissue in vivo. In contrast, the much higher IC50 (micromolar) for 
inhibition of 7-KC conversion by 11-DHC is unlikely to have a major impact given 
the nanomolar physiological levels of circulating 11-DHC (Harris et al., 2001). 
 
The effects of 7KC were not mediated at the 11β-HSD1 mRNA level. When 7KC 
levels were high, as might occur in adipocytes as they accumulate and sequester 7-
oxysterols, it appeared to promote a change in reaction direction with increased 11β-
dehydrogenation of glucocorticoids. In HEK293(11β-HSD1) cells this change in 
reaction direction driven by 7KC was overcome by over-expression of H6PDH, 
believed to be coupled physiologically to 11β-HSD1 in the endoplasmic reticulum 
and thus the major determinant of reaction direction in intact cells. It is unlikely that 
this situation would occur in mature fully-differentiated adipocytes, where 11β-
HSD1 activity is almost exclusively reductase (Napolitano et al., 1998, Bujalska et 
 113
al., 2002). However, the limiting levels of H6PDH in HEK293 cells suggest that 
where the provision of co-factor is limiting, such as in human preadipocytes 
(Bujalska et al., 2005), accumulation of this oxysterol might affect glucocorticoid 
mediated preadipocyte differentiation. Indeed when I looked at 3T3-L1 cell 
differentiation, 7KC reduced the ability of 11-DHC to promote differentiation. 
 
Neither 7-oxysterol displayed intrinsic activity towards GR, but both regulated 
glucocorticoid-dependent GR transcriptional activity. It seems plausible that 7KC 
competes as a substrate with 11-DHC, consuming endogenous NADPH. 7β-HC 
potentiated GR mediated transcription, but only when H6PDH was limiting. Thus 
7β-HC promotes the accumulation of active corticosterone in cells where cofactor is 
limiting, but is unlikely to affect GC action where H6PDH is abundant, such as in 
mature adipocytes. 7KC attenuated GR transactivation with 11-DHC and 
corticosterone when H6PDH was limiting, consistent with its role to prevent active 
glucocorticoid regeneration (HEK293 cells convert corticosterone to 11-DHC, which 
would not be then reduced back to corticosterone in the presence of 7KC). 
 
11β-HSD1-/- mice have a cardioprotective lipid profile (low LDL, high HDL) 
(Morton et al., 2004b) and pharmacological inhibition of 11β-HSD1 activity is 
atheroprotective (Hermanowski-Vosatka et al., 2005). Whilst there may be protective 
effects within the vessel wall, and on hepatic cholesterol metabolism (Morton et al., 
2001, Cai et al., 2001) the altered adipose tissue accumulation and insulin 
sensitization of 11β-HSD1 may play an atheroprotective function in clearing oxLDL 
from the plasma. Adipocytes undergoing hypertrophy increase the uptake of oxLDL 
that are high in 7KC, as they require high delivery of cholesterol for the growing 
cytoplasmic membranes and storage of triglycerides. It is hypothesised that 7KC 
accumulation in adipocytes might inhibit 11β-HSD1-dependent amplification of 
glucocorticoids and ameliorate the metabolic consequences of obesity. In that 
capacity atherogenic 7KC could be trapped in adipocytes and might play a role of a 
natural 11β-HSD1 inhibitor towards glucocorticoids. 
 
 114
It is also hypothesised that 7KC accumulation in adipocytes with low levels of 11β-
HSD1 or limiting concentrations of H6PDH (such as reported in human 
preadipocytes or in adipose tissue in lean subjects) might reduce 11β-HSD1-
dependent amplification of glucocorticoids and ameliorate some metabolic 
consequences of obesity. Moreover, 7KC inhibits de novo cholesterol biosynthesis 
via promoting SCAP-mediated release of SREBP (Brown et al., 2002) potentially 
reducing adipocyte lipid accumulation. Indeed, in humans, adipocyte size correlates 
directly with 11β-HSD1 levels. In contrast, 7β-HC may have the opposite effect, and 
some data suggest it is the more atherogenic of the two sterols (Steffen et al., 2006). 
Thus, in mature adipocytes with plentiful H6PDH, and especially in obesity when 
11β-HSD1 levels are high, 11β-HSD1 is a reductase, regenerating glucocorticoids 
and accumulating 7β-HC (as seen here in 3T3 cells) which is not only more 
atherogenic but which, unlike 7KC, does not inhibit de novo cholesterol biosythesis. 
Potentially the balance between these oxysterols, itself determined by 11β-HSD1, 
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igure.3.13 A hypothetical model of the effects of interactions between 7-oxysterol and 
lucocorticoid substrates of 11β-HSD1 in adipocytes. 
n cells with low H6PDH levels (HEK293 cells, human preadipocytes) or when 11β-HSD1 
evels are low (leanness), 7KC metabolism to 7β-HC consumes cofactor, promoting 11β-
SD1 dehydrogenation, lowering glucocorticoid levels inside cells, attenuating GR 
ctivation and reducing metabolic disease/atherogenic potential. 7KC also reduces de novo 
holesterol biosynthesis and may be less atherogenic per se. In contrast, in mature adipocytes 
especially in obesity) and differentiated 3T3 cells, 11β-HSD1 and H6PDH levels are high 
nd the enzyme is a predominant 11β-reductase. This drives regeneration of active 
lucocorticoids and formation of (putatively) more atherogenic 7β-HC from 7KC. 7β-HC 
ccumulates in adipocytes, facilitates de novo cholesterol biosynthesis and adds to the 
etabolic disease burden. 
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Chronic high fat feeding down-regulates 11β-HSD1 in fat tissue [8]. It may be 
speculated that increased plasma levels of 7KC in dyslipidemia and diabetes 
(Ferderbar et al., 2007) in mice treated with high fat diet might accumulate within 
the fat and contribute to this inhibitory effect on 11β-HSD1, at least at the level of 
enzyme activity. Additionally, the data suggest that 7KC may inhibit the 
differentiation of preadipocytes. This observation is in agreement with the previously 
reported inhibitory effect of oxLDL on the differentiation and proliferation of 3T3-
L1 adipocytes (Masella et al., 2006). Thus, we predict that in dyslipidemia high 
concentrations of 7KC in fat tissue might inhibit the formation of adipocytes and the 
diet-induced hypertrophy of adipocytes. 
 
7KC and 7β-HC are abundant oxysterols, known to be cytotoxic at high 
concentrations and are implicated in atherogenesis. My data have shown that they do 
not exert direct effects via either GR or LXR in adipocytes in vitro. However, they 
do have the potential to influence glucocorticoid access to GR, by modulation of 
11β-HSD1 in adipose tissue. These data could lead to a revision of our understanding 
of the association between glucocorticoids and atherogenesis. In the future, it will be 
critical to establish whether a similar regulation of 11β-HSD1 activity occurs in 
macrophages, and especially in foam cells where oxysterols accumulate to high 
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4 The role of 11β-HSD1-dependent conversion of 7-oxysterols 
4.1 Introduction 
Impaired metabolism of cholesterol is the most firmly established risk factor for the 
development of atherosclerosis. The concentration of plasma cholesterol is 
determined by the fine balance between the rate of cholesterol biosynthesis and its 
excretion into bile. The catabolism of cholesterol into bile acids is regulated through 
feed-forward activation by oxysterols, a pathway mediated by the liver X receptor 
(LXR), and by feedback repression by bile acids, a pathway mediated by the 
farnesoid X receptor (FXR). Nuclear hormone receptors, including LXR and FXR, 
are transcription factors involved in the regulation of cholesterol, glucose and lipid 
metabolism and are currently recognized as very attractive targets in the therapy of 
the dyslipidemia and atherosclerosis. LXR are cholesterol sensors, protecting tissues 
from its overload by inhibiting the interstitial absorption of cholesterol, activating 
efflux and enhancing its conversion into bile acids (Millatt et al., 2003). Naturally 
occurring oxysterols (22(R)-hydroxycholesterol and 24(S), 25-epoxycholesterol) 
activate LXR (Janowski et al., 1999). Interestingly, 27-hydroxycholesterol, an 
oxysterol abundantly present in atherosclerotic plaques, has a potential to activate 
LXR in cholesterol-loaded macrophages where other classical ligands were in low 
concentrations (Fu et al., 2001). This highlights a concept that certain oxysterols may 
be cell-specific activators of LXR. Moreover, it has been hypothesised that the anti-
diabetic effects of LXR ligands might be partially explained by their inhibitory effect 
upon 11β-HSD1 (Stulnig et al., 2002). This suggested that cholesterol metabolites 
might form a crucial cross-talk with glucocorticoid signaling at the transcriptional 
level via regulation of 11β-HSD1 levels. 
 
Farnesoid X receptors (FXR) are highly expressed in the liver, intestine, adrenal 
glands and in differentiated adipocytes and are activated by bile acids (Cariou and 
Staels, 2007). Their role in the pathogenesis of the metabolic syndrome has been 
emphasized by studies showing that FXR control triglyceride metabolism by 
inhibiting hepatic lipogenesis, repressing SREBP-1c expression, enhancing LPL 
activity and increasing VLDL secretion and thereby triglyceride storage in the 
adipose tissue. Additionally, FXR regulates cholesterol metabolism through the 
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inhibition of CYP7A1, the rate-limiting enzyme of cholesterol catabolism to bile 
acids (Claudel et al., 2005). Activation of the FXR also improves insulin signaling 
and insulin-dependent glucose-uptake in adipocytes (Staels and Kuipers, 2007). 
 
FXR ligands, bile acids, are synthesized in the liver via two main pathways. The first 
and rate limiting step in the classical pathway of bile acid synthesis is hydroxylation 
of cholesterol by 7α-hydroxylase (CYP7A1), followed by biochemical changes that 
consequently lead to synthesis of 7α-hydroxy bile acids, essential for lipid digestion: 
cholic acid and chenodeoxycholic acid. Bile acids are also synthesized by less active 
alternative pathways producing the 7β-hydroxy forms. Thus, the conversion of 7KC 
to 7α-HC and 7β-HC in the liver by 11β-HSD1 has been anticipated to be a novel 
alternative pathway of bile acid synthesis (Lyons M., 2002). Whether these 7-
oxysterols could activate FXR is not known with certaint. However, the inhibitory 
effect of 7KC and 7β-HC upon CYP7A1 has been reported (Schwartz and Margolis, 
1983). 
 
Retinoic acid receptor-related orphan receptor α (RORα) is less well characterised 
than other “orphan” nuclear receptors. Cholesterol sulphate, 7-dehydrocholesterol 
and hydroxycholesterols have been suggested to be potential natural ligands for 
RORα (Bitsch et al., 2003). RORα-/- mice and the natural RORα-deficient staggerer 
mice develop severe atherosclerosis when fed high fat diet (Mamontova et al., 1998) 
and present with dyslipidemia (Raspe et al., 2001). RORα plays also a role in 
inflammation and immunomodulation through the NF-κB signaling pathway 
(Besnard et al., 2001) and is involved in the regulation of fat mass accumulation 
(Lau et al., 2008). 
 
11β-HSD1 inhibition protects from atherosclerosis and the metabolic consequences 
of obesity, yet it is not known whether its role in the metabolism of 7-oxysterols 




1. To investigate the potential of 7KC and 7β-HC to activate LXR and FXR in 
transfection assays. 
2. To investigate effect of LXR agonists and 7-oxysterols on 11β-HSD1 
expression in 3T3-F442A and 3T3-L1 adipocytes. 
3. To study the expression of key LXR, FXR and RORα target genes in the liver 




4.2.1 LXR transfection assays 
HEK293 cells were maintained as described in chapter 2 in section 2.4.2. LXR and 
RXRα plasmids were transfected using GeneJuice as in section 2.7.7. 22(R)-HC 
(20µM) and T0901317 (1µM) were used as positive controls to activate LXR 
(Janowski et al., 1999). 
 
4.2.2 Regulation of LXR target genes 
3T3-L1 adipocyte were incubated with 7KC and 7β-HC (20µM) for 24 h. mRNA 
was extracted using Trisol method, converted to cDNA by SuperScript III as 
described in chapter 2 in section 2.7.4. The expression levels of SREBP1c and 
GLUT-4 was measured by qRT-PCR (section 2.7.6). 
 
4.2.3 Regulation of 11β-HSD1 mRNA 
11β-HSD1 mRNA levels were measured by qRT-PCR. 3T3-F442A and 3T3-L1 
adipocytes were cultured and differentiated as described in section 2.4.4. Cells were 
incubated for up to 48 h in serum-free medium with the addition of LXR agonists 
(22(R)-HC 20µM and T0901317 1µM) or 7KC and 7β-HC (500nM, 1µM, 20µM) 
with or without 11β-HSD1 inhibitor, as indicated. Due to the inability to repeat 
previously described inhibitory effect of LXR agonists upon 11β-HSD1 mRNA 
rosiglitazone was used as a positive control. 
 
4.2.4 FXR transfection assays 
HEK293 cells were transfected with FXR, RXRα and FXRE-pTA-Luc plasmids as 
described in section 2.7.7. CDCA (chenodeoxycholic acid) was used as a positive 
control [210].  
 
4.2.5 Expression of LXR, FXR and RORα target genes. 
Expression levels of LXR, FXR and RORα target genes were measured by qRT-PCR 
as described in chapter 2 in section 2.7.6. RNA was extracted from liver samples of 
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18 weeks HF fed 11β-HSD1-/- mice and their C57Bl6/J congenic controls, as stated 
above. 
 
4.2.6 Statistical data analysis 
Statistics was performed using SigmaStat and GraphPad software. Data were 




4.3.1 7-oxysterols do not activate LXR 
Some oxysterols (eg 22(R)-hydroxycholesterol) bind to and activate LXRs (Janowski 
et al., 1999), which may down-regulate adipocyte 11β-HSD1 expression (Stulnig et 
al., 2002). Given the previously reported atheroprotective effects of 11β-HSD1 
inhibition (Hermanowski-Vosatka et al., 2005), the ability of 11β-HSD1-mediated 7-
oxysterol metabolism to produce an LXR agonist and modulate LXR-gated 
activation of genes involved in lipid metabolism was evaluated. HEK293 cells were 
transfected with a cDNA encoding a chimeric activator comprising the Gal4 DNA 
binding domain and the LXRα ligand binding domain and a reporter plasmid in 
which a transcription factor activation from Gal4 binding sites is required for 
luciferase reporter activity (Pawar et al., 2002, Willy et al., 1995). Synthetic 
(Compound T0901317; 250nM) and physiological (22(R)-hydroxycholesterol; 
20µM) LXR agonists activated the reporter by 9- and 5-fold, respectively (Fig. 4.1.). 
7KC and 7β-HC were inactive in the transactivation assay (Fig. 4.1.). LXR agonists 
increased endogenous mRNA levels encoding SREBP1c, an LXR target gene in 
adipose tissue (Ulven et al., 2004, Repa et al., 2000). 7KC and 7β-HC were without 
effect (Fig. 4.2.). GLUT-4, another LXR and PPARγ target gene (Nugent et al., 
2001, Dalen et al., 2003), was also not regulated by 7-oxysterols (Fig.4.3.). 
 
4.3.2 No regulation of 11β-HSD1 mRNA expression by LXR agonists and 7-oxysterols 
In contrast to previously reported data (Stulnig et al., 2002), the LXR agonists 
(T0901317-1µM and 22(R)-HC-20µM ) had no effect on 11β-HSD1 mRNA levels in 
3T3-F442A or 3T3-L1 cells (Fig. 4.5.). Given that glucocorticoids regulate the 11β-
HSD1 mRNA expression (Sai et al., 2008) the potential regulation by 7-oxysterols 
has also been tested. Neither 7KC nor 7β-HC (20µM) altered 11β-HSD1 mRNA 
levels when incubated for 24h with fully-differentiated 3T3-F442A or 3T3-L1 
adipocytes (Fig. 4.5.), nor did they alter 11β-HSD1 mRNA when present in the 
medium (1µM) throughout the 10 day differentiation of 3T3-L1 adipocytes (Fig. 
4.6.). This suggests the effects of these oxysterols on 11β-HSD1 activity (as 




































igure.4.1 7-oxysterols do not activate LXR 
EK 293(11β-HSD1) cells were transfected with CMX-Gal4-hLXRα, an expression 
onstruct encoding the LXRα ligand binding domain, TK-MH100X4-Luc reporter plasmid 
nd pRSV-βgal (internal control). Transfected cells were incubated with T0901317 (250 
M), 22(R)-HC (20 µM), 7KC (20 µM) or 7β-HC (20 µM). Values represent relative mean ± 
EM from 4 independent experiments, each performed in triplicate. Statistically significant 
ffect of treatment (*p<0.05 vs basal luciferase activity, analysed by one-way ANOVA with 





























igure 4.2 7-oxysterols do not regulate SREBP1c mRNA 
ully-differentiated 3T3-F442A adipocytes were incubated with 7-oxysterols (20µM), LXR 
igands: 22(R)-HC (20µM), TO901317 (1µM) or “vehicle” (ethanol) for 24 h. Levels of 
RNA encoding SEBP1c were measured by real time-PCR. Results represent mean ± SEM 
rom 3 independent experiments, each performed in duplicate and are expressed relative to 
ehicle treated cells (arbitrarily set to 1). TATA binding protein was used as an internal 
ontrol. Statistically significant effect of treatment (*p<0.05, one-way ANOVA with 



































igure 4.3 7-oxysterols do not regulate GLUT4 mRNA expression.  
ully-differentiated 3T3-F442A adipocytes were incubated with 7-oxysterols (20µM), LXR 
igands: 22(R)-HC (20µM), TO901317 (1µM), PPARγ ligand: rosiglitazone (1µM; positive 
ontrol), 11β-HSD1 inhibitor (Merck, compound 544) or “vehicle” (ethanol) for 24 h. Levels 
f mRNA encoding GLUT4 were measured by real time-PCR. Results represent mean ± 
EM from 3 independent experiments, each performed in duplicate and are expressed 
elative to vehicle treated cells (arbitrarily set to 1). TATA binding protein was used as an 
nternal control. Inhib: selective 11β-HSD1 inhibitor (Merck, compound 544). Statistically 

















































igure 4.4 No regulation of 11β-HSD1 mRNA by 7-oxysterols and LXR agonists.  
T3-L1 adipocytes were incubated for 24 h with 7KC (20µM), 7βHC (20µM), 22(R)-HC 
20µM) and T0901317 (1µM), rosiglitazone (1µM; positive control) and selective 11β-
SD1 inhibitor (5µM), as indicated. Values are 11β-HSD1 mRNA levels relative to TATA-
inding protein mRNA, used as internal standard, and are expressed relative to vehicle 
reated cells (arbitrarily set to 1). Data are mean ± SEM of 4 independent experiments, each 
erformed in duplicate. *p<0.05 was considered significant (one-way ANOVA with 



































igure 4.5 No regulation of 11β-HSD1 mRNA by 7-oxysterols during adipocyte 
ifferentiation.  
T3-L1 cells were differentiated according to the standard protocol with supplementation of 
µM 7KC (gray bars), 7βHC (open bars) or “vehicle” (ethanol; black bars) in the 
ifferentiation medium through the whole 10 day process of differentiation. (added fresh 
very second day). RNA was extracted on day 0, 2, 4 and 10 of differentiation. Values are 
he ratio of 11β-HSD1 mRNA levels to TATA binding protein mRNA levels and are mean ± 
EM from 2 independent experiments, each performed in triplicate. A significant increase in 
1β-HSD1 mRNA level was detected from day 4. No significant effect of incubation with 7-
xysterols was found (two-way ANOVA with Bonferroni post hoc tests). 
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4.3.3 No activation of FXR by 7-oxysterols. 
In order to test the hypothesis that 7β-HC may be an activator of FXR/RXR, 
HEK293 cells were transfected with cDNA encoding these nuclear receptors and 
incubated with chenodeoxycholic acid (CDCA, a known FXR ligand; 20µM and 
40µM) (Howard et al., 2000), 7KC (20µM) and 7β-HC (20µM). Neither of 7-
oxysterols increased FXRE-luc activity (Fig.4.6.).  
 
4.3.4 No regulation of LXR (ABCA1, ABCG1, SREBP1c), FXR (BSEP, SHP) and RORα (Bmal1, 
Rev-erbα) gene targets in the liver of 11β-HSD1-/- and control mice. 
Finally, the hepatic mRNA expression levels of gene targets of “orphan” nuclear 
receptors described in the literature as regulators of cholesterol and lipid metabolism 
and implicated in the pathogenesis of atherosclerosis (LXR, FXR, RORα) were 
measured. None of the examined genes showed differential regulation between 
genotypes as presented in Table 4.1. Similarly, no difference was observed in the 
adipose tissue of HF fed 11β-HSD1-/- mice compared to HF fed C57BL/6J controls 























































































igure.4.6 7-oxysterols do not activate FXR/RXRα. 
EK 293 cells were transfected with hFXR, hRXRα and FXRE-pTA-Luc reporter plasmid 
nd pRSV-βgal (internal control). Transfected cells were incubated with CDCA (positive 
ontrol), 7KC (20 µM) or 7β-HC (20 µM). Values represent relative mean±SEM from 3 
ndependent experiments, each performed in triplicate. CDCA 20–chenodeoxycholic acid 
0µM, CDCA 40- chenodeoxycholic acid 40µM, CDCA+7KC-chenodeoxycholic acid 20 
M and 7KC 20 µM, CDCA+7β-HC-chenodeoxycholic acid 20 µM and 7β-HC 20 µM. 
tatistical analysis was performed by one-way ANOVA with Bonferroni post hoc tests, 
p<0.05 vs basal luciferase activity). 
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Gene 11β-HSD1-/- mice C57Bl6/J mice 
ABCA1 24.8±5.8 40.6±6.8 
ABCG1 20.8±7 32.7±9.2 
SREBP1c 18.34±1.2 21±2.9 
SREBP2 2.44±0.68 2.43±0.7 
BSEP 0.63±0.08 0.66±0.13 
SHP 21.9±9.4 31.3±8.7 
Bmal1 1.15±0.41 0.67±.0.11 
Rev-erbα 1.24±0.59 0.97±0.24 
Insig-1 2.37±0.54 2.09±0.57 
GPAT 1.85±0.4 1.93±0.34 
HMGCoAR 0.99±0.18 0.86±0.07 
 
Table 4.1 Relative mRNA levels of chosen LXR, FXR and RORα key target genes. 
mRNA levels were measured in the liver of HF fed 11β-HSD1-/- and congenic C57Bl6/J 
control mice. Mice (n=6) were challenged with 10 weeks of HF diet. The expression leves 
were measured by qRT-PCR as described in chapter 2 in section 2.7.6. Values represent the 
mean±SEM. TATA binding protein mRNA was used as an internal standard. Similar values 
were obtained when actin was used as an internal standard. There were no significant 




Here, I tested the hypothesis that by converting 7KC to 7β-HC 11β-HSD1 plays a 
crucial role in maintaining cholesterol homeostasis through regulation of the 
availability of a ligand for a nuclear receptor. Enzymatically produced oxysterols 
activate LXR receptors (Janowski et al., 1999). Studies on purified receptors 
described 7β-HC as a poor LXR ligand (Janowski et al., 1999). However, sulphated 
(7-ketocholesterol-3-sulfate) metabolites inhibited transactivation by LXR in vitro 
(Song et al., 2001) suggesting the activity of these oxysterols for LXR in vivo may be 
determined by their abundance and modification within the tissue. 7-oxysterols, 
known markers of the oxidative stress in dyslipidemic and diabetic patients 
(Ferderbar et al., 2007), were anticipated to be produced through peroxidation of 
diet-derived cholesterol. However, recent reports describing 7KC as a novel substrate 
for 11β-HSD1, pointed towards the plausible role of this enzymatic reaction in the 
activation of LXR pathway. Additionally, 27-hydroxycholesterol accompanied by 7-
oxysterols in atherogenic plaques, can activate LXR in cholesterol-loaded 
macrophages (Fu et al., 2001). Moreover, LXR ligands have been reported to inhibit 
the expression and activity of 11β-HSD1 in 3T3-L1 cells (Stulnig et al., 2002), 
suggesting that a cross-talk between the oxysterol and glucocorticoid pathways may 
operate also at the transcriptional level. However, 7-oxysterols failed to show any 
intrinsic activity for LXRα in the transactivation assays. Neither 7-oxysterol 
increased expression of SREBP1c and GLUT-4 mRNA, known LXR target genes in 
3T3-L1 adipocytes. I also found no differences in the mRNA levels of ABCA1 and 
ABCG5 (the reverse-cholesterol transporters controlled by LXR (Repa et al., 2002) ) 
in the liver of HF fed 11β-HSD1-/- mice, which excludes that the activation of LXR 
by 7-oxysterol metabolites may be implicated in the atheroprotective role of 11β-
HSD1 inhibition. Further, no regulation of the 11β-HSD1 mRNA levels was 
observed with either LXR ligands or 7-oxysterols in differentiated 3T3-F442A and 
3T3-L1 adipocytes, in contrast to the previous report (Stulnig et al., 2002). The basis 
for the latter discrepancy is uncertain but here at least no evidence was found for 
cross-talk between glucocorticoid and LXRα-mediated pathways in 3T3 cells. 
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Another possibility was the activation of FXR by 7β-HC since this oxysterol is an 
intermediate product of the alternative bile acid synthesis pathway in the liver. 
Neither 7β-HC not 7KC showed any intrinsic activity towards FXR in HEK293 cells 
transfected with FXR/RXR plasmids. Additionally, the mRNA expression levels of 
BSEP (Ananthanarayanan et al., 2001) and SHP (Goodwin et al., 2000) (key FXR 
target genes) in the liver of HF fed 11β-HSD1-/- mice and their congenic controls 
were measured. No differences in levels of these mRNA were found between 
genotypes. Ultimately, it cannot be excluded that by metabolizing 7-oxysterols 11β-
HSD1 may be involved in the production of a ligand for other, as yet unidentified, 
“orphan” nuclear receptor. 
 
RORα has emerged recently as a novel plausible target in the treatment of 
atherosclerosis (Laitinen and Staels, 2003). Given that the screen for the natural 
ligands for RORα revealed hydroxycholesterols and oxysterol derivatives, I 
investigated the potential of differential regulation of RORα target genes in the liver 
of HF fed 11β-HSD1-/- and wild type mice. I observed that the expression of 
putative RORα target genes was not significantly different between genotypes. 
Nevertheless future work should look at the potential activation of RORα in 
transfection assays. 
 
Pharmacological inhibition of 11β-HSD1 protects from atherosclerosis 
(Hermanowski-Vosatka et al., 2005). 11β-HSD1-/- mice presented with an 
advantageous lipid profile and lower fibrinogen (Morton et al., 2001), however, the 
molecular mechanism of the atheroprotective consequences of intracellular 
deficiency of glucocorticoids remains unclear. Here, the possibility that by inter-
converting atherogenic 7-oxysterols 11β-HSD1 may be involved in the activation of 
LXR, FXR and, although with less certainty, RORα-regulated pathways of 
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5 Adipose tissue transcriptome profiling reveals novel depot-specific 
“protective” mechanisms of 11β-HSD1 deficiency 
5.1 Introduction 
Excessive plasma glucocorticoid levels impair lipid and glucose metabolism, insulin 
sensitivity, energy homeostasis and inflammatory processes. The similarity between 
the metabolic disturbances of Cushingoid and idiopathic obesity implied a potentially 
common underlying glucocorticoid-mediated mechanism. This contention was 
supported by experiments where adrenalectomy ameliorated and glucocorticoid 
replacement restored dietary and genetic obesity in rodents. Human idiopathic 
(Bujalska et al., 1997, Rask et al., 2002, Paulmyer-Lacroix et al., 2002) and rodent 
genetic obesity (Livingstone et al., 2000a, Liu et al., 2003) is associated specifically 
with increased adipose glucocorticoid action through increased levels of the enzyme 
11β-HSD1 (an intracellular gatekeeper of glucocorticoid receptor activation), which 
may provide the molecular link between Cushingoid and idiopathic obesity (Wamil 
and Seckl, 2007, Morton and Seckl, 2008). 
 
A potentially causal role for increased adipose 11β-HSD1 in the pathogenesis of 
obesity was highlighted by the phenotype of the adipose tissue selective 11β-HSD1 
over-expressing mouse, which presented with insulin resistant diabetes, visceral 
obesity, hyperlipidemia, hyperleptinemia and hypertension (Masuzaki et al., 2001). 
Conversely, 11β-HSD1-/- mice were protected from the metabolic consequences of 
diet-induced obesity (Morton et al., 2004b). On the obesity-prone C57Bl/6J genetic 
background, high fat diet fed 11β-HSD1-/- mice gained significantly less weight than 
controls (Morton et al., 2004a). Crucially, these mice preferentially increase adipose 
tissue in the peripheral depots rather than in the metabolically disadvantageous 
visceral fat. 
 
It is clear that loss of 11β-HSD1 has few deleterious metabolic effects, at least in 
mice. Indeed, industry has produced prototypic drugs which selectively inhibit 11β-
HSD1. The first of these, the arylsulfonamidothiazoles (Barf et al., 2002a), inhibit 
11β-HSD1 and enhance insulin action in liver, lowering blood glucose 
concentrations in diabetic and obese mice (Alberts et al., 2002a, Alberts et al., 
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2003a). Many other agents are in development, so fully understanding how loss of 
11β-HSD1 acts, particularly in adipose tissue, is a crucial ambition. Given the 
hypothesis that down-regulation of adipose 11β-HSD1 is an adaptive metabolic 
response to counteract insulin resistance upon exposure to a high fat diet (Morton et 
al., 2004c), the current project explored fat depot-specific effects of glucocorticoid 
deficiency on adipose tissue gene expression that might protect an intrinsically 
obesity-susceptible model from both obesity and its cardio-metabolic consequences. 
 
The link between chronic inflammation and increased risk of cardiovascular diseases 
associated with obesity has been well described (Hotamisligil, 2007, Shoelson et al., 
2007, Shoelson et al., 2006). It has been demonstrated that pro-inflammatory 
cytokines (eg TNF-alpha, IL-1, IL-6, MCP-1) and various adipocytokines may 
influence insulin signaling in the fat and other tissue (Shoelson et al., 2007, Tilg and 
Moschen, 2006). Several transcription factors and kinases such as c-Jun N-terminal 
kinase (JNK) and inhibitor of κB kinase-β (IKKβ) have been shown to mediate the 
effect of inflammatory stimuli on the pathogenesis of insulin resistance (Yuan et al., 
2001, Hirosumi et al., 2002). Adipose tissue of obese human and rodents is 
characterised by macrophage infiltration (Weisberg et al., 2003), which produces 
pro-inflammatory factors modulating the secretion of adipocytokines (Xu et al., 
2003). It has been also reported recently that infiltration of visceral fat tissue by T 
cells may trigger the initiation of inflammation during the early phase of adipose 
tissue expansion (Kintscher et al., 2008, Wu et al., 2007). 
 
It has been suggested that the metabolic consequences of obesity are more strongly 
associated with visceral than total body adipose mass (Wajchenberg, 2000). Surgical 
removal of visceral but not subcutaneous fat causes increased hepatic and peripheral 
insulin sensitivity (Klein et al., 2004, Kelley, 2004, Gabriely et al., 2002). Visceral 
adipose tissue exhibit higher levels of a number of important adipokines that affect 
peripheral insulin sensitivity. Visceral fat also delivers lipolysis products and pro-
inflammatory cytokines to the liver and therefore may have a more pronounced 
influence on hepatic insulin sensitivity and function than other depots (Gabriely et 
al., 2002). On the other hand, peripheral fat accumulation, whilst the major source of 
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free fatty acid flux in humans, may be relatively protective from metabolic disorders 
(Votruba et al., 2007, Jensen et al., 2003, Guo et al., 1999). Thus, redistribution of 
fat stores to the periphery with overall weight gain is a feature of insulin sensitization 
following treatment with anti-diabetic thiazolidenediones (Adams et al., 1997, 
Yamauchi et al., 2001). Indeed fat mass-matched obese populations with contrasting 
peripheral versus central fat distribution suggest peripheral fat accumulation is 
metabolically protective (Talebizadeh and Butler, 2005). Whilst the basis for adipose 
tissue redistribution to subcutaneous depots on high fat diet in 11β-HSD1-/- mice is 
uncertain, these mice show adipocyte insulin sensitisation and a ‘favourable’ 
adipokine profile (Morton et al., 2004b). Adipose tissue-specific over-expression of 
the glucocorticoid-inactivating 11β-HSD2 enzyme recapitulated many of the 
adipose-mediated beneficial effects observed in 11β-HSD1-/- mice (Kershaw et al., 
2005) suggesting that direct effects of 11β-HSD1 deficiency within adipose tissue as 
well as beneficial hepatic effects (Morton et al., 2004b, Morton et al., 2001) were a 
likely feature of this model. Here I investigated the depot-specific transcriptomic 
profile of adipose tissue that underlies the fat redistribution. This also presents the 
first report suggesting that reduced infiltration of T cells in the mesenteric fat depot 




1) To investigate the depot-specific transcriptomic profile of adipose tissue that 
underlies the fat redistribution and resistance of 11β-HSD1-/- mice to high fat diet-
induced metabolic disease.  
2) To dissect the critical pathways downstream of 11β-HSD1 in visceral and 
subcutaneous fat. 
3) To validate the micro-array data by qRT-PCR for chosen gene targets. 
4) To confirm the up-regulation of PI3K/AKT insulin signaling pathways in 





Male 11β-HSD1-/- mice and their congenic controls were maintained as described in 
section 2.3. Animals were matched for age and weight and allocated into two groups 
of seven. Animals were housed singly and maintained on HF diet (58% calories as 
fat, Research Diets D12331) for 4 weeks (section 2.3.2.). Body weight and food 
intake were recorded on a weekly basis.  
 
5.2.1.1 Analysis of plasma glucose and insulin  
Mice were fasted for 6 h for glucose and insulin measurements before and after the 
study. Plasma fasting glucose and insulin were measured as described in section 
2.3.4. 
 
5.2.2 Genomic analysis 
Adult male age-matched 11β-HSD1-/- and C57Bl6/J mice (n=7) were given a HF 
diet for 4 weeks, a diet previously optimized for weight gain and insulin resistance. 
Animals were fasted for 6h for glucose and insulin measurements before and after 
the study. Mice were killed at 8:00 am within 1min of disturbing each cage. Glucose 
was measured with the Sigma HK assay (Sigma, UK) and insulin with the Ultra 
sensitive Rat Insulin ELISA kit (Crystal Chem, UK) and corticosterone by RIA as 
described in section 2.3.4 and (Morton et al., 2004c). Two fat depots (subcutaneous, 
mesenteric) and the liver were frozen on dry ice and stored at -80ºC. RNA was 
extracted using RNeasy Lipid Tissue Midi kit (Qiagen, UK) or Trisol method 
(Invitrogen, UK). RNA quality was verified with the 2100 BioAnalyzer (Agilent 
Technologies, Palo Alto, CA). Samples that demonstrated high quality (i.e. the ratio 
of 28S rRNA to 18S rRNA was greater than 1.9) and had a minimum of 1µg of RNA 
were submitted for micro-array analysis. Micro-array experiment was performed as 
described in chapter 2 in section 2.8.4 (Fig. 5.1.). 
 
5.2.3 Data validation  
Chosen gene targets were validated by qRT-PCR in bigger groups of animals (n=10-
14) as described in section 2.7.6. 
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5.2.4 Insulin signaling in vivo.  
12-week-old male 11β-HSD1-/- and C57Bl/6J mice were divided into four groups 
(n=6) with similar body weight and assigned to receive two kinds of diet: standard 
chow diet or HF diet (as described above) for 10 weeks. At the end of diet period 
mice were fasted for 6h and then injected i.p. with 0.75mU/g humulinS or saline. 
Blood samples were taken before and after fasting for glucose and insulin 
measurements. At 15min after the injection subcutaneous and mesenteric fat depots 
and liver were dissected and snap frozen in liquid nitrogen and stored at-80. Tissues 
were processed as described in chapter 2.9. 
 
5.2.5 Adipocyte cell sizes measurement 




5.3.1 Fat redistribution in 11β-HSD1-/- mice.  
After 4 weeks of HF diet 11β-HSD1-/- mice gained less weight, had lower 
mesenteric fat-depot mass (gross mass: p=0.0113; organ to body weight ratio: 
p=0.0159), lower fasting glucose (p<0.0001) and insulin levels (p=0.0012) than 
control group (Table 5.2.). The redistribution of fat mass to peripheral subcutaneous 
fat depot confirmed the observations previously reported for an intra-abdominal 
metabolically “peripheral-like” fat depot (epididymal fat) (Morton et al., 2004b). 
 
5.3.2 Differential expression of genes in subcutaneous and mesenteric fat depot-overall 
analysis. 
Micro-array analysis using Affymetrix 430 2.0 GeneChips revealed a large number 
of differentially expressed genes between the genotypes. I identified 565 and 1622 
transcripts as being ≥1.5-fold differentially expressed between genotypes in 
subcutaneous adipose tissue and mesenteric fat, respectively. The majority of these 
genes were down-regulated in mesenteric adipose tissue of 11β-HSD1-/- mice (73%; 
Fig. 5.3.) and up-regulated in subcutaneous fat depot (79%; Fig. 5.3.). The 
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Figure 5.1 Schematic representation of the micro-array experiment. 
11β-HSD1-/- and C57Bl6/J mice (n=5) were challenged with 4 weeks HF diet (58% calories 
from fat). Fasting glucose and insulin was measured at the end of the study period. Mice 
were killed and two fat depots (subcutaneous and mesenteric) were dissected. RNA was 
extracted using RNeasy Lipid Tissue Midi kit (Qiagen, UK). RNA samples were used for 
target preparation and subjected to hybridization to 20 Affymetrix mouse Genome 430 2.0 
GeneChips. Samples were processed according to standart Affymetrix protocols by the 
micro-array team at The Sir Henry Wellcome Functional Genomics Facility in Glasgow. 
Data were extracted through the GCOS software and processed with the Robust Multichip 
Average algorithm. Differential expression was determined by Limma tool on BioConductor 
(as described in Methods in section 2.8.4). Genes with >1.5-fold differential expression 
levels between genotypes in the subcutaneous and mesenteric adipose tissue were imported 
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Table 5.1. Physiological characteristics of 11β-HSD1-/- and control mice fed HF for 4 
weeks. 
Adipose depot fat mass was assessed in C57Bl/6J (control) and 11β-HSD1-/- mice after 4 
weeks of high fat diet. Glucose and insulin were measured in plasma samples obtained after 
6h of fasting at the end of the 4 week study period. Data are the means ±SE (n=7) analysed 





Figure 5.2 Comparison of scatter plots of log intensity values. 













Figure 5.3 Schematic representations of genes differentially regulated in mesenteric and 
subcutaneous fat depot of 11β-HSD1-/- mice. 




5.3.3 Up-regulated genes in the subcutaneous fat of HF fed 11β-HSD1-/- mice. 
Analysis of gene expression in subcutaneous fat of HF fed 11β-HSD-/- mice revealed 
consistently higher expression of genes involved in glycolysis and lypolysis, β-
oxidation and oxidative phosphorylation compared to HF fed controls. When the 
altered genes were analysed by gene ontology, activation of genes in subcutaneous 
fat of 11β-HSD1-/- mice were associated with tissue morphology changes, 
myogenesis, cellular assembly and organization, permeability and cellular growth 
and proliferation. The most significant pathways included: calcium signaling (ASPH, 
ATP2A1, CACNA1S, CACNA2D1, CACNB1, CACNG1, CAMK2A, CASQ1, 
MYH1), and β-adrenergic signaling (AKAP6, ATP2A1, PKIA, PPM1L, PPP2R3A, 
SLC8A3) followed by glucose metabolism (FOXA1, ENO3, FBP2, PFKM, 
PGAM2), mitochondrial transport and lipid metabolism (CPT1, ACSL6, Fabp3), 
insulin signaling (PHKB, PHKA1, PHKG1, PKM2, Fbp2, PFKM) and oxidative 
phosphorylation (Cox6a2, Cox7a1, Cox8b) (Table 5.2.). Fabp3, one of the fatty-acid 
transporters determining the delivery of fatty acids to the mitochondria for β-
oxidation, showed 3.8-fold increase. Additionally, carnitine palmitoyltransferase 1 
(Cpt1), a key gene controlling the β-oxidation of long-chain fatty acids, showed a 
similar increase. Interestingly, a component of cytochrome c oxidase, Cox6a2 (3-fold 
increase), was up-regulated exclusively in the subcutaneous adipose tissue of 11β-
HSD1-/- mice, whereas mesenteric fat of both genotypes and the subcutaneous fat of 
control mice had very low expression levels. Moreover, two putatively 
“cardioprotective” (Fan et al., 2005) heat shock proteins: Hspb3 and Hspb6, known 
to be implicated in smooth muscle relaxation and inhibition of platelet aggregation , 
were increased 2.5 and 2.3-fold, respectively. Recently, it has been reported that 
alteration in phosphorylation of Hspb6 was associated with dexamethasone-induced 










    
ASPH Aspartate β-hydroxylase 65973 2.73 enzyme 
ATP2A1 ATPase calcium transportin 11937 2.25 transporter 
CACNA1S Calcium channel, voltage dependent, L type, 
alpha 1S subunit 
12292 2.97 ion channel 
CACNA2D1 Calcium channel voltage dependent, 
alpha2/delta subunit 1 
12293 2.17 ion channel 
CACNB1 Calcium channel, voltage dependent, β subunit 
1 
12295 2.39 ion channel 
CACNG1 Calcium channel, voltage dependent, gamma 
subunit 1 
12299 2.44 ion channel 
CAMK2A 
 
Calcium/calmodulin-dependent protein kinase 
(CaM kinase)II alpha 
12322 2.49 kinase 
CASQ1 Calsequestin 1 12372 2.47 other 




    
AKAP6 A kinase (PRKA) anchor protein 6 238161 2.57 other 
PKIA Protein kinase (cAMP-dependent, catalytic) 
inhibitor alpha 
18767 2.67 transporter 
PPM1L Protein phosphatase 1 242083 1.97 other 
PPP1R14C Protein phosphatase 1, regulatory (inhibitor)  76142 2.65 other 
PPP2R3A Protein phosphatase 2 regulatory subunit B, 
alpha 
19054 2.11 phosphatase 
SLC8A3 Solute carrier family 8 (sodium-calcium 
exchanger), member 3 




    
PRKAA2 
 


















E NO3 Enolase 3 13808 2.65 enzyme 
FBP2 Fructose-1,6-biphosphatase 2 14120 2.13 phosphatase 
PFKM Phosphofructokinase 18642 2.52 kinase 




    
CACNA2D1 Calcium channel voltage dependent, 
alpha2/delta subunit 1 
12293 2.17 ion channel 
CACNB1 Calcium channel, voltage dependent, β subunit 
1 
12295 2.39 ion channel 
CACNG1 Calcium channel, voltage dependent, gamma 
subunit 1 
12299 2.44 ion channel 
EGF Epidermal growth factor 13645 2.11 growth factor 
MEF2C Myocyte enhancer factor 2C 17260 1.67 transcription 
factor 
MAPK12 Mitogen-activated protein kinase 12 29857 1.54 kinase 




    
PHKB Phosphorylase kinase β 102093 1.6 Kinase 
PHKA1 Phosphorylase kinase alpha 1 18697 2.42 Kinase 
PHKG1 Phosphorylase kinase gamma 1 18682 2.79 kinase 
PKM2 Pyruvate kinase 18746 1.57 kinase 
SOCS3 
 











    
CPT1b Carnitine palmitoyltransferase 1 12895 2.02 kinase 
ACSL6 
 





















    
Cox6a2 
 








Cox7a1 Cytochrome c oxidase, subunit VIIa 12865 1.94 transporter 




Table 5.2 Selected genes up-regulated in the subcutaneous fat depot more than 1.5-fold. 
Selection criteria were based on the analysis of most significant pathways by the WebGestalt 
and Ingenuity Programs. Fold change represents the ratio of mean mRNA expression level 
between HF fed 11β-HSD1-/- and C57Bl/6J. 
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5.3.4 Down-regulated genes in the subcutaneous fat of HF fed 11β-HSD1-/- mice. 
Among 23 genes down-regulated in the subcutaneous fat of 11β-HSD-/- mice, the 
growth hormone receptor (GHR) belongs to the best described in relation to 
glucocorticoid regulation (Beauloye et al., 1999). GHR was decreased 3.28-fold in 
subcutaneous fat. Additionally, leptin was down-regulated by 1.66-fold confirming 
previous reports in this murine model (Morton et al., 2004b). 
 
5.3.5 Down-regulated genes in the mesenteric fat of HF fed 11β-HSD1-/- mice. 
Among the set of genes down-regulated in the mesenteric fat depot pathways 
associated with immune cell, NF-kappaB, Jak/STAT, SAPK/JNK, and chemokine 
signaling ranked highest in the functional classification (Table 5.3.). Functional 
analysis showed that the largest number of differentially expressed genes were linked 
to the proliferation, differentiation, movement and adhesion of immune cells (Table 
5.3.). This indicated that an early phase of diet-induced obesity in C57Bl/6J mice is 
characterized by changes in tissue morphology and cellular organization, most 
probably by the infiltration and activation of the mesenteric fat depot by immune 
cells, in agreement with the literature (Weisberg et al., 2003). This process is 
distinctly reduced in the HF fed 11β-HSD1-/- mice. Genes with the highest scores in 
that group included Marco (macrophage receptor with collagenous structure), which 
showed a 5-fold down-regulation exclusively in the mesenteric fat depot. Marco is 
expressed predominantly on macrophages and dendritic cells and is implicated in 
scavenging and immune function (Elomaa et al., 1995). L-selectin, an adhesion 
molecule implicated with the lymphocyte trafficking into the atherosclerotic aorta 
(Galkina et al., 2006), showed 4-fold lower expression, again only in mesenteric fat. 
Examples of significantly regulated chemokines included: CCL5, CCR6, CXCR4, 
LTB, PRKCB1 and several members of the tumor necrosis factor receptor 
superfamily implicated in chronic inflammatory processes in obesity (Hotamisligil, 
1999, Hotamisligil et al., 1995). CCL5 mRNA levels are increased in murine and 
human visceral obesity and are associated with T cell infiltration of white adipose 
tissue (Wu et al., 2007). Several gene members of the two pathways highly 
implicated in the pathogenesis of insulin resistance, NF-kappa B pathway (LCK, 
KLRD1, LAT, LCP2, PIK3CD, PRKCB1, PTPN6, VAV1) and SAPK/JNK 
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signaling (LCK, MAP4K1, PIK3CD, RAC2, TRA) were down-regulated in the 11β-
HSD1-/- mice. Moreover, IL2R (CD25) and CD4, highly expressed on regulatory T 
cells (CD4+CD25+ T cells; Treg) associated with the development of insulin-
dependent diabetes (Yamanouchi et al., 2007, Lowe et al., 2007) were 2.5 fold and 
1.85 lower in 11β-HSD1-/- mice, respectively. Interestingly, two downstream 
effectors of Wnt signaling pathway (LEF1 and Tcf7) have been highlighted by the 
Ingenuity Pathway Analysis (IPA). Recently, genome-wide studies revealed a strong 
association of polymorphisms in IL2R with increased risk of diabetes type 1 (Vella et 
al., 2005) and in Tcf7 with diabetes type 2 in various ethnic populations (Grant et al., 
2006, Elbein et al., 2007, Chang et al., 2007). Finally, a transcription factor-STAT4, 
implicated in chronic inflammation linked to obesity (Torpey et al., 2004) was down-
regulated in 11β-HSD1-/- mice. 
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CD28 CD28 antigen 12487 3.04 Other 
CD3d CD3-TCR complex 12500 3.47 Transmembrane 
receptor 
CD3G CD3-TCR complex 12502 3.55 Transmembrane 
receptor 
CD8A CD8A  12525 3.34 other 
CD8B CD8B 12526 3.4 Other 
ITK IL-2-inducible T-cell kinase 16428 3.52 Kinase 
LAT Linker for activation of T cells 16797 2.6 Other 
LCP2 Lymphocyte cytosolic protein 2  16822 2.29 other 
PIK3CD Phosphoinositide-3-kinase, catalytic, 
delta polipeptide 
18707 2.32 Kinase 
PTPRC Protein tyrosine phosphatase, receptor 
type C  
19264 2.77 Phosphatase 
RASGRP1 RAS guanyl releasing protein 1 (calcium 
and DAG regulated) 
19419 2.42 other 
VAV1 Vav 1 oncogene 22324 2.19 Transcription 
regulator 
KLRD1 Killer cell lectin-like receptor subfamily 
D, member 1 
16643 2.73 Transmembrane 
receptor 
BCL2A1 BCL2-related protein A1 12044 2.27 Other 
CAMK2B Calcium/calmodulin-dependent protein 
kinase II β 
12323 2.57 Kinase 
CD19 CD19 12478 3.18 Other 
CD22 CD22 12483 4.46 Other 
CD79A CD79A immunologlobulin associated 
alpha 
12518 3.59 Transmembrane 
receptor 







Colony stimulating factor receptor, β 2 














    
CD40 CD40, TNF receptor superfamily 
member 5 
21939 2.25 Transmembrane 
receptor 
PRKCB1 Protein kinase C, β 1 18751 2.29 kinase 
TLR1 Toll-like receptor 1 21897 2.26 Transmembrane 
receptor 
TCR ALPHA T cell receptor alpha locus 21473 3.51 other 
ZAP70 Zeta-chain (TCR) associated protein 
kinase 
22637 2.36 kinase 
LCK Lymphocyte-specific protein tyrosine 
kinase 
16818 3.37 kinase 





HLA-DMB Major histocompatibility complex, class 
II, DM β 
14999 2.96 Transmembrane 
receptor 
HLA-DOA Major histocompatibility complex, class 
II, DO alpha  
15001 3.33 Transmembrane 
receptor 
HLA-E Major histocompatibility complex, calss 
I, E 















    
LCK 
 








MAPK4K1 Mitogen-activated protein kinase1 26411 2.5 kinase 
RAC2 
 
Ras-related C3 botulinum toxin 
substrate 2 (rho family, small GTP 











    
CCR6 Chemokine (C-C motif)receptor6 12458 3.21 other 
CCR7 Chemokine (C-C motif)receptor7 12775 3.93 other 
CXCR4 
 






PRKCB1 Protein kinase C, β 1 18751 2.81 Kinase 
LTB lymphotoxin B 16994 3.91 Other 
Tnfrsf13c 
 
tumor necrosis factor receptor 
superfamily, member 13c 
72049 3.5 Other 
IL-2 /IL-4 signaling 
 
    
IL2RG 
 


















Protein tyrosine phosphatase, non-




















    
STAT 1 
 





























CBLB Casitas B-lineage lymphoma b 208650 1.78 Other 
IL7R interleukin 7 receptor 
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Cxcl10 chemokine (C-X-C motif) ligand 10 15945 2.82 Other 
Ccl5 Chemokine (C-C motif) ligand 5 20304 2.81 Other 
STAT 1 
 





















Lef1 lymphoid enhancer binding factor 1 16842 3.03 other 
Tcf7 
 
transcription factor 7, T-cell specific 21414 2.91 Transcription 
regulator 
 
Table 5.3 Selected genes down-regulated in the mesenteric fat depot more than 1.5-fold. 
Selection criteria were based on the analysis of most significant pathways by the WebGestalt 
and Ingenuity Programs. Fold change represents the ratio of mean mRNA level between HF 
fed 11β-HSD1-/- and C57Bl/6J. 
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5.3.6 Genes up-regulated in the mesenteric fat depot of HF fed 11β-HSD1-/- mice. 
The smaller set of genes up-regulated in the mesenteric fat depot of 11β-HSD1-/- 
mice included regulators of sarco-endoplasmic reticulum Ca2+-ATPase activity 
(phospholamban 2.25-fold, Kcnk2 2.63-fold), retinol binding protein-transthyretin 
(2.3-fold), neurotransmitters: VIP (2-fold) and tachykinin (2-fold), and cell surface 
receptors: GNAO1, Htr2b, GPR85, CAP2, TAC1, GALR2.  
 
5.3.7 Data validation 
Overall there was a high level of congruency between micro-array and qRT-PCR 
measurement of transcript levels (Fig. 5.4.). 8 selected differentially expressed genes 
with highest fold-changes were found to be significantly regulated in qRT-PCR (Fig 
5.4.). Leptin and PPARγ, showed a similar expression pattern to that measured 
previously by northern blot (Morton et al., 2004b). However, leptin did not reach 
statistical significance when measured by qRT-PCR in the present study. GLUT4 
was up-regulated 2-fold in the subcutaneous fat depot of 11β-HSD1-/-mice (p<0.05), 
in agreement with previous findings of higher basal and insulin-stimulated glucose 
uptake in isolated 11β-HSD1-/-adipocytes [3]. Similar to the micro-array data, 
PRKAA2 was approximately 2-fold up-regulated in both fat depots in 11β-HSD1-/- 
mice (p<0.05). Gene expression changes associated with lipid metabolism were 
confirmed, eg CPT1 (1.7-fold up-regulation) a lipid β-oxidation gene, which is also 
up-regulated in adipose tissue with 11β-HSD1 inhibition (London et al., 2007), 
whereas FABP3 presented the same trend. HSP6 was 1.8-fold up-regulated in the 
subcutaneous fat (p<0.05). Down-regulated genes STAT4, CD8 and MARCO in the 
mesenteric adipose tissue of 11β-HSD1-/- mice showed the same differential 
expression (Fig 5.4.). However, IL7R and selectin, which showed 3-fold down-






























































































































































Figure 5.4 qRT-PCR validation of micro-array data. 
11β-HSD1-/- (black bars) and their congenic C57Bl6/J control mice (open bars) were HF-fed 
for 4 weeks. mRNA expression levels were measured in two fat depots: subcutaneous (s) and 
mesenteric (m). Data are presented as a mean ± SEM of two independent HF diet studies 
expressed in arbitrary units (ratio of mRNA expression level of a gene of interest divided by 
an internal control-TBP), total n number for quantification was 7-10. Statistical analysis was 
performed by Student’s t-test (*p<0.05). 
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5.3.8 Insulin signaling in vivo.  
To determine whether up-regulation of the insulin signaling pathway observed in the 
genomic analysis led to improved insulin sensitivity in 11β-HSD1-/- subcutaneous 
fat, in vivo insulin sensitivity was measured in HF fed 11β-HSD1-/- and control 
C57Bl6/J mice. Total IRS-1, PI3K and AKT proteins did not differ in the liver, 
subcutaneous and mesenteric adipose tissue between genotypes (Fig 5.5.). There was 
a progressive reduction in insulin-stimulated AKT tyrosine phosphorylation in the 
liver in both genotypes on a high fat diet (Fig.5.5A). However, the decrease was less 
pronounced in the 11β-HSD1-/- mice when compared to controls (Fig 5.5A). 
Similarly, in subcutaneous fat, insulin-stimulated phosphorylation of AKT and IRS-1 
was decreased in HF-fed control mice (Fig 5.5C and D). However, 11β-HSD1-/- 
mice did not show a reduction in the AKT phosphorylation level indicating 
preservation of insulin signaling (Fig 5.5C). IRS-1 showed similar trend (Fig 5.5D). 
Neither phosphorylation levels of IRS-1 nor AKT were regulated in control and 11β-


























































Figure 5.5 Insulin signaling (15min stimulation) in the liver and two fat depots of control 
and 11β-HSD1-/- mice on normal chow and HF diet. 
A) HF diet decreases insulin-stimulated Akt phosphorylation in the liver of HF-fed 11β-
HSD1-/- and C57Bl/6J mice. However, the effect is less pronounced in the 11β-HSD1-/- 
mice. B) No regulation of Akt phosphorylation was found in mesenteric fat depot of HF-fed 
11β-HSD1-/- and control mice. C) Enhanced insulin-stimulated phosphorylation of Akt in 
the subcutaneous fat of HF-fed 11β-HSD1 mice. D) Enhanced insulin-stimulated 
phosphorylation of IRS1 in the subcutaneous fat of HF-fed 11β-HSD1 mice. Data are means 
± SEM of two independent experiments, each performed on n=5 per group. Representative 
Western blots are shown with the quantification (n=10) of phosphorylated protein relative to 
total level of protein measured (Akt or IRS1). Open and black bars represent C57Bl/6J 
(control) and 11β-HSD1-/- mice, respectively. Symbol N and HF represent normal chow diet 
and high fat diet, respectively. *p<0.05 vs control as assessed by Student’s t-test. 
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5.3.9 Adipocyte cell size 
It has been demonstrated recently that chronic activation of β-adrenergic signaling 
stimulated cellular plasticity and remodelling of white adipose tissue (Himms-Hagen 
et al., 2000, Granneman et al., 2003). The appearance of small multilocular 
adipocytes with induced mitochondrial biogenesis and oxidation of fatty acids 
resembling brown fat cells could explain the anti-diabetic and anti-obesity effect of 
β3-adrenergic agonists (Granneman et al., 2005). The micro-array analysis suggested 
an increased β3-adrenergic signaling in the subcutaneous fat of 11β-HSD1-/- mice. I 
investigated whether this may be associated with the smaller cell sizes in this 
peripheral fat depot. 10 weeks of high fat diet caused increased fat mass in both 
geneotypes, with a greater increase in C57BL/6J mice. However, hypertrophy of 
adipocytes occurred only in subcutaneous fat depot of C57Bl6/J mice but not 11β-
HSD1-/- mice (Fig. 5.6.). No differences in adipocyte cell size were detected 
between genotypes in mesenteric adipose tissue (Fig. 5.6.). This along with higher 
CPT1 and FABP3 suggests that the subcutaneous fat tissue of 11β-HSD1-/- mice is 
composed of smaller adipocytes with maintenance of higher local metabolic 






























SUBQ chow SUBQ HF MES chow MES HF
igure 5.6 Cell sizes in subcutaneous and mesenteric adipose tissue of 11β-HSD1-/- and 
57Bl6/J mice on chow and 10 weeks high fat (HF) diet. 
 count of cell number within 25 randomly selected (by computer) areas on H&E stained 
lides of n=5-6 from each group. Y axis represents 1/cell number, *p<0.05 three-way 
NOVA (genotype, diet and depot) with Holm-Sidak method post tests (F=10.22 for the 
nalysis of genotype, F=0.381 for the analysis of fat depots, F=213.9 for the analysis of diet 
ypes). Significant effect of diet was observed in both fat depots and genotypes but with 
ore pronounced effect in C57Bl6/J mice. There was no difference in cell sizes in 
esenteric fat depot between genotypes after 10 weeks HF diet. Subq=subcutaneous fat 
epot, mes=mesenteric fat depot. 
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5.4 Discussion 
Here I describe the global genomic analysis of 11β-HSD1 deficiency in two 
contrasting fat depots, which provide novel insights into how therapeutic inhibition 
of 11β-HSD1 may produce the metabolically “protective” phenotype seen in 11β-
HSD1-/- mice. Combining genomic analysis with previously described physiological 
characteristics of the model it is reasonable to speculate about the implication in the 
aetiopathology of glucocorticoid-induced metabolic syndrome.  
 
My data suggest that the metabolically “protective” phenotype of 11β-HSD1-/- mice 
derives from the following novel adipose depot specific mechanisms: 1. Increased 
accumulation of fat in “safer” peripheral depots through a combination of increased 
insulin sensitivity and substrate flux and 2. Reduced mesenteric fat mass, in part due 
to a reduction in the infiltration and activation of immune and inflammatory cells and 
their signaling.  
 
Cushing’s syndrome is characterized by the accumulation of fat predominantly in the 
metabolically disadvantageous intra-abdominal depot and a reduction of peripheral 
fat (Mayo-Smith et al., 1989). 11β-HSD1 over-expression selectively in adipose 
tissue triggers visceral obesity and an associated metabolic syndrome in mice 
(Masuzaki et al., 2001). Conversely, on a high fat diet, 11β-HSD1-/- mice 
preferentially gain adipose tissue in peripheral rather than visceral depots and are 
protected from the cardio-metabolic consequences of the diet (Morton et al., 2004b). 
Here I report that 11β-HSD1-/- mice show lower body weight, fasting glucose and 
insulin levels during the early stages of obesity (4 weeks of high fat). Importantly, 
these mice have decreased mesenteric but not subcutaneous fat depots at this stage 
and thus offer insight into the early molecular mechanisms governing fat 
redistribution, function and metabolic protection with 11β-HSD1 deficiency. 
 
The data suggest deficiency of glucocorticoids enhances basal insulin signaling, an 
effect that becomes more pronounced with HF diet. The genomic comparison 
between mesenteric and subcutaneous adipose tissue highlighted the up-regulation of 
genes functionally related to lipid oxidation and glucose uptake specifically in the 
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subcutaneous fat of 11β-HSD1-/- mice. An increase in PI3K/Akt and the MAPK 
pathway further supported the preserved insulin sensitivity of this fat depot. 
Concomitantly, there was a marked elevation of GLUT4 mRNA measured by qRT-
PCR in this depot. Analysis of the phosphorylation status of IRS-1 and Akt 
(downstream targets of the insulin receptor) confirmed maintained insulin sensitivity 
in the subcutaneous fat of 11β-HSD1-/- mice in face of HF feeding. Although the 
mesenteric fat has been mostly related to the detrimental consequences of obesity 
(Kissebah and Krakower, 1994) and is more sensitive to glucocorticoids (Masuzaki 
et al., 2001), it did not appear to display differences in insulin sensitivity when 
compared with the control mice. 
 
Thus, sustained insulin signaling likely plays a crucial role in the regulation of 
appropriate lipid storage preferentially in the peripheral fat in the 11β-HSD1-/- 
mouse model. The inability to appropriately expand the subcutaneous adipose tissue 
has been suggested to be a crucial factor linking the calorie excess with the insulin 
resistance and diabetes type 2 (Kim et al., 2007). An increase storage of lipids in 
peripheral depots may protect from the redistribution of triglycerides to the liver and 
the muscle when food is in excess. Increased storage through insulin sensitization is 
offset by increased metabolism via β-oxidation, and hence subcutaneous cell size 
does not increase in the 11β-HSD1 deficient adipocytes. Hence, the observations 
reported here support the notion that enhancing subcutaneous adipose tissue 
proliferation and its capacity for lipid retention leads to protection from 
metabolically detrimental consequences of HF diet. Parallel observations have been 
described in a model of chronic over-expression of insulin-sensitizing adipose cell 
protein, adiponectin (Kim et al., 2007) and in the several studies investigating the 
insulin sensitizing effect of the treatment with PPARγ agonists (Adams et al., 1997, 
Yamauchi et al., 2001). 
 
The global gene expression analysis revealed changes in genes involved in tissue 
morphology, cellular development and organization in the subcutaneous fat of 11β-
HSD1-/- mice, presumably reflecting changes in the proliferation and differentiation 
of adipocytes. This suggests that insulin sensitivity of subcutaneous adipocytes is 
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accompanied by morphological remodeling. Indeed it has been shown previously that 
mesenteric adipose tissue of 11β-HSD1-/- shows reduced differentiation in response 
to chronic HF feeding in vivo (De Sousa Peixoto et al., 2008) and the data on 
adipocyte size demonstrate that subcutaneous adipocytes are smaller in 11β-HSD1-/- 
mice, whereas mesenteric fat adipocyte size does not change. 
 
Another intriguing finding was a marked increase in genes functionally related to 
calcium signaling specifically in the subcutaneous adipose tissue. Intracellular 
calcium content modulates lipid metabolism and adipogenesis. It also contributes to 
the phosphorylation cascade of insulin signaling (Kruger et al., 2008). Ultimately, 
several genes involved in the β-adrenergic signaling were also up-regulated in 11β-
HSD1-/- subcutaneous adipose tissue. Lipid storage in the adipose tissue is under the 
control of insulin and the actions of catecholamines, which act through α and β-
adrenergic receptors. Chronic β-adrenergic activation has been shown to be an 
effective anti-obesity and anti-diabetes strategy in rodents (de Souza et al., 1997). 
Moreover, β-adrenergic stimulation activates lipolysis and drives expression of genes 
controlling oxidative metabolism and thermogenesis in adipose tissue (Granneman et 
al., 2005) and might reflect the process of acquiring features of brown adipocytes by 
white fat cells (Gesta et al., 2007). These adipocytes are smaller, more metabolically 
active and converted towards cells with high fatty acid oxidation capacity. 
Glucocorticoids decrease thermogenesis (Strack et al., 1995) and inhibit adrenergic 
stimulation of uncoupling proteins (Soumano et al., 2000). Hence, it is not surprising 
that 11β-HSD1-/- mice might be protected from glucocorticoid-mediated inhibition 
of β-adrenergic signaling (Morton et al., 2004b). Further, the analysis of gene 
expression in the subcutaneous depot of 11β-HSD1-/- mice revealed high expression 
of the nuclear-encoded mitochondrial genes involved in glycolysis, tricarboxylic acid 
cycle, β-oxidation and oxidative phosphorylation. These changes in gene expression 
were associated with increased expression of PPARγ and CPT1 in qRT-PCR. This 
could explain an interesting dichotomy. 11β-HSD1-/- mice are leaner and have 
improved metabolic parameters on high fat diet despite increased food intake 
(Densmore et al., 2006, Morton et al., 2004b). At the whole body level, mice over-
expressing 11β-HSD2 in the adipose tissue (parallel to 11β-HSD1-/- mice) 
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demonstrated an increase in basal metabolic rate and respiratory exchange ratio 
(Kershaw et al., 2005). Although these finding could represent the transformation of 
white adipocytes to brown fat cells or more likely an increased differentiation of 
pluripotent stem cells of stromovascular fraction towards brown adipocytes, the 
mRNA encoding key brown adipose tissue markers UCP-1 and β3-adrenergic 
receptors were unchanged (in micro-array study and in qRT-PCR data validation). 
Another plausible explanation would be that increased PPARγ enhances lipid 
oxidation (Bogacka et al., 2005). Thiazolidinediones down-regulate 11β-HSD1 in 
adipose tissue (Mai et al., 2007, Berger et al., 2001) and the possible cross-talk 
between PPARγ and 11β-HSD1 downstream pathways may be important in the 
pathogenesis of obesity-induced metabolic syndrome. Thus, the lack of 
glucocorticoid amplification by genetic ablation of 11β-HSD1 in this murine model 
might accelerate the effect of activated PPARγ. It is noteworthy that, 
thiazolidinediones and PGC-1α stimulate the transformation of adipocytes in cells 
with a high lipid oxidative profile (Tiraby et al., 2003). 
 
Ultimately, along with an increase in β-adrenergic signaling, oxidative 
phosphorylation and glucose metabolism, the highlighted changes support the 
hypothesis that adipocytes in subcutaneous fat of 11β-HSD1-/- mice are smaller, 
more insulin sensitive and more metabolically active in relation to the mesenteric 
(visceral) fat depots. 
 
Consistent with an increase in genes involved in glucose uptake and lipid oxidation 
in the subcutaneous fat of 11β-HSD1-/- mice, I also detected an enhancement in 
mRNA level of AMP-kinase alpha2 subunit (PRKAA2). AMPK, a target for the anti-
diabetogenic drug metformin and PPARγ agonists in the adipose tissue (Zhou et al., 
2001, Fryer et al., 2002), is likely to be responsible for increased lipid oxidation and 
protection from redistribution of lipids in liver and muscle. Glucocorticoid treatment 
inhibits AMPK activity in the visceral adipose tissue but not in the subcutaneous fat, 
and this has been suggested to underlie lipid deposition in intra-abdominal depots in 
Cushing’s syndrome (Christ-Crain et al., 2008). In 11β-HSD1-/- mice model I 
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observed an increased mRNA of AMPK in both fat depots. Thus, its contribution to 
the fat redistribution in our model remains unclear. 
 
Increasing evidence suggests the role of low-grade inflammation in the pathogenesis 
of obesity (Hotamisligil, 2006, Shoelson et al., 2007). The link between innate 
immunity and insulin resistance has been supported by the crucial role of cytokines 
and chemokines (TNFalpha, IL6, MCP-1) produced by adipocytes and/or immune 
cells in the in the development of insulin resistance (Tilg and Moschen, 2008). Gene 
expression analysis revealed down-regulation of numerous genes associated with 
immune and inflammatory responses in the mesenteric fat of 11β-HSD1-/- mice 
suggesting decreased infiltration of T cells in the mesenteric fat. It may reflect the 
protection of 11β-HSD1-/- mice from the chronic adipose tissue inflammation 
associated with obesity. 
 
Furthermore, growing evidence suggests infiltration by T cells and other immuno-
competent cells of adipose tissue in obesity (Herder et al., 2005a, Wu et al., 2007, 
Herder et al., 2005b, Rausch et al., 2007, Caspar-Bauguil et al., 2006, Caspar-
Bauguil et al., 2005). Mesenteric fat of HF fed 11β-HSD1-/- mice revealed down-
regulation of genes functionally involved in proliferation, differentiation, movement 
and adhesion of immune cells. There was an indication that mesenteric fat in the 
control mice had changes in tissue morphology by the presence of activated T cells. 
The most significantly regulated pathways were associated with chemokine and 
cytokine signaling. NF-κB and c-Jun NH2-terminal kinase (JNK), two signaling 
pathways linking the immune response with the insulin resistance, which have 
recently attracted major attention (Shoelson et al., 2007). These pathways were 
down-regulated in mesenteric fat of HF fed 11β-HSD1-/- mice (or rather not induced 
by high fat to the same extent as in C57BL/6J mice). Genetic disruption of these 
pathways improves insulin resistance (Hirosumi et al., 2002, Cai et al., 2005), 
suggesting a further basis for insulin sensitization in the 11β-HSD1-/- mice. 
 
11β-HSD1 is also expressed in cells of stromo-vascular fraction, such as 
preadipocytes (De Sousa Peixoto et al., 2008) and in activated macrophages (Ishii et 
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al., 2007, Gilmour et al., 2006a) that are increased in adipose tissue with obesity 
(Weisberg et al., 2003). Glucocorticoids are well known anti-inflammatory drugs, 
however, their physiological action may be distinct from their pharmacological 
properties and they are better described as “immunomodulatory” (Chapman et al., 
2006b). Interestingly, 11β-HSD1-/- mice have been described to be more sensitive to 
LPS-induced endotoxaemia (Zhang and Daynes, 2007). Thus, the role of 11β-HSD1 
deficiency in immune cells and their contribution in the development of 
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6 Summary, conclusions and implications for future studies 
The rationale behind this thesis was based on the fact that 11β-HSD1 inhibitors are 
currently in development as a therapy for the metabolic syndrome and obesity-
induced insulin resistance. A comprehensive understanding of what implications 
11β-HSD1 deficiency has (as a model of therapeutic inhibition), particularly in 
adipose tissue, is crucial for the safety of that novel therapy. While focussed 
discussion has been included in relevant chapters, some points need to be addressed 
here as they have significant implications for further studies. 
 
The intention of this study, from the outset, was to explore fat depot-specific effects 
of 11β-HSD1 deficiency on adipose tissue gene expression. 11β-HSD1 deficiency 
protects an intrinsically obesity-susceptible model from both obesity and its cardio-
metabolic consequences. The recently reported novel role of hepatic 11β-HSD1 in 
the metabolism of alternative oxysterol substrates, in conjunction with a complete 
lack of studies describing the metabolism of these cholesterol derivatives in fat 
tissues prompted the investigations presented in the first part of the thesis. It is 
important to note that the biological interpretation of the genomic analysis was 
hampered until the involvement of oxysterols metabolised by the enzyme in 
regulating pathways downstream of 11β-HSD1 in the fat tissue could be excluded or 
defined. This meant that, initially my efforts were concentrated on the understanding 
whether 11β-HSD1 in adipocytes metabolises 7-oxysterols and further whether 
glucocorticoid and oxysterol substrate interact with each other and influence the 
expression of genes in adipose tissue. 
 
6.1 7-oxysterols and glucocorticoids are competitive substrates for 11β-
HSD1 in adipocytes. 
The seminal work in our lab established that increased reactivation of glucocorticoids 
by 11β-HSD1 in human and rodent adipose tissue may underlie aspects of obesity 
and metabolic syndrome (Morton et al., 2004b, Morton et al., 2004c, Masuzaki et al., 
2001, Morton et al., 2001). Here I proposed a novel hypothesis that the amplification 
of glucocorticoids in fat may be inhibited by oxysterols. This cross-talk between 
glucocorticoids and oxysterols could be particularly relevant when both substrates 
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are plentiful, as would be expected in obesity and dyslipidemia. Here I report for the 
first time that fully-differentiated 3T3-L1 and 3T3-F442A adipocytes metabolise 
atherogenic oxysterols and that this reaction is specific for 11β-HSD1. It is important 
to point out that none of the previously published studies investigating the 
metabolically protective effect of 11β-HSD1 inhibition took into account its role in 
converting 7-oxysterols. Furthermore, this thesis highlights the complex interactions 
between the atherogenic oxysterols and glucocorticoid signaling through GR that is 
dependent on 11β-HSD1. The model presented, and supported by the data, describe a 
novel link between obesity, atherogenesis and glucocorticoid action in adipose tissue. 
 
Firstly, I showed that 7-oxysterols selectively accumulate and act as competitive 
substrates to glucocorticoids for 11β-HSD1 in adipocytes. Secondly, 7-oxysterols 
have a novel effect to modulate the activation of the glucocorticoid receptor and this 
is dependent on the availability of a glucocorticoid ligand. Lastly, acting through 
inhibition of 11β-HSD1, 7KC impaired the differentiation of preadipocytes, a 
glucocorticoid dependent process. 
 
Several aspects requiring further analysis need to be addressed here. During the 
preliminary stage of method development for the conversion of 7-oxysterols by 11β-
HSD1, I tested extraction of oxysterols from both serum-free and serum-enriched 
medium (as described in detail in chapter 2). I encountered difficulties in extracting 
oxysterols from serum-enriched medium (30% oxysterols recovery from medium 
enriched with serum compared with 50-70% from serum-free medium) and therefore 
chose to perform experiments in serum-free medium. This step was also dictated by 
the intention to simplify the model and exclude the influence of possible modifiers of 
oxysterol metabolism in the bovine serum. However, it has to be acknowledged that 
in vivo in the presence of serum lipoproteins, 7-oxysterols might undergo 
influx/efflux not seen in the absence of these “carriers”. Recently, it has been 
reported that, selectively, ABCG1 expression is necessary to promote efflux of 7KC 
and 7β-HC from cells to HDL (Terasaka et al., 2007). Thus, it has been hypothesised 
that restricted efflux of 7KC is dependent on ABCG1 and the presence of 
lipoproteins in the medium. This may explain high concentrations of 7-oxysterols in 
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atherosclerotic plaques (Terasaka et al., 2007). Interestingly, ablation of ABCG1 in 
adipocytes has been shown to reduce obesity (Buchmann et al., 2007). 
 
6.2 The putative role of 11β-HSD1 in producing oxysterol ligands for yet 
unknown “orphan” nuclear receptors. 
11β-HSD1 inhibition protects from atherosclerosis and metabolic consequences of 
obesity (Hermanowski-Vosatka et al., 2005), yet it is unknown whether its role in the 
metabolism of 7-oxysterols might explain the molecular mechanism underpinning 
these effects. Given the previously reported inhibitory effect of LXR ligands upon 
11β-HSD1 mRNA and activity (Stulnig et al., 2002), I investigated whether 7-
oxysterols may activate LXR and regulate LXR target genes. 7KC and 7β-HC did 
not activate LXRα in a transactivation assay, nor did they regulate mRNA 
expression of SREBP1c, GLUT4 and 11β-HSD1 in 3T3-F442A adipocytes. 
Additionally, I tested the regulation of key gene targets of LXRα, FXR/RXR and 
RORα in the liver and fat of HF fed 11β-HSD1-/- and wild type mice. No differential 
regulation was observed. Thus, it remains hypothetical that 7β-HC, the product of 
11β-HSD1-dependent oxysterol conversion, or indeed the 7KC substrate, play a role 
in the pathogenesis of atherosclerosis through activation of an unknown “orphan” 
nuclear receptor. However, this thesis excludes important plausible candidates from 
this hypothetical mechanism of action. 
 
Contrary to previously reported observations of the inhibitory role of LXR ligands 
upon 11β-HSD1 (Stulnig et al., 2002), here, neither physiological nor 
pharmacological LXR ligands showed regulation of 11β-HSD1 mRNA. The 
discrepancy beween these finding is difficult to explain. Indeed despite various 
modification of the protocol for these experiments, included a longer times of 
incubation, more differentiated adipocytes with higher expression of the enzyme, and 





Figure.6.1 Hypothetical model describing a role of 11β-HSD1-dependent conversion of 7-
oxysterols. 
7-oxysterols modulate glucocorticoid induced GR activity. The inhibition of 11β-HSD1 may 
cause an increase of adipose level of 7KC. High concentrations of 7KC are cytotoxic and 




6.3 Genomic analysis of fat depots uncovers novel mechanisms of the 
metabolically protective phenotype of 11β-HSD1-/- mice. 
Having established the molecular mechanism underlying the cross-talk between 
glucocorticoid and oxysterol substrates of 11β-HSD1, I proceeded to the second 
major part of this study. Micro-array technology combined with bioinformatic data 
analysis strategies provide a chance to determine to what extent a manipulation of a 
single gene affects tissue gene expression globally.The short-term HF feeding study 
aimed to detect early changes in genes possessing the regulatory role in metabolic 
processes rather then to confirm the changes that had been already described on 
chronic HF diet regimens. The current trend in obesity research is to look for the 
central molecules that potentially affect enzymes activity and transcription factors 
involved in inflammation and metabolism. Consistent with this belief I made an 
attempt to investigate early, fat depot-specific effects of 11β-HSD1 deficiency on 
adipose tissue gene expression that might result in the protection from cardio-
metabolic consequences of obesity. I aimed to describe what preceeds diet-induced 
obesity and subsequent metabolic disturbances. This approach was dictated by the 
assumption that previously described changes in genes reflect, at least in part, a 
consequence rather than a cause of diet–induced metabolic syndrome. 
 
Transgenic overexpression of 11β-HSD1 in adipose tissue models the metabolic 
syndrome, whereas 11β-HSD1-/- mice resist visceral obesity and metabolic 
syndrome with high fat diet. To dissect the molecular mechanisms underpinning the 
beneficial physiology of these mice, a genomic analysis of mesenteric and 
subcutaneous fat depots of high fat fed 11β-HSD1-/- and control mice was 
performed. The data suggest that loss of 11β-HSD1 enhances lipid oxidation and 
glucose up-take in the peripheral fat depots. Up-regulation of genes of PI3K/Akt and 
the MAPK pathways further supported by increased phosphorylation of IRS1 and 
Akt proteins confirmed preserved insulin sensitivity in the subcutaneous fat of high 
fat fed 11β-HSD1-/- mice. Moreover, these changes in gene expression were 
associated with smaller sizes of adipocytes in “peripheral” (subcutaneous) adipose 




However, the most intriguing finding was revealed by the analysis of gene clusters 
down-regulated in the mesenteric fat of 11β-HSD1-/- mice showing changes 
associated predominantly with immune and inflammatory cells. Thus, I hypothesised 
that infiltration of adipose tissue by activated T cells may be involved in the 
development of insulin resistance in the early phase of high fat diet-induced obesity. 
Changes in NF-κB signaling, Jak/Stat signaling and SAPK/JNK signaling suggested 
further that down-regulation of these pathways may underpin resistance of 11β-
HSD1-/- mice for the development detrimental consequences of high fat feeding. 
However, these observations clearly require further functional studies. 
 
6.4 Future work 
6.4.1 Measurment of levels of 7-oxysterols in adipose tissue in vivo. 
The estimation of oxysterol levels in the adipose tissue has never been described. 
Quantitation of oxysterols is associated with several methodological problems (eg 
recovery of extraction, conditions of saponifications, artifactual generation of 
oxysterols through autoxidation of cholesterol). Studies have indicated that 
oxysterols occur in fresh normal human plasma at levels of 0.01-0.1µM (Schroepfer, 
2000). The levels measured in liver tissues were estimated for 0.4µg/g tissue of 7KC 
and 5µg/g tissue 7β-HC (Saucier et al., 1989). Lund et al (Lund et al., 1992) reported 
the similar findings for 7KC but lower levels of 7β-HC (0.12µg/g). The values 
increased significantly when animals were fed high cholesterol diet. It will be crucial 
to establish reliable methodology allowing measurement of levels of 7KC and 7β-HC 
in adipose tissue. The use of 11β-HSD1-/- and adipose tissue 11β-HSD2 
overexpressor mice will be beneficial to distinguish between the contribution of 
glucocorticoids and oxysterols to the development of metabolically protective 
features of these mice models. 
 
6.4.2 Investigation of the role of 7β-HC in cholesterol metabolism. 
Based on the current knowledge it is impossible to distinguish between the effect of 
7KC and 7β-HC (Ferderbar et al., 2007, Lemaire-Ewing et al., 2005). Increased 
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concentration of both oxysterols has been correlated with dyslipidemia and 
atherosclerosis. In this thesis I investigated the potential of 7-oxysterols to act as 
ligands for LXRα, FXR/RXR and RORα receptors getting consistently negative 
results. It remains plausible that 7β-HC may activate another, as yet unidentified, 
nuclear receptor involved in the regulation of lipid and cholesterol metabolism and 
implicated in the atherosclerosis. This requires further studies. Alternatively, not 
receptor mediated effect of 7-oxysterols on cellular membrane function may be 
involved. 
 
Another potentially interesting aspect will be the cytotoxic effect of the accumulation 
of 7KC in hypertrophic adipocytes. Growing adipocyte increases the intake of 
cholesterol and its oxysterol metabolites to the level when it crystalises and become 
highly cytotoxic. One could predict it will contribute to initiation of local 
inflammation and infiltration of fat tissue by macrophages. This might explain the 
link between increased risk of atherosclerosis in obesity. 
 
6.4.3 Infiltration of mesenteric fat by activated T cells and their contribution for the initiation 
of obesity-induced insulin resistance. 
It may be hypothesised that infiltration of mesenteric adipose tissue with immune 
cells (activated T cells) may trigger the initiation of chronic inflammation in the fat 
tissue and its subsequent infiltration by macrophages. Studies investigating the 
infiltration of fat by T cells will involve immunohistochemistry and flow cytometry 
to distinguish between 11β-HSD1-/- and wild type mice and then to establish specific 
antigen markers of these immune cells. Importantly, the data indicate that the role of 
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